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ABSTRACT 
 
Glucosinolates found in cruciferous vegetables are degraded by plant myrosinases into 
bioactive isothiocyanates (ITCs) which have been recognised as potent anticancer 
compounds. During cooking, plant myrosinases are heat inactivated so ITC production is 
dependent on the myrosinase-like enzymes produced by the gut bacteria. This study is 
focused on investigating glucosinolate metabolism by the human gut bacteria and identifying 
the enzymes that play a crucial role. 
 
Human gut bacteria that were previously reported to metabolise glucosinolates were 
investigated in this study. In addition, 98 more human gut strains were isolated using a 
glucoraphanin enrichment method. It was hypothesised that bacterial myrosinases are β-
glucosidases with specificity for glucosinolates. To identify the first bacterial myrosinase from 
the human gut, four putative β-glucosidases from Enterococcus casseliflavus CP1 and 
Escherichia coli FI10944 were cloned and heterologously expressed in E. coli. An alternative 
approach using a combination of ion exchange chromatography and gel filtration was also 
carried out to identify the bacterial myrosinase of E. coli FI109444.  
 
It has been reported that some gut bacteria require a reduction step to metabolise 
methylsulfinylalkyl glucosinolates (such as glucoraphanin) that converts them into 
methylthioalkyl glucosinolates (such as glucoerucin) to produce ITCs. To identify the 
responsible reductase, candidate reductase genes were cloned and expressed in E. coli. 
Methionine sulfoxide reductase B (MsrB) from Escherichia coli VL8 and Lactobacillus agilis 
R16 was found to reduce glucoraphanin to glucoerucin under the conditions tested.  
 
A bacterial myrosinase of Citrobacter WYE1 of soil origin was previously identified and 
myrosinase activity of this enzyme was characterised using cell-free extracts. In this study the 
myrosinase gene was heterologously expressed in E. coli to allow purification and 
characterisation. The recombinant enzyme showed activity against several glucosinolate 
substrates and protein was produced for crystallographic studies. 
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Abbreviation Amino acid  Symbol 
Ala Alanine A 
Arg Arginine R 
Asn Asparagine N 
Asp Aspartic acid D 
Cys Cysteine C 
Gln Glutamine Q 
Glu Glutamic acid E 
His Histidine H 
Ile Isoleucine I 
Leu Leucine  L 
Lys Lysine K 
Met Methionine M 
Phe Phenylalanine F 
Thr Threonine T 
Trp Tryptophan W 
Tyr Tyrosine Y 
Val Valine V 
Ser Serine S 
Pro Proline P 
Gly Glycine G 
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1.1 GLUCOSINOLATES  
Glucosinolates are found in cruciferous vegetables such as broccoli and are known to confer 
health promoting effects when consumed; notably, reduction in prostate, pancreatic and 
bladder cancer has been reported. This was attributed to chemopreventation effect of them 
and their degradation products. Plant myrosinases are responsible for transforming 
glucosinolates into the bioactive isothiocyanates (ITCs) that are known to have 
chemopreventative effects. During cooking, plant myrosinases are heat inactivated so ITC 
production is dependent on the myrosinase-like enzymes produced by the gut bacteria. This 
study is focused on glucosinolate metabolism by the human gut bacteria and identifying the 
bacterial enzymes and mechanisms that play a crucial role. 
1.1.1 General Structure and Biological Importance of Glucosinolates 
Glucosinolates are sulphur containing glycosides found in cruciferous vegetables mainly 
belonging to the Brassicaceae family. They are mostly present in the Brassicaceae, 
Capparaceae and Caricaceae families [1]. These include Brassica oleracea var italica 
(broccoli), Raphanus sativus (radish), Brassica oleracea var capitata (cabbage) or Brassica 
oleracea var gemmifera (Brussels sprouts), Brassica oleracea var botrytis (cauliflower) and 
Brassica rapa subsp rapa (turnip). Cabbage, broccoli and Brussels sprouts are the main source 
of glucosinolates for the human diet and they are frequently consumed vegetables in 
Western and Eastern countries [2]. 
The general structure of a glucosinolate is shown in Figure 1.1. Glucosinolates are β-
thioglucosides and (Z)-cis-N-hydroximinosulfate esters with a side chain R and sulfur-linked d-
glucopyranose moiety [2]. The chemical and biological nature of glucosinolates are defined by 
the side chain in the structure. So far glucosinolates are known to have little biological activity 
while their degradation products serve as a defence against herbivores including insects, 
birds, aphids and mammals [3]. Glucosinolate hydrolysis in plant is avoided by storing 
glucosinolate and the degradation enzyme in different plant compartments (such as 
glucosinolates in S-cells and myrosinases in myrosin cells)[4-7] or by separating them at 
subcellular level [8]. 
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Figure 1.1 General structure of a glucosinolate. The image was adapted from [8]. R; variable 
side chain.  
There are more than 120 different glucosinolates identified but only a few have been 
investigated deeply. They are known as sulphur and glucose contaning compounds and some 
of the benzyl glucosinolates may have an additional sugar moiety such as rhamnose and 
arabinose bound to aromatic ring [1]. Some of the glucosinolates found in the plants are 
given in Table 1.1. Amino acids are the precursors of glucosinolates. Depending on which 
amino acid acts as a precursor for glucosinolate formation, they can be divided into three 
groups. Aliphatic glucosinolates are derived from alanine (Ala), leucine (Leu), isoleucine (Ile), 
valine (Val), and methionine (Met). Aromatic glucosinolates are derived from phenylalanine 
(Phe) and tyrosine (Tyr) and indole glucosinolates are derived from tryptophan (Trp) [9]. As an 
example, methionine is the precursor in glucoraphanin biosynthesis.  
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Common Name Structure of the Glucosinolate 
Aliphatic Glucosinolates  
Sinigrin 2-Propenyl 
Glucoraphanin 4-methylsulfinylbutyl 
Glucoraphenin 4-methylsulfinyl-3-butenyl 
Glucoiberin 3-methylsulfinylpropyl 
Glucoiberverin 3-methylthiopropyl 
Glucoerucin 4-methylthiobutyl 
Progoitrin 2-hydroxy-3-butenyl 
Glucoalyssin 5-methylsulfinylpentyl 
Glucocapparin Methyl 
Glucobrassicanapin 4-pentenyl 
Gluconapin 3-Butenyl 
Aromatic Glucosinolates  
Glucotropaeolin Benzyl 
Glucosinalbin p-hydroxybenzyl 
Gluconasturtiin 2-phenethyl 
IndoleGlucosinolates  
Glucobrassicin 
Neobrassicin 
3-Indolylmethyl 
1-methoxy-3-indolylmethyl 
4-Hydroxyglucobrassicin 4-hydroxy-3-indolylmethyl 
4-Methoxyglucobrassicin 4-methoxy-3-indolylmethyl 
Table 1.1 Some of the glucosinolates found in Brassica vegetables. Adapted from [1] and 
[2]).  
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Glucosinolates are found in almost every part of the plant varying in concentration 
throughout the plant development. Their content in plant is quite variable but they make up 
almost 1% of the dry weight in some tissues of Brassica [1]. Normally, up to 4 different 
glucosinolates dominate the glucosinolate occurance in the plant within a single species [2]. 
Seeds or young sprouts of broccoli (Brassica oleracea var italica) were reported to contain 70 
- 100 µmol of total glucosinolates per g fresh weight and it was found that the content was 
entirely dominated by aliphatic glucosinolates; glucoraphanin, glucoerucin and glucoiberin 
[10]. The same cultivar was reported to have around 1 - 4 µmol glucosinolates per g fresh 
weight at late stages of growth possessing aliphatic and indolic glucosinolates at equal levels 
[10]. The concentration, variation and distribution of glucosinolates in the Brassica family 
depends on a number of criteria including the species [11], varieties [12], season [13] 
environmental conditions such as soil fertility [14], presence of pest infestation [2], plant 
organ [11, 15], plant age [10, 15] or abiotic stress factors such as salinity or drought [16]. The 
glucosinolate accumulation of the model plant Arabidopsis thaliana among different organs 
and developmental stages was studied and it was found that dormant and germinating seeds 
had highest amount (2.5 - 3.3% per dry weight) followed by the fruits, leaves and the roots. In 
the same study, younger leaves were reported to have higher glucosinolate concentrations 
than the older leaves [15].  
Glucosinolates and their degradation products are responsible for the characteristic flavour 
and odour of Brassica vegetables. When cell-integrity is damaged, ITCs are responsible for the 
pungent and bitter flavour [17]. ITCs from progoitrin and gluconasturtiin have been found to 
relate bitterness in cabbage and Brussel sprouts.   
Glucosinolates and their degradation products have also gained attention as pest control 
agents. Many studies are focused on their biofumigant properties [18-20]. Even if 
glucosinolate-myrosinase system is a defence mechanims for plants [21], herbivores are able 
to avoid from this by biochemical mechanisms or creating their own myrosinase-glucosinolate 
system against their predators [22, 23]. For instance, the cabbage aphids (Brevicoryne 
brassicae) can do this by producing their own myrosinases and storing glucosinolates 
obtained from plants [23].  
Aqueous solubility, ionisability (pKa) and lipophilicity (octanol-water partition, log P) 
determine the dissolution of glucosinolates. Especially, log P is an important factor which 
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affects membrane permeability and inversely related to solubility. In other words, higher log 
P values mean enhanced permeability but reduced solubility. Glucosinolates have negative 
log P values and it is unlikely that they can cross cell membranes so active transport through 
aqueous pores is needed [24]. Glucosinolates have strongly acidic properties due to their 
sulfate group. Sulfate group and thioglucose moiety gives them water-solubility [24]. The 
potential roles of glucosinolates in plants can be listed as follows: 
1) Glucosinolates have roles in plant growth regulation. The plant hormone indole-3-
acetic acid (IAA) was proposed to arise from indole glucosinolates. Indole 
glucosinolates are proposed to be hydrolyzed to indole acetonitriles then nitrilase can 
convert indole acetonitriles to IAAs [25, 26]. Later, indole-3-acetaldoxime was found 
as a precursor of IAA. Arabidopsis mutants (the genes involved in late steps of 
biosynthesis of indole glucosinolates were mutated) were found to have high levels of 
IAA and resulted in dwarf phenotype. These results showed that disruption of the 
conversion of indole-3-acetaldoxime to indole glucosinolates resulted in increased 
flux into IAA [27, 28].  
2) Glucosinolates are involved in plant-insect/herbivore interactions. They are known as 
part of defensive system against their predators. Plant feeding insects can be 
categorised as generalists and specialists. Glucosinolates may be a general poison for 
generalists and a feeding attractant for specialists [29]. They show growth inhibition 
or feeding deterrence against general herbivores such as birds, slugs and generalist 
insects [29].  
3)  Glucosinolates have roles in plant/pathogen interactions. It was reported that 
glucosinolates and their hydrolysis products have antifungal and antibacterial 
properties in vitro [30-33]. The hydrolysis products of aromatic glucosinolates 
(aromatic ITCs) were found to be more toxic than aliphatic ones and aliphatic ITCs 
showed decreased toxicity due to increasing length of side chain [34, 35]. As an 
example, 4-methylsulfinylbutyl ITC was identified with a wide range of antimicrobial 
activity against fungi and bacteria, it caused 50% growth inhibition at concentration of 
28 µM for the most  sensitive organism tested, Pseudomonas syringae [36].  
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1.1.2 Glucosinolate Biosynthesis 
Amino acids were suggested to be precursors of the aglycone motiety of glucosinolates then 
this hypothesis was tested and stages of biosynthesis of glucosinolates were identified using 
labelled compounds (14C, 15N, 35S) [37-39]. The biosynthesis of glucosinolates occurs in three 
steps. In the first step, chain elongation of aliphatic or aromatic amino acids occurs by 
inserting methylene groups into their side chains (Figure 1.2). The second step is metabolic 
modification of the amino acid via an aldoxime intermediate then glucosinolate core 
structure is formed. The pathway for biosynthesis of glucosinolate core structure is shown in 
Figure 1.3. Lastly, the initial glucosinolate is modified by many secondary transformations. For 
instance, the methylthioalkyl glucosinolates are produced directly from the unmodified 
elongated methionine derivatives [2, 8, 40]. The detailed explanation of biosynthesis steps is 
given as follows:  
Initially, the parent amino acid is deaminated branched-chain aminotransferase4 (BCAT4) to 
form 2-oxo acid. The 2-oxo acid enters a cycle of 3 transformations. First, it condenses with 
acetyl-coA in a reaction catalysed by methylthioalkylmalate (MAM) and yields a 2-malate 
derivative (1). The 2-malate derivative isomerased by isopropyl isomerase (IPMI) to form 3-
malate derivative (2). This derivative undergoes oxidation-decarboxylation by the action of 
isopropylmalate dehydrogenase (IPM-DH) to form an elongated 2-oxo acid which has one 
more methylene group than the starting 2-oxo acid (3). Then elongated 2-oxo acid can 
undergo deamination to form homomethionine or enter another round of chain elongation 
[8, 41] (See Figure 1.2). 
The chain elongated amino acids are converted to aldoximes by cytochromes P450 belonging 
to the CYP79 family. CYP79F1 can metabolise all chain-elongated methionine derivatives, 
CYP79F2 only converts long-chained methionine derivates. While CYP79B2 and CYP79B3 can 
use tryptophan, CYP79A2 metabolises phenylalanine. After aldoxime formation, aldoximes 
are oxidized to either nitrile oxides or aci-nitro compounds by cytochromes P450 belonging to 
the CYP83 family. CYP83A1 converts aliphatic aldoximes and CYP83B1 converts both  
tryptophan and phenylalanine derived acetaldoximes. Then conjugation with a sulfur donor 
produces S-alkyl-thiohydroximates. This step is proposed to be catalysed by glutathione-S-
transferases [41] and the sulfur donor was found to be glutathione [42]. The C-S-lyase 
converts S-alkyl-thiohydroximates to thiohydroximates. Thiohydroximates undergo 
glycosylation by the action of glucosyltransferases of the UGT74 family and forms 
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desulfoglucosinolates then desulfoglucosinolates are sulfated by sulfotransferases to produce 
the core glucosinolate structure [8, 41] (See Figure 1.3). 
Secondary modifications of R group including oxidation, desaturation, hydroxylation, removal 
of a methylsulfinyl group and addition of methoxy group can occur to form final glucosinolate 
such as glucoiberin, sinigrin or 4-methoxyglucobrassicin [8, 41].  
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Figure 1.2 Amino acid chain elongation cycle for glucosinolate biosynthesis. Adapted from 
[8]. Three mains steps include condensation with acetyl-CoA (1), isomerization (2) and 
oxidation-decarboxylation (3). 
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Figure 1.3 Biosynthesis of glucosinolate core structure  (adapted from [8]). CYP79 enzymes 
are responsible for conversion of elongated amino acids to aldoximes then CYP83 enzymes 
act on aldoximes to form aci-Nitro compounds. Glutathione-S-transferase (GST) was proposed 
to be the sulfur-donating enzyme. R; variable side chain, S-GT; S-glucosyltransferase, ST; 
sulfotransferase.  
There are studies focusing on increasing the glucosinolate content of plant by manipulating 
the genetic pathways [43, 44]. Increasing the glucosinolate content to maximize the health 
benefits of glucosinolates is a target for plant breeders [45]. For instance, Brassica villosa wild 
species were used to develop 3 high-glucoraphanin broccoli hybrids which have 2.5-3 times 
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the glucoraphanin content of standard hybrids. Two of these high-glucoraphanin hybrids 
were commercialised as Beneforté® broccoli [44].  
Different thermal and non-thermal processes also can affect the glucosinolate content [46, 
47]. A study investigated the effect of gamma-irradiation on genes involved in glucosinolate 
biosynthesis pathway and it was found that many genes are up-regulated and sinigrin content 
was increased by 41% in the irradiated cabbage [46].  
Epidemiological evidence has shown that there is an inverse association between the 
consumption of cruciferous vegetables and the risk of cancer. The intake of cruciferous 
vegetables has been linked to a reduced risk of certain cancer types such as lung cancer, 
colorectal cancer, prostate cancer in many epidemiological studies [48-50]. This effect is 
attributed to the ITCs, the hydrolysis products of glucosinolates. Glucosinolate research 
started with toxicological aspects of glucosinolates such as progoitrin and methods for 
removing them from dietary sources and animal feed but nowadays, most of the studies are 
focused on their potential health-promoting effects [1, 2].  
1.2 GLUCOSINOLATE HYDROLYSIS AND DEGRADATION PRODUCTS 
The hydrolysis of glucosinolates is mediated by the thioglucosidase enzyme myrosinase 
(Figure 1.4). Glucosinolate containing vegetables also contain myrosinase in all parts of the 
plant including leaves, roots, stems, seeds and flowers [51]. Myrosinase is found separately 
from glucosinolates, in idioblasts or myrosin cells of the parenchymatous tissue. Cutting, 
chewing or food processing causes tissue damage so the integrity of cells is disrupted and 
glucosinolates and myrosinase come into contact. When glucosinolate degradation is initiated 
and enzymatic hydrolysis results in the formation of glucosinolate hydrolysis products such as 
ITCs, thiocyanates or nitriles [24, 51] (Table 1.2).  
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Figure 1.4 Hydrolysis of glucosinolates by myrosinase. First, myrosinase catalysed 
degradation produces glucose and unstable aglycone. The aglycone rapidly rearranges to ITC 
(a). In the presence of specifier proteins (ESP, TFP and NSP), other degradation products are 
formed (b). ESP; epithiospecifier protein, TFP; thiocyanate forming protein, NSP; nitrile 
specifier protein. The presence of a terminal double bond in the side chain is needed for 
epithionitrile formation. Thiocyanate formation has only been reported from sinigrin, 
glucoerucin and glucotropaeolin hydrolysis. The image was adapted from [52].  
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Glucosinolates are converted to an unstable aglycone (thiohydroximate-O-sulfonate) by 
myrosinase and undergo a ‘Lossen’ re-arrangement to give an ITC. Thiocyanates, 
epithionitriles and nitriles formation is dependant on pH, metal ions and specifier proteins [2, 
53, 54].  
The hydrolysis products of glucosinolates can be unstable. For instance, β-Hydroxy-ITCs are 
unstable and undergo rapid cyclisation to give oxazolidine-2-thiones [2]. Some of the ITC and 
nitrile products of glucosinolates are shown in Table 1.2. 
Glucosinolate ITC Product  Nitrile Product 
Sinigrin Allyl ITC Allyl nitrile 
Glucoerucin Erucin Erucin nitrile 
Glucoiberin Iberin Iberin nitrile 
Glucoraphanin  Sulforaphane Sulforaphane nitrile 
Glucotropaeolin  Benzyl ITC Benzyl nitrile 
Gluconasturtiin Phenethyl ITC Phenethyl nitrile 
Table 1.2 Some glucosinolate hydrolysis products catalyzed by plant myrosinase 
1.2.1 ITC Formation 
ITCs are important and valued hydrolysis products of glucosinolates owing to their 
chemopreventative effects. They are known to be produced at pH range of 5 – 7 and nitriles 
are known as degradation products in acidic conditions [2, 55]. A recent study showed that 
ITC and nitrile production can occur in a more broader pH range of 3.7-7.6 during bacterial 
fermentation [56] but it was not reported how much ITC formed at specific pH. Unlike 
glucosinolates, ITCs were reported to be unstable and easily  degraded in media, buffers and 
water [57].  
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1.2.2 Nitrile and Epithionitrile Formation 
Nitrile production was originally thought to be dependent on ferrous ions, pH and enzyme 
independent. Then epithiospecifier protein (ESP) was identified and partially characterised as 
the responsiple factor for epithionitrile formation in Crambe abyssinica seeds [58]. Later, ESP 
was purified independently by two diferent study groups and characterised [59, 60]. 
Moreover, thiocyanate forming proteins (TFP) were also identified to form nitrile and 
epithionitriles from aliphatic glucosinolates [61].  
A new group of specifier proteins, nitrile-specifier, was identified and reported to produce 
nitriles [62]. The nitrile specifier proteins (NSP) were reported to require the presence of a 
myrosinase for its nitrile specifier activity [62]. When bioactivity of sulforaphane and 
sulforaphane nitrile was studied using mouse and rats hepatoma cells, sulforaphane was 
found to be more bioactive to induce phase II enzymes than sulforaphane nitrile [63].  
In one study, fresh broccoli florets or broccoli sprouts were used to examine the effects of 
heating on sulforaphane and sulforaphane nitrile formation. It was concluded that heating 
fresh broccoli florets and broccoli sprouts to 60 °C decreased sulforaphane nitrile formation 
while increasing the sulforaphane formation. It was suggested that this was the effect of 
different thermal labilities of myrosinase and ESP. While myrosinase is respectively heat 
stable, ESP is not [64].  
1.2.3 Thiocyanate Formation 
Thiocyanates are also degradation products of glucosinolates. After breakdown of β-
thioglucosidic bond, thiohydroxymate-O-sulfonate can be transformed into thiocyanates in 
presence of thiocyanate forming proteins (TFP). Thiocyanates are normally found in 
extracellular mammalian fluids such as saliva, nasal lining fluid, milk, tears and thought to be 
originated from diet [65]. For the formation of thiocyanates, two factors are suggested to be 
important; a myrosinase and  TFP. The thiocyanate forming enzyme were identified and well 
studied [61, 66, 67]. Thiocyanate formation has only been reported from sinigrin, glucoerucin 
and glucotropaeolin hydrolysis [52]. There is no evidence for bacterial or aphid originated 
thiocyanate forming enzyme so far.  
Thiocyanates were suggested to be useful therapeutic agents as possesing antioxidant 
properties. It was found that they can protect cells against oxidizing agents like hypochlorous 
  
15 
 
acid [65]. However, thiocyanates are reported to inhibit the uptake of iodide by the thyroid 
[68]. 
1.2.4 Other Products 
β-hydroxy ITCs are reported to be unstable and cyclising to oxazolidine-2-thiones that can 
cause goiter [8]. Indole glucosinolates produce unstable ITCs and undergo on further 
hydrolysis to form 3-indolemethanol, 3-indoleacetonitrile or 3,3`-diindolylmethane then give 
dimers, trimers or tetramers [2, 24]. The unstable ITC, 3-(thiocyanatomethyl)-1H indole, is 
thought to be the origin of 3-indolemethanol (Indole-3-carbinol) which go through solvolysis 
with water [53].   
1.3 THE IMPORTANCE OF GLUCOSINOLATES AND THEIR DEGRADATION PRODUCTS 
1.3.1 Chemopreventative effects of Glucosinolates and ITCs 
Diets that are rich in fruits and vegetables are reported to be associated with reduced risk of 
many cancer types in many studies. Cruciferous vegetables are becoming known for their 
health promoting effects against various cancers [50, 69-72].  
Cancer is known as unrestricted division and proliferation of cells. It is a global burden on 
human health. According to the International Agency for Research on Cancer (IARC), there 
were 14.1 million new cancer cases and 8.2 million cancer deaths worldwide in 2012. By 
2030, the cancer incidents worldwide are estimated to rise up to 22 million 
(http://www.who.int/mediacentre/factsheets/fs297/en/). Cancer may be caused by internal 
conditions such as genetic mutations, hormones, immune conditions or external conditions 
such as tobacco, infectious organisms and unhealthy diet. The chemopreventation of cancers 
by bioactive compounds in the diet is one of the ways to combat  cancer.  
Cancer mechanism is very complicated and many theories exist about its cause [73]. 
According to the mutation theory, it is not raised because of a single mutation. For instance, 
several hundred human genes were reported to drive the unrestricted cell division and 
growth process which results in pancreatic cancers [74]. Genetic or epigenetic factors induce 
cancer by changing pathways that control cell proliferation, apoptosis and differentiation. 
There are two types of enzymes which are effective on this process, phase I and phase II 
enzymes. Phase I enzymes primarily consist of cytochrome P450 enzymes and act as 
bioactivators for chemical carcinogens to induce carcinogenesis. Cytochrome P450 is a large 
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family of transferases and located in endoplasmic reticulum and mitochondria of the cells 
[75]. On the other hand, phase II enzymes such as quinone reductase-1 , glutathione-S-
transferase (GST), thioredoxin reductase, UDP-glucuronosyltransferases and γ-
glutamylcysteine synthetases act as protectors for cells/tissues against carcinogens [2, 76-78]. 
They may perform many reactions including glucuronidation, sulfation, methylation, 
acetylation, glutathione and amino acid conjugation. Generally, they do create conjugates 
more hydrophilic than the parental compounds. They can locate in different compartments of 
the cells for example UDP-glucuronosyltransferases are membrane bound proteins, whereas 
soluble GSTs are located mainly in cytoplasm but can be found in nucleus, mitochondria and 
peroxisomes as well [79].  
ITCs derived from glucosinolates are able to modulate Phase I and Phase II enzymes, they can 
directly inhibit or down-regulate Phase I enzymes. They can reduce carcinogen activation by 
inhibiting P450 monooxygenases and activate nuclear factor (erythroid-derived 2)-like 2-
Antioxidant Response Element (Nrf2-ARE) signalling pathway to induce the detoxifying 
enzymes (Phase II enzymes). Carcinogen detoxifying enzymes in human cells such as quinone 
reductase-1 (QR-1) are induced at transcriptional level and ARE were suggested to mediate 
the process [80].  
ITCs were reported to activate caspase-3, -8, or -12 to increase apoptosis [80].  ITCs  have the 
ability to induce cell cycle arrest and they are able to inhibit cell-proliferation and invasive 
metastasis [81]. It was reported that most of the ITCs are absorbed by passive diffusion by the 
cells [78, 82, 83] and intracellular concentrations can be up to 100 - 200 times higher than 
extracellular concentrations [78].  
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1.3.2 Protective Effects of Glucosinolates and ITCs against Diseases 
In addition to their chemopreventive effects against cancer, glucosinolates were studied for 
their protection of cardiovascular and central nervous system. Rat model study fed 
hypertensive stroke-prone rats with sulforaphane by gavage and concluded that sulforaphane 
rectified pathological abnormalities in spontenously hypertensive stroke-prone rats and 
significantly improved blood pressure [84]. Moreover, consumption of high glucoraphanin 
broccoli was associated with a reduction in plasma low density lipoprotein cholesterol (LDL-C) 
[85]. Similar to the cardiovascular system, sulforaphane was determined to have positive 
effects on the central nervous system. Administration of sulforaphane was found to decrease 
infarct ratio [86], brain edema [87, 88], cortical apoptosis [88]. These effects were mostly 
attributed to activation of Nrf2 and upregulation of its target genes [89].  
ITCs have antioxidant, immunostimulatory, anti-inflammatory, antiviral and antibacterial 
properties [81]. ITCs have a electrophilic nature and may undergo reactions with N- O- or S-
based nucleophiles. The –N=C=S group of ITCs can show direct reaction with the cysteine 
sulfhydryl groups of glutathione [82] and proteins [90].  
Different ITCs have been tested for their potential bioactivity so far. For instance, Benzyl ITC 
was suggested to have anticancer effects by inhibiting initiation, growth and metastasis of 
human cancers in mouse models. The targets of benzyl ITC in the inhibition of pancreatic 
tumour growth are overexpressed proteins such as protein kinase B (AKT), signal transducers 
and activators of transcription 3 and nuclear factor kappa B (NFκB) [78, 91]. Phenethyl ITC has 
been identified for its anticancer activity and function in cell-cycle arrest and apoptosis 
induction [78].  
Sulforaphane, derived from glucoraphanin, is the best characterised ITC due to its cancer 
preventive and therapeutic properties [2, 76, 78, 92]. Sulforaphane shows its 
chemopreventative ability by inhibiting phase I enzymes and inducing phase II enzymes. 
Sulforaphane targets certain molecules like survivin and NFκB that are essential for cancer 
cell survival [93]. It was also reported that sulforaphane inhibits important proteins for breast 
cancer cells like estrogen receptor, epidermal growth factor receptor 1 (EGFR1) and human 
epidermal growth factor receptor 2 (HER2) [94] and a study showed that sulforaphane has 
efficacy against tumor growth and metastasis of breast cancer in vivo [95].  
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Allyl ITC (3-isothiocyanato-1-propene or 2-propenyl ITC) was studied for its effects on health 
and was shown to have an inhibitory effect on bladder cancer development and progression 
in rats [96].   
Erucin, an enzymatic hydrolysis product of glucoerucin, was suggested as a potential 
therapeutic agent against prostate cancer cells [97]. Erucin was investigated for its inducing 
capacity on heme oxygenase gene expression in vitro (in cultured cells) and in vivo (in mice). 
The study reported significant increase in mRNA and protein levels of heme oxygenase when 
HT-29 cells were treated with erucin [98].  
In addition to ITCs, glucosinolates were also studied for their health promoting effects. A 
study reported the potential neuroprotective role of glucoraphanin on Parkinson’s disease 
using a mouse model. Two different sets of experiment were used, an acute (2 injections, 40 
mg/kg1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) and a sub-acute (5 injections, 20 
mg/kg 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) model of Parkinson disease. The study 
revealed that glucoraphanin is able to reduce dopamine transporter degradation, tyrosine 
hydroxylase expression, interleukin-1-beta release, the triggering of neuronal apoptotic death 
pathway and the production of radical species; results focused on nitrotyrosine, Nrf2 and glial 
fibrillary acidic protein immunolocalization and concluded that glucoraphanin can protect 
neurons against neurotoxicity [99].  
1.3.3 Toxicity of Glucosinolates and Their Degradation Products  
Historically glucosinolates were studied for their toxicological effects. Many Brassica 
vegetables are used in animal feed and the main goal of studies was to remove glucosinolates 
from food and animal feed because of decreased palatability effect of glucosinolates [2]. 
Sinigrin and progoitrin are associated with the bitter taste. Especially degradation product of 
progoitrin, goitrin, is known as a very bitter product [100]. Goitrin can easily be nitrosated if it 
in contact with nitrites and form the mutagenic compound N-nitroso-oxazolidine [101]. 
Degradation products of glucosinolates were reported to be prone to disrupt iodine 
bioavailability resulting in goitrogenic effects [100, 102, 103]. 
Some of the ITCs such as allyl ITC, benzyl ITC and phenethyl ITC were reported to have 
genotoxic effects. These isothiocyanates have electrophilic reactivity and can form adducts 
with DNA. This can lead inducing gene mutations and chromosomal aberrations. It was also 
noted that the doses used in animal studies are several times higher than normal dietary 
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exposure doses. If there is a potential health risk about ITCs due to their genotoxicity, it 
should not be excluded. Therefore, further in vivo studies using the normal dietary exposure 
doses are needed to confirm and verify the in vitro findings [104].  
1.4 BIOAVAILABILITY OF GLUCOSINOLATES AND THEIR DEGRADATION PRODUCTS 
The bioavailability term consists of several sequential steps. It includes the availability for 
absorption, metabolism, tissue distribution, and bioactivity. The bioactivity measures the 
biologic activity of components on specific organs or tissues. The bioavailability and 
bioaccessibility terms can often be confused but the bioaccessibility term only refers to the 
proportion that is being available to be absorbed from intestinal tract. However, the 
bioavailability term includes transport of components to cells and bioactivity term as well 
[105] (See Table 1.3). It is not easy to determine the bioactivity so bioavailability term is 
usually used in a narrow sense. It is referred as the part that enters the blood stream from a 
consumed dose of a nutrient or the metabolites [105]. For instance, the importance of the 
mercapturic acid pathway in the metabolism of ITCs was reported and ITC mercapturic acids 
in urine were used as a biomarker to study ITC bioavailability [106, 107]. 
BIOAVAILABILITY 
BIOACCESSIBILTY BIOACTIVITY 
 Events that take place during food 
digestion 
 Transport and assimilation by the 
target tissue 
 Absorption/assimilation through 
epithelial tissue  
 Interactions with biomolecules 
 Pre-systemic metabolism   Post-absorptive metabolism or 
biotransformation  
  Physiological response 
Table 1.3 Bioaccessibility and bioactivity steps . Adapted from [105]).  
Following this terminology, the glucosinolate content of the raw or processed cruciferous 
vegetables is the first step for bioavailability. Food processing has effects on glucosinolate 
content of the Brassica vegetables [108]. For instance, the effect of boiling, low pressure 
steaming and microwaving on total glucosinolate content was studied and it was reported 
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that low pressure steaming and microwaving was responsible for a lower glucosinolate loss 
than boiling [109]. Partially or complete inactivaction of enzymes involved in glucosinolate 
degradation by heating affect the final product formation. Myrosinase and ESP proteins were 
reported to show different thermal labilities. While mild heating (60 -70°C) was enough to 
inactivate ESP, myrosinase activity can be retained and favour the ITC formation [64].   
After food processing, mastication plays a key role in the breakdown of the plant cell wall and 
enables the myrosinase to come in contact with glucosinolates. It was also reported that 
differences in chewing might cause interindiviual differences in the bioavailability of ITCs 
[107]. No additional myrosinase activity was found in the saliva so degradation of 
glucosinolates depends on the myrosinase in the plant. During digestion, four main processes 
could happen; acidic hydrolysis of glucosinolates (1), unspecific binding to biomolecules (2) 
and hydrolysis by plant myrosinase (3) and microbial breakdown by gut bacteria (4) [24]. The 
glucosinolate content from rapeseed meal and some glucosinolate degradation products 
were investigated during in vitro incubation with pepsin-HCI or with contents of porcine small 
intestine and caecum [110]. It was found that individual glucosinolates were differently 
affected from peptic and intestinal conditions. Under peptic conditions, the loss was between 
3-23% and it was 7-28% under intestinal conditions [110]. The degradation of glucosinolates 
by the acidic environment in the stomach may favour nitrile formation over ITC formation. 
Maskell et al. (1994) failed to identify ITCs or goitrin in their samples. This phenomenon might 
have occured because of extensive ITC binding [110]. Non-specific binding of glucosinolates to 
dietary fibres was reported by Michaelson et al. (1994) [111]. The microbial breakdown of 
glucosinolates will be discussed in later section 1.9.  
Absorption of the glucosinolates and their hydrolysis products occur after completion of 
digestion. Intact glucosinolates were suggested to pass through gut epithelium without 
hydrolysis [112]. As intact glucosinolates are hydrophilic compounds with negative log P 
values, they are supposed to be absorbed by active transport or paracellular route (through 
tight junctions) [24]. However, Michaelsen et al. (1994) proposed that glucosinolates can pass 
cell membranes by forming ion pairs with lipophilic cations in the matrix [111]. Owing to a 
relatively lipophilic nature and low molecular weight, degradation products of glucosinolates 
have potential to be absorbed into cell mebranes by passive diffusion [24]. ITCs can rapidly 
form conjugates with cellular glutathione (GSH) and this conjugation is the diriving force of 
accumulation of ITC within the cells and passive diffusion [24]. The excretion of ITCs was 
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revealed to be closely related with the non-enzymatic ITC-GSH conjugation reaction rate and 
cellular GSH levels [113]. It was also found that glutathione-S-transferase promoted the 
conjugation reaction [113]. There is limited data about the absorption of other degradation 
products [24]. In a study, epithionitrile 1-Cyano-2,3-epithiopropane was rapidly taken up by 
experimental animals showing the peak values after 1 h [114].  
Transport of glucosinolates or degradation products involves the transfer of compounds 
between the blood and the body tissues. Transport of these compounds might be affected by 
blood flow, membrane barriers, tissue affinity, ion trapping and plasma protein binding 
(albumin and glycoproteins) [24]. The same mechanism for intestinal absorption applies to 
the assimilation by the target tissue in general [24]. Following the absorption into the 
intestinal epithelium, ITCs were reported to pass into the systemic circulation and 
metabolised by the mercapturic acid pathway [106]. The liver and kidney are key organs in 
ITC post-absorptive metabolism where ITCs are conjugated with glutathione in the liver then 
with N-acetyl cysteine (NAC) in the kidney [115].  
The distribution of ITC metabolites in tissues was studied by Briecker et al. (2014) using a 
mice model. The mice were fed with broccoli sprout powders or pure sulforaphane for a week 
then ITC metabolite profile in different tissues were determined. ITC metabolites 
accumulated in specific sites especially bladder followed by the liver and kidney. Lower 
concentrations were detected in plasma, skin and lung tissues, these concentrations were 
almost 100-200 times less compared to their levels in the bladder. In addition, 
interconversion between sulforaphane and erucin was determined in vivo [115]. A study 
reported that complete inactivation of myrosinase in broccoli products resulted in 10% and 
29% of sulforaphane and iberin recovery in the urine respectively which indicates the role of 
human gut microbiota in glucosinolate metabolism [116]. The interaction with biomolecules 
and physicological response were discussed in section 1.3. The metabolic fate of 
glucosinolates and ITCs in the human body is illustrated in Figure 1.5.  
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Figure 1.5 Expected metabolic fate of glucosinolates in the human body. Oral intake: During 
mastication, ITC formation can also occur. Gut: Glucosinolates are hydrolysed into ITCs then 
perform conjugation with glutathione and ITC-glutathione conjugate can pass through cell 
membrane. Urine: ITC is metabolised by the mercapturic acid pathway and excreted with the 
urine. Figure was adapted from [106]. 
Oral intake 
Gut 
Urine 
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To maximize the health benefits of ITCs, bioavailability of glucosinolates and ITCs should be 
fully adressed. In this context, the human gut bacteria involved in glucosinolate metabolism 
and the enzymes responsiple for this metabolism in the gut have a key role.  
1.5 MYROSINASES 
Myrosinase (β-thioglucoside hydrolase, EC 3.2.3.147) is an enzyme responsible for hydrolysis 
of glucosinolates [117, 118]. Plants that contain glucosinolates have also myrosinase stored 
separately from their substrate glucosinolates [4-8]. The plant myrosinases belong to Glycosyl 
Hydrolase 1 (GH1) family. They  are well studied and characterised [117, 119-121].  
The β-glucosidases (EC 3.2.1.21) catalyses the breakdown of the glucosidic bond of a variety 
of saccharides and glucosides. They are classified into different Glycosyl Hydrolase families 
such as GH1, GH3, GH9 or GH30 based on amino acid sequence and structural similarity [122]. 
Mostly, there is a catalytic triad motif located at active sites of glucosidases. Two carboxylic 
residues act as acid/base and as nucleophile for double displacement at the anomeric center. 
Generally, O-β-glucosidases have an acid/base catalyst like glutamate at their active sites. 
However, plant myrosinases do not contain glutamate, instead they have a glutamine at this 
position. Once the glycosyl-myrosinase intermediate is formed, this glutamine residue 
enables placement of the water molecule at correct position, without deprotonation. This 
correct placement of water molecule is essential for hydrolysis of the glycosyl-myrosinase 
intermediate and production of breakdown products [123, 124]. This myrosinase catalysed 
step was found to be rate-limiting and ascorbate can work as a cofactor here. It can place the 
water molecule to the correct position for activation. The glucosinolate degradation in 
presence of ascorbate by Sinapis alba myrosinase (Figure 1.6) occurs in this way: First, the 
glucosinolate binds to the active site and forms myrosinase-glucosinolate complex but this 
complex has a short life. The bound glucosinolate can be cleaved by nucleophile Glu-409. 
After formation of the glucosyl-myrosinase intermediate, ascorbate binds to the active site 
and releases a proton from a water molecule then nucleophilic attack at the anomeric center 
takes place. Eventually, glucose and ascorbate are unbound from the active site [124]. 
Breakdown products can be D-glucose, hydrogen sulphate, H+, nitriles, thiocyanates, amines, 
epithionitriles and ITC depending on the substrate or the pH [24]. 
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Figure 1.6 The overall structure of S. alba myrosinase. It exists as a dimer bound with a zinc 
atom. This image is taken from pdb database (1E4M) [124]. 
Myrosinases can be substrate specific for glucosinolates. For instance, two myrosinase 
isoenzyme isolated by James and Rossiter (1991) showed different degradation rates on 
different glucosinolates [125]. The study showed that both enzymes used in the study are 
more specific for  aliphatic glucosinolates rather than indole glucosinolates [125], while 
another study reported the existence of an myrosinase that was highly specific for epi-
progoitrin [126]. The specificity of enzymes is also affected by other factors like 
epithiospecifier or myrosinase binding proteins [2]. Plant type, organ, stage of development, 
seasonal factors or climatic conditions are the factors causing variation in the myrosinase 
activity [2, 123].  
Myrosinase activity is affected by food processing conditions. Several studies tested the effect 
of processing conditions on glucosinolate content, bioavailability and myrosinase activity 
potential of Brassica vegetables [109, 116, 127-130]. Even if glucosinolates are reported to be 
heat-stable at mild temperatures [130], glucosinolate content might be affected by leaching 
to the medium during heating or enzymatic and thermal breakdown. In a study, the effect of 
boiling, low pressure steaming and microwaving on total glucosinolate content was 
investigated and it was reported that low pressure steaming and microwaving was 
responsible for a lower glucosinolate loss than boiling [109]. Oliviero et al. (2014) studied the 
potential bioavailability of sulforaphane and iberin and their conjugates in the urine after 
consumption of broccoli products. It was reported that complete inactivation of myrosinase 
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resulted in 10% and 29% of sulforaphane and iberin recovery in the urine respectively and 
this amount was the lowest recovery compared to other broccoli products with higher 
myrosinase activity. The study emphasises the importance of even a 20% residual myrosinase 
activity after food processing results in an ITC bioavailability as high as minimally processed 
broccoli with 100% myrosinase activity [116].  
Myrosinases are not only found in plants. There is myrosinase-like activity from different 
sources like fungus [131], aphids [132] and gut bacteria [56, 112]. While plant and aphid 
myrosinases are well characterised [118, 124, 132-136], gut bacterial myrosinases are not.  
The diets of aphids, butterflies, caterpillars and moths can include cruciferous vegetables [20] 
so they can also possess myrosinases and use myrosinase-glucosinolate system as a defence 
mechanim [132]. A study revealed that Brevicoryne brassicae (cabbage aphid) and Lipaphis 
erysimi (turnip aphid) can store glucosinolates separately from myrosinases which 
compartmentalized into crystalline microbodies [22]. The aphids were examined for 
myrosinase like activity and a non-plant myrosinase from cabbage aphid, Brevicoryne 
brassicae, was purified and characterised. It was the first non-plant myrosinase to be purified 
and not activated by ascorbate unlike the plant myrosinases [132]. Further study revealed 
that cabbage aphid myrosinase shows significant amino acid sequence identity to plant 
myrosinases (35% for Sinapis alba myrosinase) and enzymes from glycosyl hydrolase family 
[133]. Glutamic acid residues (Glu-167 and Glu 374) were reported to act as proton donor and 
nucleophile while lysine (Lys-173) and arginine (Arg-312) residues were proposed to have 
significant importance in the breakdown of glucosinolates by these aphids. The study 
concluded that according to sequence similarity and phylogenetic comparison, aphid 
myrosinases are more closely related to animal β-O-glucosidases [133]. In a further study with 
Brevicoryne brassicae myrosinase, the crystal structure of this enzyme was achieved. The 
general structure of this aphid myrosinase shows similarity to white mustard (Sinapis alba) 
myrosinase and plant β-O-glucosidases but plant β-O-glucosidases are not able to degrade 
glucosinolates [134].  
Myrosinase activity in human gut bacteria is attributed to the β-glucosidases which have an 
specificity for glucosinolates [137]. A bacterial myrosinase from human gut has not been 
characterised in terms of gene identification. A study investigated the induced proteins of L. 
agilis R16 and E. coli VL8 from human gut in presence of sinigrin using 2D gel electrophoresis. 
They revealed that induced proteins were mostly part of carbohydrate metabolism, 
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oxidoreduction system and sugar transport, some have roles in purine metabolism, hydrolysis 
and proteolysis [138]. Recently, a bacterial myrosinase from soil was identified and partially 
characterised. This myrosinase was a periplasmic β-glucosidase with a signal peptide from 
Citrobacter WYE1 strain. It was found that it was activated by ascorbate like plant 
myrosinases [118].  
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1.6 METHIONINE SULPHOXIDE REDUCTASES 
The enzymatic oxidation of methionine occurs in proteins and this oxidation was reported to 
impair the enzyme activity. [139-142] (Figure 1.7). Free amino acids or aminoacid residues in 
the proteins are being oxidized by reactive oxygen species (ROS) like superoxide, hydrogen 
peroxide, hydroxyl radical or hypochlorite anion [142]. This oxidation was reported to be 
oxidized by NADPH-dependent flavin monooxygenase enzymes in rabbits and humans [141]. 
The enzyme peptide methionine sulphoxide reductases are responsible for the reduction of 
methionine sulphoxide (MetSO) proteins to methionine (Met) in many organisms including 
mammals [143-145], flies [146], plants [147], yeast [148], bacteria [142, 149-151]. Methionine 
sulphoxide reductase (Msr) enzymes can repair key proteins that will lead to maintance of the 
activity of other proteins and  they enable the usage of these proteins as ROS quenchers 
[142]. While the oxidation of Met to MetSO is a reversible reaction, the oxidation of MetSO to 
methionine sulphone (MetSO2)is not [152]. The catalytic mechanism for Msr activity consists 
of sulfenic intermediate formation followed by the release of the reduced methionine and 
reduction of Msr to its original form which is called recycling step (Figure 1.8)[153]. Various 
reducing agents can perform the recycling step but thioredoxin/thioredoxin reductase system 
is the physiological electron donor [154].  
 
Figure 1.7 Structures of methionine and its oxidation products. Adapted from [152]. 
Msrs are divided in 3 main subclasses. First class, MsrAs are able to reduce free and protein-
based Met(S)SO (S-epimers of MetSO); the second class, MsrBs can reduce Met(R)SO (R-
epimers of MetSO) and the third class, free methionine sulphoxide reductases (fSMsr or 
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fRMsr) are responsible for catalysis of the reduction of free Met(S)SO and Met(R)SO [139, 
140, 153, 155].  
MsrA was knocked out in many organisms to evaluate their roles in oxidative stress and it was 
found to increase the susceptibilty to oxidative stress in mice [144], yeast [148] and bacteria 
[140]. The overexpression of MsrA in Arabidopsis [147], Drosophila [156], Saccharomyces and 
human T cells [145] was performed and it resulted in a better resistance to oxidative stress. 
 
Figure 1.8 The action mechanism of Msrs (adapted from [153]). The action of Msrs initiates 
with the formation of Michaelis complex between Msr and MetSO (Step 1a). It proceeds by 
the nucleophilic attack of Cys-X on the sulphur atom of the sulphoxide group. This leads the 
release of reduced Met (Step 1b) and formation of a sulfenic acid intermediate. Then, 
nucleophilic attack of Cys-Y on the sulphur atom of sulfenic acid takes place resulting in 
release of a water molecule and formation of a Cys-X/Cys-Y disulphide bond. Later, reduction 
of Msr to its original form is performed by reduced thioredoxin.  For E. coli MsrA, Cys-X  is Cys 
51 and Cys-Y is Cys 198.  
Thioredoxin and thioredoxin reductase  were reported to have role in reduction of 
methionine sulphoxide by transferring electrons from NADPH to Msr [141]. MsrA was 
discovered first in E. coli in 1980s [157] and there are many examples of crystallised 
structures from E. coli [158] (Figure 1.9), Mycobacterium tuberculosis [159], Populus 
trichocarpa (poplar) [160] and of bovine MsrA  in the literature [161]. Later, MsrB of Neisseria 
gnorroae was cyrstallised in 2002 [151]. The free methionine sulphoxide reductases (fMsr) 
are reported to be missing in multicellular organisms like plants, mammals [155]. A different 
version of the Msr was identified in Neiseria gnorrhoeae. This enzyme is a fused form of MsrA 
and MsrB and called as MsrA/MsrB [151]. In addition to these Msr classes, the presence of 
membrane associated Msr for R and S epimers of MetSO was also reported [162].  
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Figure 1.9 The structure of methionine sulfoxide reductase from E. coli. This image is taken 
from pdb database (1FF3) [158].   
Bacteria might have different copy number of MsrA and MsrB. While Staphylococccus has 3 
copies of MsrA and one MsrB, Escherichia coli has one copy for each [154].  
Even though Msr is mainly known due to its potential role in repair system of proteins, it has 
been shown that it can be active towards wide variety of compounds with methyl sulphoxide 
groups [163]. Sulindac is an anti-inflammatory drug and was reported to be reduced by MsrA. 
The study also reported that MsrB was not efficient at reducing methyl sulphoxide of sulindac 
even if its amount was 200 times higher than MsrA [164]. Both MsrA and the membrane 
associated Msr (mem-R, S-Msr) are able to reduce sulindac [164].  
MsrA was suggested to be responsible for reduction of methylsulfinylalkyl glucosinolates such 
as glucoraphanin into methylthioalkyl glucosinolates such as glucoerucin [55] (Figure 1.10). 
This reduction is an important step to fully understand the glucosinolate metabolism by gut 
bacteria. In one study [165], the glucosinolate bioconversion by human gut microbiota in a 
batch fermentation model using glucosinolates and faecal inoculum from a healthy volunteer 
was studied and conversion of glucoraphanin to glucoerucin did not occur with heat sterilized 
samples [165]. This suggested that this reduction might be enzymatically driven. Methionine 
sulphoxide reductases serve key roles for organisms by reduction of methionine sulphoxide 
but their role in glucosinolates metabolism is yet to be identified. In addition to reduction of 
glucosinolates, Msr might have role in reduction of ITCs such as reduction of sulforaphane to 
erucin. The interconversion between sulforaphane and erucin was reported in vivo previously 
but the detailed mechanism are not known [115].  
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Figure 1.10 Proposed action mechanism of Msr enzymes on methylsulfinyl glucosinolates 
(adapted from[137]). 
1.7 GUT MICROBIOTA 
The human gastrointestinal (GI) tract (Figure 1.11) is a complex ecosystem and hosts a wide 
variety of microorganims which have important roles and various influences on the GI tract 
and host health [166, 167] (Figure 1.9). Although the microbiota makes up a relatively small 
amount of the human body composition, it is suggested that human gut microbiota has 100 
times more gene capacity than the host [168]. 
 
Figure 1.11 Illustration of the effect of human gut microbiota on human health and disease 
(adapted from [166, 167]). 
Glucoraphanin 
Glucorerucin 
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The microbial content of GI tract can be variable and the microbiota plays an important role 
for host nutritional, physiological, immunological functions like food digestion, vitamin 
production, and disease pathogenesis [167]. The human intestinal system was initially 
thought to harbour 300-500 different species of bacteria but it has estimated recently to have 
more than 1200 different bacterial species [169]. This bacterial species refers to nearly 99% of 
microbes in the human gut, the rest (1%) consists of archaea, viruses and prokaryotes [169]. 
Only a small portion of this microbiota can be culturable but recent advances in culture-
independent high-throughput sequencing has made it possible to identify more microbes in 
human gut [168, 170]. In addition, new methods combining sequencing and bacterial 
culturing approach are being developed and promising to culture and identify the substantial 
proportion of the gut microbiota [171]. The most dominant microbiota in human gut are from 
the phylum, Firmicutes and Bacteroidetes, they make up the >98% of all 16S rRNA  sequences 
[172]. Proteobacteria, Actinobacteria, Verrucobacteria and Fusobacteria are also other 
abundant members of human gut microbiota [167, 172].  
The diversity of microbiota in the infant gut is initially low and colonisation starts with 
aerotolerant species but then aerobes are replaced by anaerobes as typical microbiota of the 
adult gut [170]. By 2.5 years of age, the gut microbiota of an individual are established fully 
and once it has established, it remains constant until old age [170, 173]. Early colonised 
bacteria can modulate gene expression of host epithelial cells to provide a suitable habitat for 
themselves. Therefore the initial colonisation is quite important and influences the final 
composition of the adult gut microbiota [166]. Generally, microbiota composition remains 
stable but under certain conditions, it can show fluctuations. For instance, acute diarrhoeal 
diseases, diet, dysfunction of immune system or antibiotic intake and age can modulate the 
gut microbiota composition [166, 167].  
Changes in diet have significant effect on the composition of gut microbiota [174]. A study 
about the effect of diet on the gut microbiota using humanized gnotobiotic mouse models 
showed that when mice diets are switched to a high in fat and sugar and low plant 
polysaccharide diet from a low in fat and rich in plant polysaccharide diet, there are 
differences in gut microbiota composition of mice just after 1 day [175]. Li et al. (2009) 
studied the effect of diet rich in cruciferous vegetables on fecal bacteria composition with a 
randomized, crossover, controlled feeding study and they concluded that human gut bacteria 
was altered by the cruciferous vegetables in the diet [176]. It was found that there was a 
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significant difference in gut bacterial composition of participants when they consumed a high 
cruciferous vegetable diet compared to consumption of a low-phytochemical, low-fiber diet. 
Specific bacteria such as Eubacterium hallii, Phascolarctobacterium faecium, 
Alistipesputredinis, and Eggerthella spp. were suggested to be linked to cruciferous vegetable 
intake. It was also reported that the response in the gut to cruciferous vegetables was 
individual-specific and there was no direct link between the response and amount of 
cruciferous vegetables taken [176].  
One of the main factors that can modulate gut microbiota composition is antibiotic intake 
[170]. Antibiotic overuse can result in an increase in antibiotic-resistant pathogens. The 
antibiotic intake reshapes the gut microbiota and the effect of intake can cause long-term 
decrease in bacterial diversity [170].  
The composition of the gut microbiota is quite variable between individuals depending on 
several factors such as host genetics [177, 178], diet [174, 175, 179] and environmental 
factors [169, 177]. The host genetics show significant effect on murine gut microbiota [177, 
178]. A study investigating the gut microbiota of human infants from birth throughout the 
first year of their life using a microarray based analysis, found that the composition and 
temporal patterns of the intestinal microbiota were more similar in a pair of dizygotic twins 
than 12 unrelated infants [180]. Turnbaugh et al. (2009) investigated the effect of host 
genotype and adiposity on gut microbial communities of female monozygotic and dizygotic 
twins and their mothers. It was concluded that there were specific bacterial lineages for each 
individual and a comparable degree of co-variation between monozygotic and dizygotic twins 
[181]. Benson et. al (2010) [177] defined a core measurable microbiota of 64 conserved 
taxonomic groups found in across most animals in studied population showing variation 
quantitatively. The core measurable microbiota was tested with 530 fully informative single-
nucleotide polymorphism (SNP) markers and 18 host quantitative trait loci (QTL) that have 
genome-wide linkage with microbial taxa were identified [177]. These QTLs were reported to 
affect the gut microbiota in different ways. Some loci have the control of individual microbial 
species or groups of related taxa and some loci are believed to have pleiotropic effects on 
groups of distantly related organisms [177].  
The gut microbiota has a barrier effect against pathogens, and plays a crucial role in host 
homeostasis, vitamin synthesis and absorption of calcium, magnesium and iron [166]. It keeps 
homeostasis of the immune system by controlling epithelial cell proliferation and 
  
33 
 
differentiation. Ligation of toll-like receptors on intestinal epithelial cells by bacterial products 
induces epithelial cell proliferation and expression of antimicrobial peptides. The intestinal 
microbiota provides epithelial cell homeostatis and a repair system in the intestine [182]. The 
gut epithelium and immune system provide protection of the host against pathogens, but the 
intestinal microbiota also has a crucial role in the inhibition of the pathogens in the gut 
environment [166]. This protective effect has been called several names including bacterial 
antagonism, bacterial interference, barrier effect, colonisation resistance and competitive 
exclusion (CE) [183]. CE can be achieved through many mechanisms that are mostly 
bacteriostatic. Firstly, CE can be performed by creating a microecology which is hostile to 
pathogens, for example by production of volatile fatty acids. Secondly, CE can occur via 
competition between pathogens and native microbiota for limiting nutrients [184]. The third 
mechanism of CE is production of antibacterial substances such as bacteriocins and hydrogen 
peroxide [184-186].  
Dysbiosis, a microbial imbalance of the gut, can be associated with several severe diseases 
like autoimmune and allergic diseases, obesity, iflammatory bowel diseases (IBD) or diabetes 
[167, 170].  Many studies have focused on search for the link between the gut bacteria and 
obesity [181] and diseases such as Crohn`s disease [187, 188], ulcerative colitis (UC) [188, 
189] and colon cancer [190]. Obesity is associated with reduced bacterial diversity [181]. In a 
mouse model, obesity was observed to cause a decrease in Bacteroidetes and increase in 
Firmicutes [191]. The decrease in Bacteroidetes in gut was confirmed with a study on human 
twins but increase in Firmicutes was shifted to increase in Actinobacterium [181]. Dysbiosis is 
thought to be involved in the pathogenesis of IBD [192], the patients with IBD are reported to 
have more bacteria, from a varied genera, attached to their epithelial surfaces than healthy 
people [166]. The genera in gut such as Lactobacillus and Bifidobacteria showed prevention 
against tumorigenesis whereas Bacteroides and Clostridium can increase the incidence [166]. 
In a human study, the presence of two Bacteroides species, Bacteriodes vulgatus and 
Bacteroides stercoris were associated with high risk of colon cancer and Lactobacillus SO6, 
Eubacterium aerofaciens or total Lactobacillus concentration were associated with low risk of 
colon cancer [193].  
Many techniques are used to study the human gut microbiota. Firstly, taxonomic profiling is 
used to identify the microbial community and determine the microbial content of that 
community. Second, metagenomics is used to provide data about abundance of genes and 
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gene transcripts. Third, the use of animal models provides us information about the effect of 
these genes on organisms and their functions [194]. Some of the techniques are listed below. 
They have both advantages and disadvantages. In the design of a study to assess the gut 
microbiota, cost and depth are key elements to select the method for taxonomic profiling. 
Sometimes, combination of a few techniques listed here is another way to study the human 
gut microbiota. 
Culture techniques: Based on isolation of bacteria on selective media. It is fairly cheap but 
labour intensive. It gives a limited information about diversity because only a small portion of 
the gut microbiota have been cultured so far [195]. However, gut microbiota are not 
necessarily unculturable, a recent study using a combined metagenomic sequencing and 
bacterial culturing approach suggested that a substantial proportion of the intestinal bacteria 
is culturable [195]. 
Quantitative PCR (qPCR): Based on amplification and quantification of 16S rRNA. The 
techniques is similar to PCR but uses a compound that fluoresces when it binds to PCR 
product. It is a fast method and provides phylogenetic discrimination. However, PCR bias is 
possible and it is unable to identify novel species [195]. 
DNA Fingerprinting Techniques: Denaturing Gradient Gel Electrophoresis (DGGE) and 
Temperature Gradient Gel Electrophoresis (TGGE) were very popular inititally but they are 
now replaced by the sequencing methods. The 16S rRNA amplicons is separated by 
denaturant/temperature. The gels used can be excised and used in further analysis. It is a 
fast, semi-quantitative method but lacks phylogenetic identification. PCR bias may also be 
problem. These methods were mainly used for comparative analysis such as comparing the 
healthy state to a disease state [195].  
Terminal restriction fragment length polymorphism (T-RFLP): Based on fragmentation of the 
16S rDNA gene amplicons by restriction endonucleases with band visualization. It is fast, 
cheap and semi-quantitative but lacks phylogenetic identification. PCR bias may again be a 
problem. T-RFLP has been  used to determine microbial community diversity in the gut 
microbiota [195].  
Fluorescence in situ hybridisation (FISH): Based on hybridisation of fluorescently labelled 
oligonucleotide probes to target 16S rRNA sequences. It is a fast, semi-quantitative method 
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and provides phylogenetic identification. However, it lacks identification of unknown species 
[195].  
DNA microarrays: Based on hybridisation of fluorescently labelled oligonucleotide probes to 
complementary nucleotide sequences. It is a fast, semi-quantitative method and provides 
phylogenetic identification. However there is a risk for cross-hybridisation (hybridisation of 
multiple probes to single targets). In addition, the detection of species which is at low levels 
in the gut microbiota can be missed out. DNA microarrays mainly used for comparison of the 
microbiota between different populations [195].  
Sequencing of cloned 16S rRNA gene amplicons: Based on cloning of full-length 16S rRNA 
amplicon using the Sanger sequencing. It is good for quantification and phylogenetic 
identification of gut microbiota and enables the analysis of uncultured bacteria. It is laborious 
and expensive [195].  
Direct Sequencing of 16S rRNA amplicons: Described as massive parallel sequencing of partial 
16S rRNA gene amplicons. It may use beads (454 Pyrosequencing®), slides (Illumina®) and 
solid surfaces (SOLiDTM). It is a quantitative method and provides phylogenetic identification 
with the chance of identification of unknown bacteria. However, it is labour intensive and 
expensive [195].  
Microbiome Shotgun Sequencing: Based on massive parallel sequencing of the whole 
community DNA.  It is a quantitative method, enables the phylogenetic identification. While 
other techniques analyse only genetic diversity, microbiome shotgun sequencing is based on 
both the genetic diversity and functions of the gut microbiota.  It is an expensive method and 
needs an intense computational analysis of the data [195].  
Animal models (in vivo): Based on rat, mouse, pig or zebrafish models. For instance, 
gnotobiotic rats can be used to study the link of one bacterial species or a group to a putative 
function or diversity of the gut microbiota but these models lack the full microbial community 
context [196].  
In vitro colon models: These models are designed to mimic microbial processes throughout 
the gastrointestinal tract but they typically lack human cells. They are cheaper and offer an 
alternative to in vivo models for hypothesis testing [196].  
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1.8 THE ROLE OF GUT MICROBIOTA IN BIOTRANSFORMATION OF DIETARY 
COMPOUNDS 
As diet can shape the human gut bacteria composition diversity and abundance [197, 198], 
the human gut bacteria also affects and directs the biosynthesis and metabolism of many 
compounds [176]. One of the main metabolic functions of the gut microbiota is fermentation 
of non-digestable dietary residues (such as non-digestable carbohydrates) and endogenous 
mucus [166, 199]. The microbial community of the gut provides a broad range of enzymes to 
the host which are different from its own resources. The main source of energy in the gut is 
the fermentation of carbohydrates. These carbohydrates include large polysaccharides, 
resistant starch, cellulose, hemicellulose, pectins and gums [166]. Short-chain fatty acids 
(SCFA) like acetate, propionate and butyrate are end products of fermentation by some 
members of the gut microbiota [199]. These fatty acids have crucial role in host physiology. 
For instance, butyrate is the major energy source of colonocytes [199]. Propionate [200] and 
acetate [166] are utilised by liver. These two fatty acids act as modulator in glucose 
metabolism so the intake of propionate and acetate are related with lower glycaemic 
responses [166]. A study showed that butyrate and propionate provides protection against 
high-fat diet induced weight gain and glucose intolerance and stimulate gut hormone 
secretion predominantly [200].  
Some studies also suggest that gut bacteria are able to metabolise polyphenolic compounds 
in gut. This might result in with the formation of more biologically active compounds than the 
parent compounds [201]. For instance, certain health promoting gut bacterial species 
belonging to the genera Bifidobacterium and Lactobacillus are involved in phenolic acid 
metabolism in the gut [202] and five Bifidobacteria species are related with hydrolysis of 
soymilk isoflavones [203]. A study showed that Eubacteruim limosum, a strict anaerobe from 
the human intestinal tract, is able to metabolise some isoflavonoids [204]. An anaerobic 
bacterium strain isolated from mouse intestine was reported to be involved in the conversion 
of soy isoflavones [205]. Lignan metabolism is also performed by human gut bacteria. Plant 
lignans were reported to be metabolised by intestinal microbiota and β-glucosidases in the 
mucosal brush border were suggested to be responsible for this metabolism [206]. It was 
reported that 7-79% of hop derived isoxanthohumol was degraded to 8-prenylnaringenin 
after 72 h when fecal samples from female volunteers were used in a colon model [207]. A 
ten fold difference in 8-prenylnaringenin production was estimated between individuals 
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consuming beer moderately. Similarly, inter-individual differences in degradation of 
naringenin was reported [40]. In addition to other benefits of human gut bacteria, they are 
also involved in biotransformation of glucosinolates into their bioactive derivatives, ITCs.  
1.9 GLUCOSINOLATE METABOLISM BY GUT BACTERIA    
During cooking, plant myrosinases can be heat inactivated so biotransformation of 
glucosinolates becomes dependent on human gut bacteria. Many studies have reported 
bacteria with ability to metabolise glucosinolates. These studies are summarized in Table 1.4. 
In addition, some of the human gut bacterial strains including Lactobacillus agilis R16, 
Enterococcus casseliflavus CP1, Escherichia coli VL8 [56, 57] and Bacteroides thetaiotaomicron 
[112] were reported to show glucosinolate degrading ability.    
Bacteria/faecal microbiota Study Method Reference 
Enterobacter cloacae in vitro incubation in media [208] 
Bacillus, Pseudomonas and 
Lactobacillus species 
in vitro incubation in media [209] 
Lactobacillus agilis R16 in vitro incubation in media  [210] 
Bacteroides thetaiotaomicron Rat model [112] 
Human feacal microflora in vitro incubation in media [211] 
Human feacal microflora in vitro large-intestinal model [212] 
Human feacal microflora Gnotobiotic rat model [213] 
Bifidobacterium species in vitro incubation in media  [214] 
Rat cecal microbiota Rat model [215] 
Human feacal microflora in vivo and in vitro incubation 
in media 
[216] 
Lactic acid bacteria and 
Staphylococcus cornosus UM 123M 
in vitro incubation in media [217] 
Table 1.4 Studies reporting bacteria which have glucosinolate metabolising ability. 
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Bacteria/faecal microbiota Study Method Reference 
Escherichia coli O157:H7 
Staphylococcus carnosus 
Staphylococcus auerus       
Pediococcus pentosaceus    
Salmonella typhimurium            
Listeria monocytogenes    
Enterococcus feacalis      
Pseudomonas fluorescens 
in vitro incubation in media [218] 
Human feacal microflora a batch fermentation model [165] 
Lactococcus lactis subsp lactis KF147 
Lactobacillus plantarum KW30 
Escherichia coli Nissle 1917 
Enterobacter cloacae ATCC13047 
in vitro incubation in media [55] 
Listeria monocytogenes and              
Salmonella  
in vitro incubation in media [219] 
Enterococcus casseliflavus CP1          
Escherichia coli VL8 
in vitro incubation in media [56] 
Table 1.4-Continued  
A previous study investigated the sinigrin degrading activity of 42 lactobacilli and a strain 
called Lactobacillus agilis R16 showed the highest sinigrin transformation. The study showed 
this activity with sinigrin can be induced by the presence of the substrate sinigrin itself in 
culturing media. When L. agilis R16 was grown in media with sinigrin and glucose, the glucose 
was used immediately then sinigrin degradation started and resulted in 80% reduction of 
sinigrin in 4 h and total reduction in 24 h. Analysis of sinigrin degradation products showed 
the production of allyl ITC (AITC) and lactic acid [210]. The study also showed that cell-free 
extracts lack sinigrin degrading activity. This indicates that a cell-associated activity is 
involved. This phenomenon was further supported by another study by Luang-In et al. (2014) 
[56].  
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Bacteroides thetaiotaomicron, a human gut isolate, was studied for its ability to degrade 
sinigrin in a gnotobiotic rat model [112]. An oral dose of 50 µmol sinigrin was given to 
gnotobiotic rats harbouring B. thetaiotaomicron. Sinigrin was metabolised in the large bowel 
that host high level of B.  thetaiotaomicron. By GC-MS analysis, allyl ITC, hydrolysis product of 
sinigrin, was detected in the digestive contents [112]. 
NMR spectroscopy was used to study the biotransformation of two dietary glucosinolates, 
sinigrin and glucotropaeolin by the human digestive microflora in vitro. It was shown that 
sinigrin and glucotropaeolin were transformed into allylamine and benzylamine, respectively 
and there was a low ITC formation (10-20% of the initial glucosinolate amount). Whether 
these amines are produced in vivo from dietary glucosinolates or not remains to be 
established. The effect of glucose in transformation of glucosinolates was also examined and 
the study showed that the presence of glucose did not modify the nature of the metabolites 
or the rate of transformation [211].  
The dynamic in vitro large intestinal model was used to study the AITC production from 
sinigrin by human gut microbiota [212]. Sinigrin and AITC concentrations were determined in 
the lumen and dialysis fluid of the model using two different concentrations (1 mM and 15 
mM) of sinigrin. AITC formation was observed and the percentage conversion of sinigrin to 
AITC was 1% and 4% in the lumen, respectively. The control experiment with inactivated 
microflora did not result in AITC formation. The concentration of AITC peaked between 9 and 
12 h after addition of sinigrin. The study also suggested that different individual human 
microbiota result in significantly different conversion rate of sinigrin to AITC (9.6-30. 4% of 
sinigrin) [212].  
The role of plant myrosinase and gut bacterial myrosinase on transformation of 
glucosinolates to ITCs were studied in a gnotobiotic rat model [213]. Glucosinolate 
biotransformation in gnotobiotic rats with a whole human fecal microbiota (Flora +) was 
compared to germ-free rats (Flora-). Active (Myro+) or inactive myrosinase (Myro-) were 
added to rat diet to determine the effect of plant myrosinase. The excretion of ITCs as 
mercapturic acid derivatives in urine was determined. The results indicated that highest 
excretion was performed by germ-free rats having active myrosinase in their diet (Flora-, 
Myro+ treatment) and a lower excretion was seen in rats with human flora when fed with 
inactive myrosinase (Flora+, Myro- treatment). The study suggested that the human 
microbiota can reduce the available ITC for intestinal absorption and this can be caused by 
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further metabolism of ITCs in the digestive tract. This study concluded that plant myrosinase 
and human gut microbiota both contributed to the degradion of glucosinolates into ITCs in 
vivo [213].  
Cheng et al. studied B. pseudocatenulatum, B. adolescentis and B. longum for their ability to 
utilise sinigrin and glucotropaelin in vitro [214]. It was found that bacteria used in the study 
were hardly able to grow in basal medium without glucose in presence of 2.3% sinigrin but 
these bacterial strains used sinigrin as a glucose source. The study concluded that 
Bifidobacterium strains are able to utilize both sinigrin and glucotropaelin. However, GC-MS 
analysis results showed that the main products were 3-butene-nitrile. Phenylacetonitrile and 
AITC or benzyl isothicyanate (BITC) were hardly detectable. This result might be caused by 
rapid degradation of ITCs or transformation into non-volatile derivates [214].  
The study examining the ex vivo degradation of glucoraphanin by rat cecal microbiota 
produced evidence for glucoraphanin hydrolysis to sulforaphane and its absorption across the 
cecal walls of rats [215]. Glucoraphanin (150 µmol/kg BW) was directly introduced into the 
cecum and ITC was detected in the mesenteric plasma by 120 min and plasma levels were 
stably maintained for an hour [215].  
A study tested if individual differences in the human gut microbiota can result in different 
levels of glucosinolate metabolism. Twenty-three healthy individuals were fed with cooked 
broccoli and ITC levels in urine samples were measured. The highest and lowest 5 ITC 
excreters were selected for feacal sample collection. T-RFLP analysis of 16S rRNA gene 
revealed that there was no significant differences between high or low excreters' microbiota 
composition. However, high ITC excreters were able to degrade more glucoraphanin than low 
excreters. The study could not find a direct link between glucosinolate metabolism and 
specific bacterial species. It was suggested that this might be caused the complexity and 
functional redundancy of the gut microbiota [216].  
Saha et al. (2012) studied the glucosinolate bioconversion by the human gut microbiota in a 
batch fermentation model using glucosinolates and fecal inoculum from a healthy volunteer. 
Glucoraphanin decreased after 4 h of incubation and mostly degraded after 24 h incubation. 
Glucoerucin was first detected at 8 h and further increased after 24 h. The study concluded 
that glucoraphanin was transformed into glucoerucin and erucin nitrile by the gut microbiota 
[165].  
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Luang-In et al. (2014) investigated the metabolism of glucoerucin, glucoiberin and 
glucoraphanin by gut bacterial strains in vitro. Lactobacillus agilis R16, Enterococcus 
casseliflavus CP1 and Escherichia coli VL8 were tested for the metabolism of glucosinolates 
supplied to their media. All three bacteria were able to degrade glucoerucin to erucin and 
erucin nitrile by 16 h. E. coli VL8 showed degradation of glucoiberin and glucoraphanin. The 
metabolism of glucoraphanin and glucoiberin by E. coli VL8 also resulted in erucin, erucin 
nitrile and iberverin, iberverin nitrile production respectively. A potential reductase enzyme 
has been proposed to be responsible for this bioconversion and the enzyme was reported to 
require both Mg2+ and NAD(P)H as cofactors. E. casseliflavus CP1 could consume 41 ± 7% of 
glucoiberin and 53 ± 8% of glucoraphanin and resulted in the formation of iberin and 
sulforaphane in low concentrations over a 24 h anaerobic fermentation. However, L. agilis 
R16 degraded only 11 ± 1% of glucoiberin and 10 ± 2% of glucoraphanin without giving any 
detectable products [56]. Following this study, desulfoglucosinolates were used to test their 
degradation by L. agilis R16, E. casseliflavus CP1 and E. coli VL8. All three metabolised 
desulfo-glucosinolates and gave pure nitriles products excluding L. agilis R16 which failed to 
produce  phenethyl nitrile from gluconasturtiin [57].  
Rats were found to be capable of metabolising glucosinolates in rapeseed meal after the 
myrosinase in the meal was inactivated [220]. This study was followed by more research and 
axenic rat and chickens were tested for glucosinolate metabolism in their guts. However, 
these studies did not result in identifying a responsible bacterial strain for this metabolism.  
In brief, all these studies showed that several different phylogenetic families are involved in 
glucosinolate metabolism. It has not been possible to attribute glucosinolate degrading ability 
to only a specific group of bacteria so far.  
1.10 SCOPE OF THE THESIS 
As cancer is a very dreadful disease that is on the increase. It is important to take every single 
measure to fight with this cancer. The chemopreventation against cancer by bioactive 
compounds in the diet is one of the ways to combat the cancer. ITCs are very promising 
compounds for chemopreventation so it is essential to determine the glucosinolate 
metabolism and the effects of degradation products on human health. A better 
understanding of glucosinolate metabolism by human gut bacteria and identification of the 
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key enzymes in the metabolism are needed. So far, various bacteria from human gut have 
been reported to have glucosinolate degrading and ITC producing ability and their myrosinase 
activity was characterised. However, we lack the information about the enzymes responsible 
for glucosinolates metabolism in the human gut. In order to investigate these enzymes: 
1. A glucoraphanin enrichment method will be used to isolate various bacteria 
possessing glucosinolates degrading ability from the human gut. Genomes of the 
isolated bacteria will be sequenced, annotated and assembled for interrogation in 
search for candidate myrosinase enzymes. 
2.  Selected candidate myrosinase genes from the bacteria will be cloned and 
expressed in E. coli. Enzyme activity of recombinant proteins will be examined and 
characterised in detail.  
3. In addition to myrosinases, reductases which are proposed to play a key role in 
glucosinolates metabolism will be investigated. Different putative reductase genes 
from the genomes of human gut bacteria will be cloned and expressed in E. coli. 
The reductase activity of the recombinant reductases will be assessed.  
4. Finally, a bacterial myrosinase of soil origin will be cloned and expressed in E. coli 
to achieve enzyme activity characterisation.  
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CHAPTER TWO 
 
2 GENERAL MATERIALS AND METHODS 
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2.1 MICROBIOLOGY METHODS 
All chemicals were purchased from Sigma Aldrich (Dorset, UK) unless stated otherwise.  
2.1.1 Culture Media 
All media used in the study are given below with their compositions. 
Chemostat Media:  2 g peptone water (Oxoid), 2 g yeast extract (Oxoid), 0.1 g NaCI, 0.04 g  
K2HPO4, 0.04 g KH2PO4, 0.01 g MgSO4.7H2O, 0.01 g CaCI2.2H20, 2 g NaHCO3,  2 ml Tween 80, 
10 µl Vitamin K1, 0.5 g cysteine. HCI, 0.5 g bile salts (Oxoid), 0.02 g Hemin in 1 liter of water 
adjusted to pH 8.6 with 1 M NaOH.  
M9 Minimal Media (without glucose): 6 g Na2HPO4, 3 g KH2PO4, 0.5 g NaCI, 1 g NH4CI, 0.147 g 
CaCI2, 2.47 g MgSO4, 1.5 ml of 10 mg/ml threonine stock, 11 ml of 10 mg/ml leucine stock, 
0.23 g proline, 0.13 g arginine, 6.5 ml of 10 mg/ml histidine stock, 1.7 ml of 10 mg/ml 
thiamine stock in 1 liter of water.  
Rogosa Agar:  10 g tryptone (Oxoid), 5 g yeast extract (Oxoid), 20 g glucose, 1 ml Tween 80, 
6.0 g KH2PO4, 2.0 g ammonium citrate, 17.0 g anhydrous NaOAc, 0.575 g MgSO4, 0.12 g 
MnSO4, 0.034 g FeSO4, 20 g agar (Oxoid) in 1 liter of water, pH was adjusted to 5.4 with glacial 
acetic acid.   
Beerens Agar: 39 g Colombia agar base (Oxoid), 5 g glucose, 0.5 g cysteine. HCI, 5 g agar 
(Oxoid), 5ml   propionic acid in 1 liter of water, pH was adjusted 5 with 1 M NaOH.   
Wilkins Chalgren Media (without glucose): 10 g tryptone (Oxoid), 10 g peptone (Oxoid), 5 g 
yeast extract (Oxoid), 5 g NaCI, 10 g agar (Oxoid) 1 g L-Arginine, 1 g sodium pyruvate, 0.005 g 
Hemin, 0.0005 g Vitamin K in 1 liter of water (pH 6.5 ± 0.2). Solid media contains 10 g agar 
(Oxoid).  
Bacteriodes Agar: 13 g agar, 10 g casein peptone, 1 g glucose, 10 g meat peptone (Oxoid), 5 g 
NaCI, 2 g yeast extract (BD), 10 ml of 0.5 mg/ml Hemin solution, 3 ml of 25 mg/ml Kanamycin, 
7.5 ml of 1 mg/ml Vancomycin, 50 ml laked horse blood (Oxoid) in 1 liter of water (pH: 7.0 ± 
0.2) 
Clostridia Agar: 10 g tryptone (Oxoid), 10 g peptone (Oxoid), 5 g yeast extract (Oxoid), 5 g 
NaCI, 10 g agar (Oxoid), 1 g L-Arginine, 1 g sodium pyruvate, 0.005 g Hemin, 0.0005 g Vitamin 
K, 8 ml of  1 mg/ml Novobiocin solution, 8 ml of 1 mg/ml Colistin solution in 1 liter of water 
(pH 6.8 ± 0.2).  
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BHI Media: 12.5 g brain heart infusion solids (Oxoid), 5.0 g beef heart infusion solids, 10.0 g 
proteose peptone (Oxoid), 2.0 g glucose, 5.0 g NaCI, 2.5 g Na2HPO4 in 1 liter of water (pH 7.4 
± 0.2).  
MRS Media (without glucose): 8 g Lab Lemco (Oxoid), 10 g peptone (Oxoid),  5 g Difco yeast 
extract (BD), 5 g NaOAc.3H2O, 2 g K2HPO4, 2 g triammonium citrate, 1 ml Tween 20, 5 ml of 
11.5% MgSO4.7H20 solution, 5 ml of 2.8% MnSO4.4H2O solution in 1 liter of water (pH 6.5 ± 
0.2). Solid media contains 20 g agar (Oxoid). 
Nutrient Broth (without glucose):  5 g peptone (Oxoid), 1.5 g Lab Lemco (Oxoid), 1.5 g yeast 
extract (Oxoid), 5 g NaCI in 1 liter of water (pH 6.8 ± 0.2).  
L Broth: 10 g Difco Bacto tryptone (BD), 5 g Difco Bacto yeast extract (BD), 10 g NaCI, 1 g 
glucose in 1 liter water (pH 7.0 ± 0.2).   
SOC Broth: 20 g Difco Bacto tryptone  (BD),  5 g Difco Bacto yeast extract (BD), 0.5 g NaCI in 1 
liter of water.   
2.1.2 Preparation of Antibiotic Stock Solutions 
The antibiotic stock solutions were prepared according to laboratory cloning manual [221] 
then sterilised by filtration using 0.22 µm filters. The aliquots were stored at -20°C until 
usage. The stocks were listed below in Table 2.1.  
Antibiotic Concentration of the stocks Final concentration 
Ampicillin 50 mg/ml in H2O 100 µg/ml 
Kanamycin 10 mg/ml in H2O 30 µg/ml 
Table 2.1 Antibiotic stock solutions used in this study.  
2.1.3 Isolation of Glucosinolate Degrading Bacteria by Glucoraphanin Enrichment 
A faecal sample from a healthy volunteer (5 g) was homogenized in 45 ml of phosphate 
buffered saline (PBS) with a stomacher (Stomacher 400 Circulator, Seward) at 230 rpm for 2 
min. The homogenate (100 µL) was used to inoculate the chemostat media or M9 minimal 
media both containing 8 mM glucoraphanin (900 µL) and these cultures were grown in an 
anaerobic cabinet (Whitley A95 anaerobic work station, Don Whitley Scientific) under an 
atmosphere of 5% CO2, 10% H2 and 85% N2. Aliquots were diluted (10 fold) in corresponding 
media containing 8 mM glucoraphanin every two days. At day eleven, cultures were diluted in 
PBS and plated on 6 different media including Rogosa, Beerens, Wilkins Chalgren, 
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Bacteriodes, Clostridia and BHI. Individual colonies from these plates were selected and 
streaked on BHI agar twice for purity.  
2.1.4 Bacterial Strains and Culture Conditions 
Escherichia coli VL8, Escherichia coli FI10944 and Enterococcus casseliflavus were isolated 
from human gut by using sinigrin enrichment by Dr. Vijitra Luang-In at Institute of Food 
Research and Lactobacillus agilis R16 was provided by Dr. Llanos-Palop (Table 2.2).   
Bacterial Strain Enrichment 
Method 
Growth 
Condition 
Media 
Lactobacillus agilis R16 [56] * 37°C, 200 rpm MRS Broth 
Escherichia coli VL8 [56] Sinigrin 37°C, 250 rpm L Broth 
Escherichia coli FI10944 Sinigrin 37°C, 250 rpm L Broth 
Enterococcus casseliflavus CP1 [56] Sinigrin 37°C, 200 rpm BHI Broth 
Escherichia coli FC44 Glucoraphanin 37°C, 250 rpm Nutrient Broth 
Citrobacter freundii FC50 Glucoraphanin 37°C, 250 rpm Nutrient Broth 
Citrobacter WYE1 [118] Sinigrin 37°C, 250 rpm Nutrient Broth 
Escherichia coli DH5αa * 37°C, 250 rpm L Broth 
Escherichia coli BL21(DE3)b * 37°C, 250 rpm L Broth 
Table 2.2 Bacterial strains used in the study. a Escherichia coli DH5α and b Escherichia coli 
BL21(DE3) were obtained from ThermoFisher Scientific. *These strains were not isolated by a 
glucosinolate enrichment method.  
 
Bacterial isolates were grown overnight and cultures were used to prepare 1 ml of glycerol 
stocks (20% v/v) then stocks were frozen on dry ice and stored at -80°C.  
Optical cell density (OD600) was measured with a JENWAY 6715 UV/Vis Spectrophotometer 
(Staffordshire, UK) using bandwidth 1.5 nm wavelength 600 nm.  
2.1.5 Bacterial Growth Analysis 
Growth of strains was analysed over time using a Bioscreen C machine (Labsystems). 
Corresponding media for each strain was inoculated with 1% (v/v) concentration of overnight 
grown culture then inoculated media was transferred to Bioscreen plate wells (Honeycomb, 
ThermoFisher Scientific), 300 µl of each inoculated media was used per well. Growth was 
screened for 48 h at an appropriate temperature for each strain. Measurements were 
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performed at 600 nm with 10 min measurement intervals with shaking for 10 seconds before 
each measurement.  
2.1.6 Scanning Electron Microscopy (SEM) 
L. agilis R16, E. coli FI10944 and E. casseliflavus CP1 were grown overnight from bacterial 
stocks. These cultures (2 X 1 ml) were centrifuged at 3000 x g for 2 min at room temperature. 
The supernatants were removed and the pellets were resuspended in 1 ml PBS. To produce a 
final concentration of 2.5% (v/v) glutaraldehyde (Sigma, UK), 110 µl of 25% (v/v) 
glutaraldehyde was added to the tubes and left for 1 h to complete the fixation.  
After fixation, each sample analysed by Rachael Stanley at Institute of Food Research. 
Scanning electron microscopy was performed using a Zeiss Supra 55 VP FEG SEM (Zeiss, 
Germany) operated at 3 kV.   
2.2 MOLECULAR BIOLOGY  
2.2.1 Polymerase Chain Reaction (PCR) 
Bacterial genomic DNA was used as template to amplify the genes of interest using High 
Fidelity Phusion Polymerase (Finnnzymes) according to supplier`s instructions. Reactions were 
set up as in Table 2.3 and performed as in Table 2.4. 
Components Volume (µl) Final 
Concentration 
5X Phusion Buffer 10 1X 
100 mM dNTPs 0.4 0.2 mM each 
20 µM Forward Primer 1.25 0.5 µM 
20 µM Reverse Primer 1.25 0.5 µM 
Phusion Polymerase (2 U/µl) 0.4  
Template DNA 1 <50 ng/50 µl 
Sterile MQ water 34.7  
Total Volume 50  
Table 2.3 Components of one PCR for amplification of the gene of interest. 
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The annealing temperatures and conditions were changed depending on primers. In general, 
the reactions were carried out as shown in Table 2.4 for 5 cycles using Tm of 100% sequence 
match part of primers first and then 20 cycles using the Tm of entire primers.  
 
           Steps 
Temperature 
(°C) 
Time Cycle(s) 
1  Initial Denaturation 98 30 s 1 
2 Denaturation 98 10 s  
 Annealing T1 30 s 5 
 Extension 72 30 s/kb  
3 Denaturation 98 10 s  
 Annealing T2 30 s 20 
 Extension 72 30 s/kb  
4 Final Extension 72 5min 1 
Table 2.4 PCR conditions for amplification of the gene of interest. 
2.2.2 Gel Electrophoresis 
To check the sizes of DNA fragments, agarose gels were prepared at 0.6% (to check genomic 
DNA samples) or 1% (g w/v). 5-10 µl of DNA samples were loaded to the wells of agarose gel 
and run in 0.5X Tris Borate EDTA buffer (ThermoFisher Scientific). The gels were stained in 1 
mg/ml ethidium bromide for 20-30 min then rinsed in deionized water. After electrophoresis, 
the gels were visualised with an Alphaimager (Alpha Innotech) using UV light. The size of 
products was determined by running a DNA marker for every electrophoresis (HyperLadder, 
Bioline).  
2.2.3 Plasmid Preparation 
For cloning and expression of the genes of interest, either pET15b or pET28b vectors 
(Novagen) were used. While the pET15b vector has an N-terminal His Tag sequence, the pET-
28b vector also carries an optional C-terminal His Tag sequence (maps of the vectors are 
given in Appendix 1). The E.Z.N.A Plasmid Mini Kit I (Omega Bio-Tec) was used to purify the 
plasmids following the supplier`s protocol.  
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2.2.4 Enzyme Restrictions   
Reactions were set up in 15-40 µL volumes following the supplier`s advice (New England 
Biolabs, UK). After digestion, enzymes were heat inactivated and the products were purified 
by SureClean (Bioline) to remove the restriction enzymes.  
2.2.5 Dephosphorylation of Digested Plasmids 
To prevent the recirculation of digested plasmids, Antarctic Phosphatase (New England 
Biolabs, UK) was used to remove 5’ phosphate groups. The dephosphorylation reactions 
contained ~ 1 µg of the digested vector, 1X Antarctic Phosphatase Buffer, 1 µl Antarctic 
Phosphatase and incubated for 15 min at 37°C for 5’ extensions or blunt ends or 60 min for 3’ 
extensions. After incubation, enzymes were heat-inactivated by incubating at 65°C for 5 min.  
2.2.6 Primer Design 
Primers were ordered from Sigma Genosys. For subcloning, primers were designed with 
restriction sites on forward (shown as blue) and reverse (shown as green) site of the target 
gene (shown as red) (Figure 2.1).   
 
Figure 2.1 Illustration of a PCR with forward and reverse primers. 
Primers were designed to be between 18-24 nucleotide long with an annealing temperature 
between 45-65°C. It is advised to have a GC clamp at 3′-end of the primers and not to have 
the more than 4 repeats of the same nucleotide. The restriction enzymes need a certain 
amount of base pairs at the start of recognition site to cleave efficiently. The numbers of base 
pairs needed for successful recognition was obtained from the New England Biolabs website 
(https://www.neb.com/tools-and-resources/usage-guidelines/cleavage-close-to-the-end-of-
dna-fragments) and these amount of base pairs were added to the primers. The primers also 
consisted of at least 15 bp of 100% complementary sequence to the gene of interest if 
introducing a new restriction site.  The melting temperature of the entire primers and  100% 
match part were calculated by using the ThermoFisher Scientific Tm Calculator 
(https://www.thermofisher.com/uk/en/home/brands/thermo-scientific/molecular 
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biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-
scientific-web-tools/tm-calculator.html). Sigma OligoEvaluator tool was also used to assess 
primer design (http://www.sigmaaldrich.com/technical-documents/articles/biology/oligo-
evaluator.html). 
2.2.7 PCR Product Purification 
The PCR products (5 µl) were analysed on 1% agarose gel and checked to have expected 
product sizes. The rest of the products were purified using SureClean (Bioline) and quantified 
using Nanodrop 2000 (ThermoFisher Scientific). 
2.2.8 DNA Ligation 
Ligations were performed using Fastlink DNA Ligase (Epicentre) following the supplier`s 
protocol with the given components in Table 2.5. The reactions were performed in a total 
volume of 15 µl. The volumes of insert and vector were varied depending on their 
concentrations but final concentration of vector in all ligations was kept as 10 ng/µl and the 
molar ratio between vector and insert was 1:3 (vector: insert). The ligations were incubated 
at room temperature overnight and then heat-inactived at 70°C for 15 min. The heat-
inactivated ligations were used directly for transformation of E. coli. 
Components Volume 
Double Digested Vector 3 µl (10 ng/ml, in 15 ml reaction) 
Gene Insert 1 µl  
10X Fast Link Ligation Buffer 1.5 µl 
10 mM ATP 1.5 µl 
Sterile MQ water 7 µl  
Fast Link DNA Ligase (2  U/µl) 1 µl 
Total Volume 15 µl 
Table 2.5 Components of one DNA ligation reaction. The molar ratio of vector: insert was 
1:3.  
2.2.9 Preparation of Chemically Competent Cells 
Transformation buffers were prepared as given in the Table 2.6. Buffer 1 was adjusted to pH 
5.8 with 0.2 M acetic acid and Buffer 2 was adjusted to pH 6.4 with KOH then they were both 
filter sterilised and kept at 4°C. L Broth (5 ml) was inoculated with E. coli DH5α or BL21(DE3) 
strains from -80°C stocks and grown overnight at 37°C, 200 rpm with shaking. Next day, 
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overnight cultures were subcultured (1:100) into 50 ml of fresh L Broth. Cultures were grown 
at 37°C, 200 rpm shaking until OD600 reached 0.3-0.35. The cells were spun down for 7 min at 
1,500 x g at 4°C then resuspended in 20 ml of Buffer 1 and were left on ice for 5 min. The cells 
were then spun down for 7 min at 1,500 x g at 4°C and resuspended in 2 ml of Buffer 2. The 
cell suspension was transferred to prechilled Eppendorf tubes as 110 µl stocks. The stocks 
were used as soon as possible or frozen immediately on dry ice for long term storage and 
kept at -80°C.  
Buffer 1 composition Stock solutions V of stock solution for 50 ml 
TFbI 
30 mM potassium acetate 300 mM 5 mL 
100 mM rubidium chloride 500 mM 10 mL 
10 mM calcium chloride 100 mM 5 mL     
50 mM manganese chloride 200 mM 12.5 mL 
15% glycerol (v/v) 100% 7.5 mL 
Distilled water  10mL 
    
Buffer 2 composition   Stock 50 ml 
10 mM 3[N-Morpholino]Propanesulfonic 
Acid (MOPS) 
 100 mM 5 mL 
75 mM calcium chloride  100 mM 37.5 mL 
10 mM rubidium chloride  500 mM 1 mL 
15% glycerol (v/v)  7.5 mL 
Table 2.6 Components of buffers used in competent cell preparation. 
2.2.10 Transformation of E. coli  
Freshly prepared or stored E. coli DH5α or BL21 (DE3) chemically competent cells were 
thawed and incubated on ice for 10 min. The transformation was set up by adding ligation 
reactions (<100 ng DNA per 50 µl cells) to 50 µl of competent cells and incubated on ice for 30 
min. After incubation, cells were exposed to heat shock at 42°C for 45 s and immediately put 
on ice again for 2 min then 250 µl of SOC broth was added.  The cells were incubated at 37°C 
for at least 1 h shaking, 200 rpm.  After incubation, 25 µl and 100 µl of cultures were plated 
on selective agar. The final antibiotic concentration was 100 µg/ml of ampicillin for pET15b 
and 30 µg/ml kanamycin for pET28b. 
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2.2.11 Selection of the Positive Transformants 
L Agar plates were prepared with the final antibiotic concentration of 100 µg/ml ampicillin 
and 30 µg/ml kanamycin for pET15b and pET28 respectively. After transformation, the 
colonies grown on selective plates were selected randomly and colony PCR was performed to 
determine if these colonies have the right gene fragment of interest. Colony PCR was set up 
to screen the colonies for plasmids with right insert. The colonies were picked and 
resuspended in 10 µl of sterile Milli-Q water (1 µl of this was used as DNA template for PCR). 
The products were amplified by PCR using the primers T7P2: 5': TGAGCGGATAACAATTCCC, 
Tm: 62.3 oC and T7_T: 5': GCTAGTTATTGCTCAGCGC, Tm: 60.1oC (Sigma Genosys) and 1 µl of 
toothpicked colony suspension as DNA template. Colony suspension was replaced with sterile 
MQ water or empty vector control (pET15b or pET28b) for negative and positive controls. The 
reactions were set up as shown in Table 2.7.    
a 
Component  Quantity  b 
DNA Template 1 µl  PCR conditions 
5X GoTaq Reaction Buffer 
(Promega) 
10 µl  Temp , time cycles 
dNTP 25 mM each (Bioline) 0.4 µl  95°C, 2 min 1  
Primer F 20 mM 1 µl  95°C, 30 s  
Primer R 20 mM 1 µl  55°C, 30 s 25 
GoTaq DNA Polymerase (5 U/µl) 0.25 µl  72°C, 1min/kb  
Water 36.35 µl  72°C, 5min 1 
Total  50 µl    
Table 2.7 Components in one colony PCR (a) and thermal cycling conditions (b).  
2.2.12 16S rDNA Sequencing 
An overnight culture (150 µl) was centrifuged at 13000 x g, the pellet was washed and 
resuspended in 15 µl sterile Milli-Q water. The pellet was boiled at 95°C for 5 min, cooled on 
ice and 1 µl of this was used as DNA template in PCR.  The gene was amplified using the 
primers AMP_F: 5'-GAG AGT TTG ATY CTG GCT CAG Tm: 60.5, AMP_R: 5'-AAG GAG GTG ATC 
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CAR CCG CA Tm: 68.9 [222] to give a product of approximately 1500 bp. PCR was set up as 
given in Table 2.8.  
    a 
Component  Quantity  b 
DNA Template 1 µl  PCR conditions 
5X GoTaq Reaction Buffer 
(Promega) 
10 µl  Temp, time cycles 
dNTPs 25 mM each (Bioline) 0.4 µl  95°C, 2 min 1  
Primer F 20 µM 1 µl  95°C, 30 s  
Primer R 20 µM 1 µl  55°C, 30 s 20 
GoTaq DNA Polymerase (5 U/µl) 0.25 µl  72°C, 1min 30s  
Water 36.35 µl  72°C, 5min 1 
Total  50 µl    
Table 2.8 Components in one PCR reaction (a) and thermal cycling conditions (b)In addition, 
a negative control (without template) was prepared. PCR products (10 µl) were analysed by 
agarose gel electrophoresis to check the size of the products. PCR products were purified by 
QIAquick PCR purification kit (QIAGEN) and quantified by a Nanodrop 2000 spectrometer 
(ThermoFisher Scientific). Products were sequenced with both primers (Eurofinn Genomics). 
Finch TV was used to check chromatogram quality (sequence quality), the reliable sequences 
were selected and copied to EditSeq (DNAStar) and saved. Then these sequences were 
assembled by using Seqman (DNAStar) to create a contig and this contig was searched on RDP 
database (https://rdp.cme.msu.edu/seqmatch/seqmatch_intro.jsp). 
2.2.13 Genomic DNA Extraction, Sequencing, Assembly and Annotation 
Genomic DNA of strains was extracted by using the Genomic DNA extraction kit with Genomic 
Tip 20/G columns (QIAGEN) as advised by the supplier. To enhance the cell lysis of L. agilis 
R16, 50 Units of mutanolysin (Sigma) was added. Genomic DNA of E. coli FI10944, E. 
casseliflavus CP1, L. agilis R16 and C. WYE1 was sequenced by The Genome Analysis Centre 
(TGAC), Norwich, UK, using the Illumina MiSeq platform. DNA sequencing resulted in small 
reads of DNA with a read length of 251bp (2x251, paired end). These small reads were 
analysed using different bioinformatics tools step by step. Sickle [223] , Abyss [224] and CAP3 
[225] were used to produce quality-trimmed extended contigs from these small reads.  
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Genomic DNA of Isolate 44 and E. coli VL8 was sequenced at University of Birmingham, 
MicrobesNG Unit, Birmingham, UK. The sequencing was performed using NexteraXT library 
prep on two MiSeq runs and produced 2x250bp paired-end reads. Genomic DNA assembly of 
E. coli FC44, E. coli VL8 and C. WYE1 was performed by using SPAdes. The reads were 
analysed and quality-trimmed extended contigs were produced by using the SPAdes program 
version 3.5.0 [226].  
Genomic DNA of C. freundii FC50 was sequenced at the Animal and Plant Health Agency, NGS 
Services Unit, Surrey, UK. The sequencing was performed using the Ilumina MiSeq platform, 
producing 150bp paired end reads. Genomic DNA assembly was performed using SPAdes 
program version 3.7.1 [226]. Following assembly, contigs were analysed by ARTEMIS [227] 
and annotated by RAST [228]. 
2.2.14 Preparation of Phylogenetic Tree 
The 251 bp length of DNA reads from Genomic DNA sequencing were analysed and quality-
trimmed extended contigs were produced by using SPAdes program version 3.6.1 [226]. 
These contigs of Citrobacter were used to construct a phylogenetic tree. Draft genomes of 
different Citrobacter species were obtained from Genbank whole genome shotgun projects. 
Core genome SNPs in draft genomes and  C. WYE1 were used to prepare the 
phylogenetic  tree using the parSNP program Version 1.2 by Dr. Arnoud Van Vliet [229].  
2.3 PROTEIN BIOCHEMISTRY 
2.3.1 Induction of Protein Expression and Cell-Free Extract Preparation 
Isopropyl-β-D-1-thiogalactopyranoside (IPTG) was used to induce protein expression in E. coli 
BL21(DE3) expressing the gene of interest. The cells were inoculated in L broth with antibiotic 
(10 ml) from -80°C stocks and grown overnight at 37°C, 250 rpm. Next day, 10 ml L broth with 
antibiotic medium was inoculated with 200 µl of the overnight culture and grown until midlog 
(OD600=0.4) then cells were induced with 0.5 mM IPTG.  
For each of the expressed protein, the effect of several time points and temperatures on 
protein expression was tested to determine the optimum protein expression conditions. E. 
coli BL21 (DE3), transformed with pET15b or pET28b (empty vector control) was also induced 
as a negative control.  After induction, cells were harvested by centrifugation for 15 min at 
3200 x g at 4°C, the supernatant was removed and the pellet was frozen at -20°C. Later, the 
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cell pellet was resuspended in 500 µl of 20 mM Tris base 50 mM NaCI pH 7.5 (resuspension 
buffer) unless a different buffer is stated. The cells were extracted by sonication (Soniprep 
150, MSE) by sonicating for 15 s and were keeping on ice for 30 s to cool down. This step was 
repeated 7 times for each sample.  After sonication, the suspensions were centrifuged for 25 
min, 13000 x g at 4°C. The supernatants were transferred into new clean tubes (soluble 
extracts), 500 µl resuspension buffer was added to the cell pellet (insoluble extracts). The 
suspensions and extracts were always kept on ice.  
2.3.2 Protein Quantification 
The protein concentration of samples was determined using the Bradford assay (Bio-Rad, UK). 
The reactions were set up in 96 well plates (Greiner Bio-One, Austria) in triplicates. Bovine 
serum albumin (BSA) (New England Biolabs, UK) was used to prepare a calibration curve. BSA 
was prepared in different concentrations between the range of 0-200 µg/ml then the samples 
were diluted to ensure that protein concentration will fall within a 0-200 µg/ml range. 
Bradford assay concentrate was diluted 100X and added to samples and BSA solutions. The 
absorbance was measured at 600 nm using a ThermoMax Plate Reader (GMI, US).  A 
calibration curve of BSA was prepared (Figure 2.2) and protein concentrations of samples 
were determined.  
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Figure 2.2 A reference calibration curve of Bradford assay. Different amounts of BSA were 
plotted against the absorbance at 600 nm.  
2.3.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE materials were purchased from Invitrogen (ThermoFisher Scientific, UK). The 
proteins were mixed with LDS sample buffer and reducing agent (under reducing conditions) 
as advised by the supplier and then heat denaturated by heating at 70°C for 10 min. The 
proteins (mainly ~10 µg) were loaded on a NuPAGE®4-12% Bis-Tris protein gel in MES buffer 
and placed in a X-Cell Sure Lock electrophoresis cell.  
The SeeBlue Plus2 protein marker (Figure 2.3) was used to determine the protein sizes of the 
samples. For reducing conditions, 500 µl of NuPAGE® antioxidant was added to the internal 
reservoir. The protein gel was run for 35 min at 200 V. Then the gel was removed from cell 
then either washed three times in MQ water and stained with Simply Blue SafeStain or 
directly stained by Instablue dye (Expedeon, US) for 1 h.  
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Figure 2.3 See Blue Plus2 protein marker (Invitrogen) on a 4-12% Bis-Tris gel with different 
buffers.  
2.3.4 Western Blotting 
Western Blot procedure was used to purify the 6XHis- tagged proteins of interest.  SDS-PAGE 
gel was run as described previously (Section 2.3.3) and the proteins were transferred from 
protein gel to polyvinylidene difluoride (PVDF) membrane using a XCell II Blot module 
(Novagen, Germany).  NuPAGE® Transfer Buffer (20X) buffer was prepared as advised by 
supplier and used in preparation of 1X transfer buffer (See Table 2.9).  
Components Volume (ml) 
NuPAGE®Transfer Buffer (20X) 
 
 25 
  NuPAGE® Antioxidant  0.5 
  Methanol  50 
  Deionized water 424.5 
Total 500.0 
Table 2.9 Components in NuPAGE® Transfer Buffer (20X) buffer. 
The blotting pads were soaked in transfer buffer at least 20 min before use. The PVDF 
membrane was pre-wetted in methanol and rinsed in deionised water and placed in 50 ml of 
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NuPAGE® Transfer Buffer before use. The filter papers were briefly soaked in NuPAGE® 
Transfer Buffer prior to use. The blot module was set up as shown in the Figure 2.4 within the 
order from cathode core; two blot pads, filter paper, protein gel, PVDF membrane, filter 
paper and two more blot pads.  All components were set up to contact each other to perform 
the transfer efficiently and blot module was placed in buffer chamber. The blot module was 
filled with 1X NuPAGE® Transfer Buffer to cover the gel and membranes. Excessive amount of 
buffer was avoided for a successful transfer. The outer chamber was filled with ~650 ml of 
MQ water and transfer was performed at 12V for 3 h. 
 
Figure 2.4 Western blot module set up order. 
The transfer membrane was removed from the Blot module and placed in a clean container. 
The membrane was washed twice for 10 min with 10 mM Tris.CI 150 mM NaCI pH:7.5 (TBS 
buffer) then incubated in 10 ml of 3% BSA in TBS buffer (blocking buffer) at room 
temperature by shaking. After blocking, membrane was washed twice with 50 ml of TBS-
Tween/Triton buffer then once with TBS buffer and incubated with primary antibody, His-tag 
monoclonal antibody, (Novagen) for 1 h by shaking gently. The primary antibody was 
prepared in 5 ml of blocking buffer by adding 2.5 µl of antibody (200 ng/µl). The membrane 
was washed twice with TBS-Tween/Triton buffer to remove unbound antibody then washed 
once with TBS buffer for 10 min at each step. The membrane was incubated with the Anti-
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Mouse IgG (Sigma, UK), Alkaline phosphatase produced in goat, as the second antibody for 1 
h by shaking gently. The secondary antibody was prepared in 5 ml of blocking buffer by 
adding 2.5 µl of antibody. The membrane was washed 4X with TBS-Tween/Triton buffer and 
stained with BCIP/NBT solution (Sigma, UK) until clear visible bands were seen. The reaction 
was stopped by rinsing the membrane with distilled water. The membrane was dried and 
imaged. Washing and blocking steps were performed at room temperature.  
2.3.5 Ni-NTA Purification 
E. coli BL21 (DE3) cells expressing the protein of interest were grown overnight in 10 ml of L 
broth with antibiotic (final concentration of 100 µg/ml ampicillin for pET15b and 30 µg/ml 
kanamycin for pET28b). The overnight culture was used to inoculate prewarmed 250 ml of L 
broth with antibiotic at 37°C with 250 rpm shaking until an OD600 of 0.6 was reached.  The 
culture was induced with IPTG at a final concentration of 1 mM IPTG.  The cells were 
harvested by centrifugation for 20 min at 3200xg, 4°C. The supernatant was removed and the 
pellet was frozen overnight. The pellet was thawed on ice for 15 min, resuspended in 10 ml of 
50 mM Tris pH 8.0 300 mM NaCI 1% Triton X-100 10 mM Imidazol 1mg/ml Lysozyme 25U/ml 
Benzonase nuclease (lysis buffer), incubated on ice for 30 min by swirling occasionally. The 
cell lysate was spun down for 30 min at 14000 x g, 4°C. The Ni-NTA column was prepared by 
adding 1 ml of Ni-NTA agarose resin slurry (QIAGEN, Germany) and letting resin to settle 
down on frit. The column was washed with 5 ml of 10 mM Tris pH 8.0 500 mM NaCI 10 mM 
Imidazol (wash buffer) without disturbing the resin. The cleared supernatant from 
centrifugation was removed and loaded on to the resin. All of the flow through was collected. 
The resin was washed with 5 ml of wash buffer twice and each wash was collected separately. 
Finally, the 6X His-tagged protein was eluted 3 times with 1 ml of 10 mM Tris pH 8.0 150 mM 
NaCI 200 mM Imidazol (elution buffer). The benzonase nuclease used in lysis buffer was 
purchased from Sigma-Aldrich.  
2.3.6 Measurement of Myrosinase Activity by God-Perid Assay 
God-Perid assay (Figure 2.5) was used to measure the glucose release upon glucosinolate or 
β-glucoside breakdown by myrosinase activity or β-O-glucosidase activity respectively [137].  
The God-Perid reagent was prepared in 250 ml of Tris HCI buffer pH 7.2 (1.2 g/ml) consisting 
of 2-2’-azino-bis (3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) (1 mg/ml), glucosidase 
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oxidase (8 U/ml) and peroxidase (0.35 U/ml). This reagent was stored in cold and dark place 
away from light until use. All chemicals were purchased from Sigma-Aldrich.  
 
Figure 2.5 The principle of the God-Perid assay. The glucose (GLC) formed by myrosinase 
activity becomes the substrate of glucose oxidase and glucose oxidase releases H2O2 then 
H2O2 is catalysed by peroxidase forming a green product (ABTS radical cation). The green 
product gives an absorbance at 420 nm and can be measured by spectrophotometry.  
 
The reaction mixture (300 µl), consisted of enzyme and 2 mM sinigrin in 0.1 M citrate 
phosphate buffer pH 7.0 (Buffer can change depending on enzyme used in the assay), was 
incubated aerobically for 30 min at 37°C. The mixture was boiled for 5 min to inactivate the 
enzyme and then 1 ml of God-Perid reagent added to the mixture and incubated for 15 min at 
37°C. The mixture was transferred to a spectrophotometer cuvette and the absorbance at 
420 nm was measured using 6715 UV/Vis Spectophotometer (JENWAY, UK). A calibration 
curve (Figure 2.6) was prepared using glucose (0.1 mg/ml-0.7 mg/ml) to quantify the glucose 
released by the enzyme activity.  
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Figure 2.6 A reference calibration curve for God-Perid assay. Absorbance at 420 nm versus 
various amounts of glucose was plotted (n=3).  
One unit of myrosinase activity was defined as the amount of enzyme liberating 1 µmol of 
glucose per min. Total activity and specific activity of enzyme can be determined from the 
formulae: 
 
 
 
 
 
 
 
 
2.4 CHROMATOGRAPHY METHODS 
2.4.1 High Performance Liquid Chromatography (HPLC) 
HPLC was used to detect the degradation rate of glucosinolates by myrosinases or reductases. 
The method needs a prior desulfation for glucosinolates.  
2.4.1.1 Preparation of sulfatase 
Sulfatase type H-1 from Helix pomatia was purchased from Sigma-Aldrich (UK). 300 mg of 
sulfatase was dissolved in 12 ml of cold MQ water then 12 ml of cold ethanol was added and 
stirred. Dissolved sulfatase was centrifuged at 4°C, 3000 x g for 6 min. The precipitate was 
Total activity = 
Average of A
420nm    
x Dilution factor x F 
               M of glucose x 30 min 
 = X µmol glucose/min 
Specific activity = 
Total activity  
Total protein 
 = X µmol glucose/min/mg 
F; Gradient from calibration curve, M; molecular weight of glucose 
  
62 
 
discarded and 1.5 volumes of cold ethanol was added to supernatant and stirred. Then 
centrifugation was performed as before  
and the supernant was discarded. The precipitate was dissolved in 8 ml of MQ water and 
loaded on A25 Sephadex (GE Healthcare) layered reservoir then flow through was loaded on 
C25 Sephadex (GE Healthcare) layered reservoir and flow through was used in HPLC sample 
preparation.  
2.4.1.2 Desulfation of glucosinolates 
A needle and a frit was placed to a 3 ml capacity reservoir then the reservoir was pre-packed 
with 1 ml diethylaminoethyl (DEAE) Sephadex suspension and washed with 0.5 ml of MQ 
water. Each sample (200 µl) was mixed with 4.8 ml of 70% methanol with 50 µl of internal 
standard (16 mM sinigrin or glucotropaeolin), 3 ml of sample was loaded on pre-packed 
column and allowed to drip slowly. The column was washed twice with 0.5 ml 20 mM sodium 
acetate buffer pH 5.0 then twice with MQ water. The HPLC vials were placed under columns 
and 75 µl of sulfatase was layered on the surface of the columns. The columns were left 
overnight at room temperature. The next day, elution was performed with 1.25 ml MQ water 
in 3 steps (0.5 ml, 0.5 ml and 0.25 ml). The vials were sealed, vortexed and analysed on HPLC.   
2.4.1.3 HPLC analytical conditions 
Desulfonated glucosinolates were analysed by HPLC using a C18 reversed-phase column, 
Waters Spherisorb 5µM ODS2 4.6 x 250mm Cartridge.  The column was fitted with Spherisorb 
ODS2 Guard Column, 80Å, 5 µm, 4.6mm X 10 mm (Waters, UK) and connected to an Agilent 
Technology 1100 pump series and an autosampler Agilent 1100 series. The samples (10 µl) 
were injected and HPLC runs were carried out using MQ water (solvent A), acetonitrile 
(Solvent B).  A gradient program was used on HPLC: 5% (v/v) acetonitrile for 10 min, 35% (v/v) 
acetonitrile for 5 min, 40% (v/v) acetonitrile for 1 min, 50% (v/v) acetonitrile for 4 min 30 s, 
100% (v/v) acetonitrile for 4 min 30 s and finally 5% (v/v) acetonitrile for 7 min. All runs were 
performed at 30°C with a flow rate of 1 ml/min. The desulfonated glucosinolates were 
detected at 229 nm using a Diode Array Detector (Agilent). Glucosinolates were identified 
using the retention times of known glucosinolate standards and quantified based on the peak 
areas of samples compared to peak areas of the internal standard. The response factors (Area 
for standard/Area for equimolar amount glucosinolate) [230] were used to determine 
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glucosinolate amount in the samples. The glucosinolate content of samples was determined 
for each glucosinolate (Table 2.10) and calculated as given below.  
 
 
 
Glucosinolate Relative Response Factor 
Sinigrin 1 
Glucoraphanin 1.07 
Glucoerucin 1.04 
Glucotropaeolin 0.95 
Table 2.10 Response factors for desulfo-glucosinolates at 229 nm relative to desulfo-
sinigrin.  
For further fragmentation of glucosinolates, the same column and analytical conditions of 
HPLC with 0.1% formic acid in MQ water (solvent A), 0.1% formic acid acetonitrile (Solvent B) 
were used. The glucosinolates were detected using an Agilent 1100 LC/MSDF model mass 
detector Autosampler HP 1200 version.  
 
 
 
 
 
 
 
 
 
Amount of Glucosinolate (mol) = Area (Glucosinolate/Internal Standard) * RF *Amount 
of Internal Standard 
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CHAPTER THREE 
 
3 MYROSINASES FROM HUMAN GUT BACTERIA 
INVOLVED IN GLUCOSINOLATE METABOLISM 
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3.1 INTRODUCTION 
Consumption of cruciferous vegetables has been reported to provide health promoting 
effects against various cancers and this effect was attributed to glucosinolates and especially 
to their degradation products, ITCs [50, 69-72]. Myrosinase is the enzyme responsible for 
degradation of glucosinolates and formation of valued ITCs. Glucosinolates and myrosinases 
are kept separately from each other in the plants. Due to tissue damage, integrity of cells is 
disrupted and glucosinolates and myrosinase come into contact with each other. The 
hydrolysis of glucosinolates occurs and hydrolysis products such as ITCs, thiocyanates or 
nitriles are formed [8, 24]. In addition to plant myrosinases, many organisms show 
myrosinase activity including fungi [131], aphids [132] and gut bacteria [56, 112].  
During cooking, plant myrosinases can be heat inactivated then biotransformation of 
glucosinolates to ITCs is dependent on human gut bacteria. Studies reported that the gut 
bacteria including Enterococcus casseliflavus CP1, Escherichia coli VL8 and Lactobacillus agilis 
R16  [56, 57] and Bacteroides thetaiotaomicron [112] can possess glucosinolate metabolism. 
While the plant [117, 119-121] and aphid myrosinases [132, 133] are well characterised, 
bacterial myrosinases are not. The first bacterial myrosinase was purified 43 years ago from 
Enterobacter cloacae but this study could not identify the gene or protein sequence [231]. 
There were attempts to identify a bacterial  myrosinase with its amino acid sequence for 
years but they had a limited success [137, 232]. Recently, the very first bacterial myrosinase 
sequence was identified from a soil strain C. WYE1 by Albaser et al. (2016)[118]. This 
myrosinase was a periplasmic β-glucosidase from Glycosyl Hydrolase 3 (GH3) family with a 
signal peptide. A preliminary characterisation was performed and this myrosinase was found 
to be activated by ascorbate like plant myrosinases [118]. However, its crystal structure is yet 
to be achieved.  
Luang-In et al. (2014) isolated several strains from the human gut using a sinigrin enrichment 
method and studied their glucosinolate degrading ability. The strains E. casseliflavus CP1, E. 
coli FI10944 and L. agilis R16 were found to degrade sinigrin and produce ITCs and nitriles. E. 
casseliflavus CP1 and L. agilis R16 were further studied and it was found that they degraded 
53 ± 8% and 10 ± 2% of the glucoraphanin in the media after 24 h. When cell-free extracts of 
E. casseliflavus CP1 and L. agilis R16 were tested for myrosinase activity, the extracts did not 
show myrosinase activity. It was suggested that myrosinase activity of E. casseliflavus CP1 and 
L. agilis R16 is cell wall-associated [56]. 2D gel electrophoresis was used to identify sinigrin-
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induced bacterial proteins of E. coli VL8 and L. agilis R16 involved in glucosinolate 
metabolism. It was concluded that induced proteins mostly belong to carbohydrate 
metabolism, oxidoreduction and sugar transport system [138].  
Myrosinase activity in the human gut bacteria is attributed to the β-glucosidases which also 
have specificity for glucosinolates. A bacterial myrosinase from human gut has yet to be 
identified in terms of gene identification. In previous studies, candidate genes from E. 
casseliflavus CP1  [137] and Lactobacillus strains [232] which were proposed to have 
myrosinase activity were cloned and expressed in E. coli to identify the myrosinase. However, 
the recombinant proteins of Lactobacillus species from GH1 family 
(http://www.cazy.org/)[233] were found to be insoluble and no myrosinase activity was 
determined. In addition, the recombinant proteins of E. casseliflavus CP1 (both from GH1 and 
GH3 family) failed to show myrosinase activity.  Some of the recombinant proteins of E. 
casseliflavus CP1 were found to show β-glucosidase activity against various glucosides. Luang-
In et al. (2013) performed their study lacking the annotated genome of E. casseliflavus CP1, 
the Uniprot database was used to get information on the β-glucosidases of E. casseliflavus 
CP1. As the genome of E. casseliflavus CP1 was sequenced, assembled and annotated in this 
study, this revealed that many putative β-glucosidases (40 β-glucosidases) are found in the E. 
casseliflavus CP1 genome. It was thought that Luang-In et al. (2013) had not cloned the 
correct β-glucosidase with myrosinase activity [137]. In this context, E. casseliflavus CP1 and 
E. coli FI10944 were studied in this chapter to identify their myrosinase. Cloning and 
chromatography approches were used for identification.  
3.2 HYPOTHESIS  
Specific β-glucosidases are responsible for degradation of glucosinolates by human gut 
bacteria and can be identified using molecular biology or chromatography techniques.  
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3.3 MATERIALS AND METHODS 
3.3.1 Bacterial Strains  
The bacterial strains that are mentioned in this chapter were given in Table 3.1. 
Bacterial Strain Source of the strain 
L. agilis R16 [56] Human gut (provided to us) 
E. coli FI10944 Human gut (provided to us) 
E. casseliflavus CP1 [56] Human gut (provided to us) 
C. freundii FC50 Human gut (isolated in this study) 
C. WYE1 [118] Soil (provided to us) 
Table 3.1 Bacterial strains used in the study.  
3.3.2 Genome Assembly of Glucosinolate Degrading Bacteria 
Bacterial cultures (10 ml) in appropriate culture broth were grown aerobically at 37°C until 
the culture reached an optical density OD600=1.0. Genomic DNA extraction was performed 
according to QIAGEN Genomic DNA Protocol (QIAGEN, 2001) and genomic DNA of strains was 
sequenced and assembled as described in Chapter 2-section 2.2.13.  
3.3.3 Screening Glucosinolate Metabolism by Human Gut Bacteria 
E. casseliflavus CP1, E. coli FI10944 and L. agilis R16 were reported to show glucosinolate 
degradation and ITC formation previously [56]. These strains were checked for their 
glucosinolate degradation ability in this study to confirm they are still able to degrade 
glucosinolates. The cultures were grown in the same way as described previously by Luang-In 
et al. (2014)[56]. Human gut bacteria were cultured in 5 ml of Wilkinson Chalgren (E. 
casseliflavus CP1), MRS-glucose media (L. agilis R16) and Nutrient Broth (E. coli FI10944) 
containing 1 mM glucoraphanin at 37°C anaerobically for 24 h. Negative controls consisted of 
only glucoraphanin incubated in appropriate media for each bacteria. After incubation, cells 
and negative controls were centrifuged for 15 min at 20000 x g at 4°C. The supernatants were 
removed and transferred into clean tubes. HPLC samples were prepared from these 
supernatants (200 µl used) and analysed as described before in Chapter 2-section 2.4 to 
determine glucosinolate degradation. The degradation products were not characterised 
because the main focus of this part of the study was to confirm that they were still showing 
the ability to degrade glucosinolates.  
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E. coli FI10944 was tested for glucosinolate metabolism under different conditions. Instead of 
using a rich medium, it was grown in M9 minimal media (recipe in Chapter 2-section 2.1.1) 
with glucoraphanin or sinigrin as sole carbon source. The growth of E. coli FI10944 was 
screened over 16 h by Bioscreen C (Labsystems), also testing the effect of different 
glucosinolate concentrations on growth. The addition of more glucosinolate after 4th hour 
was tested to understand the consumption of glucosinolates by cells.  
It was also examined if the myrosinase activity of E. coli FI10944 cell-free extracts (CFEs) was 
inducible. E. coli FI10944 was grown in 10 ml of Nutrient Broth with or without 1 mM 
glucoraphanin anaerobically overnight at 37°C then the cultures were used to prepare CFEs 
by sonication. Cell pellets were washed twice with 0.1 M citrate phosphate buffer pH 7.0 to 
remove any traces of glucoraphanin from culture in sonication step. Protein concentrations of 
CFEs were determined by Bradford assay. The CFEs were incubated in 1 ml reaction volume 
with 0.25 mM glucoraphanin in 0.1 M citrate phosphate buffer pH 7.0 anaerobically for 16 h 
at 37°C. After incubation, samples were centrifuged at 16000 x g for 15 min at 4°C and 
supernatants were transferred into clean tubes. The supernatants (200 µl) were used in 
sample preparation for HPLC to determine glucoraphanin degradation by CFEs.  
L. agilis R16 was examined to see if pre-culturing in MRS media with sinigrin or glucoraphanin 
would affect its myrosinase activity and whether this affect would be dependent on 
glucosinolate type. L. agilis R16 cells were pre-cultured in 5 ml of MRS-glucose, MRS with 1 
mM glucose, MRS with 1 mM sinigrin, MRS with 1 mM glucoraphanin media anaerobically at 
37°C overnight. These pre-cultures were used to inoculate 1 ml of MRS with 1 mM sinigrin, 
MRS with 1 mM glucoraphanin media. The rest of the MRS with 1 mM sinigrin and MRS with 
1 mM glucoraphanin pre-cultures were centrifuged 13000 x g for 15 min at 4°C. Clear 
supernatants (200 µl) were used in sample preparation for HPLC analysis to determine 
glucosinolate concentration left after incubation. The cultures inoculated from the pre-
cultures were incubated anaerobically for 24 h at 37°C. Controls without inoculum were also 
set up. Later, cultures were centrifuged at 13000 x g for 15 min at 4°C. Clear supernatants 
were transferred to clean tubes and 200 µl of supernatants used in sample preparation for 
HPLC analysis to determine glucosinolate degradation. While 16 mM sinigrin was used as 
internal standard for HPLC to determine glucoraphanin degradation, it was replaced with 16 
mM glucotropaeolin for sinigrin degradation.  
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In addition to these strains, 98 new strains from human gut were isolated by glucoraphanin 
enrichment in this study (Chapter 2-section 2.1.3). Fifteen of them degraded 100% of 
glucoraphanin in the media. They were identified by 16S rDNA sequencing then results were 
analysed on The Ribosomal Database Project (RDP) database [234] (Method is in Chapter 2-
section 2.2.12). One of the isolates was further studied. This strain, C. freundii FC50 was 
further screened for its growth in M9 minimal media including glucoraphanin or sinigrin. To 
test the myrosinase activity of CFEs of C. freundii FC50, it was grown in 5 ml Nutrient Broth 
(NB) with or without 1 mM sinigrin and CFEs were prepared as described before. CFEs were 
quantified by Bradford assay (Method is in Chapter 2-section 2.3.2) then myrosinase activity 
of CFEs was examined by God-Perid assay (Chapter 2-section 2.3.6).  
3.3.4 Identification of β-glucosidases to Clone and Express 
The genomes of E. casseliflavus CP1 and E. coli FI10944 were sequenced, assembled and 
annotated as described in Chapter 2-section 2.2.13. As bacterial myrosinases are suggested to 
be β-glucosidases and more closely related to aphid myrosinases than plant myrosinases 
[133, 137], all β-glucosidases in the genome of E. casseliflavus CP1 and E. coli FI10944 were 
interrogated for significant similarity to aphid myrosinases and a recently identified bacterial 
myrosinase, C. WYE1 myrosinase [118]. The candidate genes were selected and checked for 
conserved domains then best candidates were cloned and expressed in E. coli.  
3.3.5 Cloning, Expression of β-glucosidases and Purification of Proteins 
The selected genes were cloned using the pET expression system (Novagen). Genomic DNA of 
E. casseliflavus CP1 and E. coli FI10944 were extracted by using the Genomic DNA extraction 
kit with Genomic Tip 20/G columns (QIAGEN) as advised by the supplier. The primers 
introducing new restriction sites were designed to amplify the candidate genes from E. 
casseliflavus CP1 and E. coli FI10944 genome are listed in Table 3.2. When pET28b vector was 
used, primers were designed to enable in-frame translation of C-terminal 6XHis-tag by 
insertion of new nucleotides if this was needed. The nucleotide sequences of the cloned 
genes are shown in Appendix 2. PCR was set up using 5 ng or 10 ng genomic DNA as template 
and PCR products were checked on agarose gel (Chapter 2-section 2.2.1 and 2.2.2). The 
annealing temperatures are also given in Table 3.3. 
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Name Primer Sequence (5’-3’) Restriction Site  
ECG44-F GAAACATATGGATCATAAACAACTAAA NdeI  
ECG44-R GTTTCTCGAGGCTAGCACTCTTG XhoI  
ECG4-F GAATACATATGGAGACCGTAAAACTAAA NdeI  
ECG4-R GAAAGAATTCAAAATCGTGAGCGTACC EcoRI  
ECG39-F GGAGATCATATGAAAATTGATGTGAAT NdeI  
ECG39-R AACCCTCGAGATAAACAGTTATAGTTTCTTT XhoI  
ECOLG3-F GAGGAAGAAAAATCCATATGAAATG NdeI  
ECOLG3-R AAAGGAATTCAGCAACTCAAACTCG EcoRI  
Table 3.2 Primers used in the PCR experiments to amplify the candidate β-glucosidase 
genes . The restriction sites are underlined. The altered nucleotides to introduce the 
restriction sites are in bold. The inserted nucleotides are highlighted. 
 
Name TA, time, cycles TE, time Product Size 
ECG44-F 
ECG44-R 
51°C, 30 s, 5X   
72°C, 40s 
 
1436 bp 
 63°C, 30 s, 20X   
ECG4-F 
ECG4-R 
55°C, 30 s, 5X  
72°C, 1 min 
 
2162 bp 
 65°C, 30 s, 20X   
ECG39-F 
ECG39-R 
50°C, 30 s, 5X  
72°C, 1 min 
 
  2101 bp 
 67°C, 30 s, 20X   
ECOLG3-F 
ECOLG3-R 
54°C, 30 s, 5X  
72°C, 1 min 
 
2321 bp 
 66°C, 30 s, 20X   
Table 3.3 Conditions used in the PCR to amplify the candidate β-glucosidase genes. TA; 
annealing temperature, cycles; cycles used in annealing step of PCR, TE; extension 
temperature and time used in PCR, Product size; the expected PCR product sizes for β-
glucosidase genes. The annealing step was performed using Tm of 100% sequence match part 
of primers first (5X) and then using the Tm of entire primer (20X).  
 
The insert was ligated to double digested pET15b or pET28b expression vector and gene 
constructs were transformed into E. coli Top10 competent cells (Thermo-Fischer Scientific) for 
ecg44 and E. coli DH5α chemically competent cells (homemade, See Chapter 2-section 2.2.9) 
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for ecg4, ecg39 and ecolg3. Transformant colonies were screened by colony PCR using GoTag 
polymerase and primers T7P2 (5’-TGAGCGGATAACAATTCCC) and T7T (5’-
GCTAGTTATTGCTCAGCGG) (See Chapter 2 section 2.2.11 for method). The clones that gave 
positive results for PCR were selected for plasmid purification. These clones were inoculated 
in L Broth with ampicillin (100 µg/ml final concentration) or L Broth with kanamycin (30 µg/ml 
final concentration) and grown overnight at 37°C, with shaking at 250 rpm. The recombinant 
plasmids were purified using EZNA Plasmid Mini Kit II (Omega Bio-Tek) and then sequenced. 
T7P2 and T7T primers were used to sequence pET15b-ecg44 construct. Due to the larger size 
of the other recombinant plasmids, internal primers were designed to sequence the whole 
gene. The internal primers used in sequencing of pET28b-ecg4, pET28b-ecg39 and pET28b-
ecolg3 constructs were ECG4_I (5’-GACCTCCTTTAATACGATCCA), ECG39_I (5’-
GCTTTGTCATTAGTGATTTCGT) and ECOLG3_I (5’-GATTATATGCCGCCGTACA) respectively. The 
plasmids used and created in this study are shown in Table 3.4. The sequences were 
compared with the expected sequences to confirm that there was no mutation in the cloned 
genes. After that, the plasmid was transformed into E. coli BL21(DE3) cells (One Shot 
competent cells, Invitrogen). The colonies were picked and checked by colony PCR. The 
positive colonies were grown overnight in L Broth plus antibiotic then overnight grown 
cultures were used to prepare bacterial stocks. Bacterial stocks were kept at -80°C and one of 
the positive clones was further used in protein expression and induction studies. 
Plasmid Relevant Characteristics Antibiotic Resistance 
pET15b Expression vector Ampicillin 
pET28b Expression vector Kanamycin 
pET15b-ecg44 ecg44 gene insert from E. casseliflavus CP1 
ligated to pET15b 
Ampicillin 
pET28b-ecg4 ecg4 gene insert from E. casseliflavus CP1 
ligated to pET28b 
Kanamycin 
pET28b-ecg39 ecg39 gene insert from E. casseliflavus CP1 
ligated to pET28b 
Kanamycin 
pET28b-ecolg3 ecolg3 gene insert from E. coli FI10944 
ligated to pET28b 
Kanamycin 
Table 3.4 Plasmids used and generated in this study.  
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Protein expression in E. coli BL21(DE3) encoding the cloned genes was induced with IPTG at a 
final concentration of 0.5 mM for different time intervals. For E. coli BL21(DE3) cells 
expressing pET15b-ecg44, inductions were performed for 1 h, 2 h, 3 h, or 4 h at 37°C, shaking 
at 250 rpm. Protein expression in E. coli BL21(DE3) encoding pET28b-ecg4, pET28b-ecg39 and 
pET28b-ecolg3 were induced at 37°C for 3 h or 25°C for 4 h. Control cultures with E. coli 
BL21(DE3) pET15b (or pET28b) grown in presence of 0.5 mM IPTG (empty vector controls) 
and control cultures of E. coli BL21(DE3) expressing the cloned genes grown without 0.5 mM 
IPTG (uninduced cultures) were always included. After each induction period, the cells were 
centrifuged at 3220 x g for 15 min at 4°C. The supernatant was removed and cell paste was 
frozen at -20°C. The CFEs were prepared by sonication as described in Chapter 2-section 2.3.1 
and run on a SDS-PAGE gel (denaturing, reducing conditions) including negative controls too. 
The CFEs were checked for the presence of 6XHis-tag by Western Blot (Chapter 2-section 
2.3.4) and partially purified by Ni-NTA columns as described in Chapter 2-section 2.3.5.  
3.3.6 Dialysis of the Recombinant Proteins  
Purified proteins were dialysed overnight to remove excessive amounts of imidazole from Ni-
NTA column purification (Method is in Chapter 2-section 2.3.5). Spectra/Por porous 
membrane tubing with 500-1000 Da cut off (Spectrum Labs) was used for dialysis. The 
membrane tubing was soaked in MQ water for 30 min in advance and rinsed with MQ water 
before use. The dialysis was performed in an appropriate amount of buffer (at least 100X 
bigger than volume of the protein) at 4°C for 18 h. The proteins were removed from the 
tubing and transferred into new clean tubes. The dialysed proteins were quantified by 
Bradford assay and tested by God-Perid assay for myrosinase activity. In addition, dialysis was 
performed in ammonium sulphate precipitation steps to exchange buffer.  
3.3.7 Measurement of Myrosinase Activity 
God-Perid assay was used to measure the glucose release upon glucosinolate or β-glucoside 
breakdown by myrosinase activity or β-glucosidase activity respectively [137]. The method 
was described in Chapter 2-section 2.3.6 in detail. The reaction mixture (300 µl), consisted of 
enzyme and 2 mM sinigrin in 0.1 M citrate phosphate buffer pH 7.0 was incubated aerobically 
for 30 min at 37°C. The buffer used in the assay can change depending on the enzyme. The 
mixture was boiled for 5 min to inactivate the enzyme and then 1 ml of God-Perid reagent 
added to the mixture and incubated for 15 min at 37°C. The mixture was transferred to a 
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spectrophotometer cuvette and the absorbance at 420 nm was measured. A calibration curve 
was prepared using glucose to quantify the glucose released by the enzyme activity.  
The effect of ascorbic acid on myrosinase activity of a recombinant protein, ecg44, was tested 
using God-Perid assay. The reactions were set up in 300 µl of volume consisting of 2 mM 
sinigrin, 5 µg of ecg44 and 1 mM ascorbic acid in 0.1 M citrate phosphate buffer pH 7.0. To 
test the effect of different cofactors and the amount of enzyme, the assays were set up using 
10, 50, 200 µg of ecg44 with or without 10 mM MgCI2 or ZnCI2.  
3.3.8 β-glucosidase Assay Using 4-nitrophenyl β-D-glucopyranoside as Substrate 
This assay measures transformation of 4-nitrophenyl β-D-glucopyranoside (p-NPG) into the 
product p-nitrophenol (p-NP) that absorbs light at 405 nm [235].  
      p-NPG (COLOURLESS)                                       d-glucose + p-NP (YELLOW)    
The samples were prepared in 100 µl of sodium phosphate buffer pH 8 containing 4 mM 4-
Nitrophenyl β-D-glucopyranoside and incubated for 30 min at 37°C then 100 µl of 1 M Na2CO3 
was added to stop the enzymatic reaction. To determine the enzyme activity, a standard 
curve was prepared using 5-50 nmol of p-nitrophenol in 100 µl sodium phosphate buffer pH 8 
(Figure 3.1). The enzyme assays were set up in 96 well plates. The absorbance was measured 
using a ThermoMax Plate Reader (GMI, US) at 405 nm. One activity unit was defined as the 
amount of activity generating 1 μmol p-nitrophenol per minute.  
 
Figure 3.1 A reference calibration curve for β-glucosidase assay. Absorbance at 405nm 
versus various amounts of p-nitrophenol was plotted (n=3).  
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3.3.9 Purification of the Bacterial Myrosinase using Fast Protein Liquid 
Chromatography (FPLC) 
The method was adapted from a previous study [231]. Purification attempt 1: E. coli FI01944 
was grown in 500 ml of Nutrient Broth with 1 mM sinigrin at 37°C overnight (OD600= 1.7) then 
the protein extract prepared from this overnight grown culture by (NH4)2SO4 precipitation. 
The overnight grown culture was spun down at 18000 x g for 20 min at 4°C. The cell pellet 
was resuspended in 0.2 M sodium phosphate buffer pH 7.0 (9 ml/ g cell paste) with 1X 
protease inhibitor cocktail (100X concentrate, Melford). The cells were sonicated for 45 s and 
kept on ice for 1 min to cool down and this step was repeated 7 times. After sonication, the 
suspension was centrifuged at 13000 x g for 25 min at 4°C. The supernatant was removed as 
soluble CFE. CFE was saturated with (NH4)2SO4 at 80% (w/v) saturation at 4°C then 
centrifuged at 3220 x g for 15 min at 4°C. The supernatant was removed and the precipitate 
was dissolved in 30 ml of 0.2 M sodium phosphate buffer pH 7.0 as a protein extract. The 
protein extract was dialysed against 10 mM sodium phosphate buffer pH 7.0 for 18 h at 4°C. 
This protein extract was used in Ion Exchange (IEX) Chromatography to purify the bacterial 
myrosinase of E. coli FI10944.  
Anion exchange chromatography was performed using Resource Q 1 ml column (GE 
Healthcare) attached to an ÄKTA FPLC (GE Healthcare) equipped with a UPC-900 wavelength 
detector (GE Healthcare) using Unicorn 3.20 software (GE Healthcare). The buffers used in IEX 
chromatography were 10 mM Na-phosphate buffer pH 7.0 as starting buffer and 10 mM Na-
phosphate plus 1 M NaCI buffer pH 7.0 as elution buffer. These buffers were prepared freshly 
and filtered through 0.22 µm Millex-GS filters (Merck Millipore). The column was equilibrated 
with starting buffer at 4 ml/min flow rate and then samples were run at 4 ml/min flow rate 
and the fractions (1.25 ml) were collected. The fractions from IEX chromatography were 
tested for myrosinase activity by God-Perid Assay using sinigrin as the substrate. The fractions 
showing myrosinase activity were further purified by gel filtration (GF). GF was performed 
with a Superdex 75 10/300 GL column (GE Healthcare). The column was attached to ÄKTA 
FPLC (GE Healthcare) equipped with a UPC-900 wavelength detector (GE Healthcare) using 
Unicorn 3.20 software (GE Healthcare). The buffer used was 10 mM Na-phosphate 150 mM 
NaCI pH 7.0 and it was filtered using a Millipore 0.22 µm GSTF membrane filter before use. 
The column was equilibrated with this buffer. Following column equilibration, the proteins 
were eluted and the fractions (1.25 ml) were collected. Collected fractions were tested for 
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myrosinase activity by God-Perid assay and the fractions with myrosinase activity were 
determined. These fractions from IEX and GF with myrosinase activity were analysed by 
LCMS/MS to determine the protein sequences.  
Purification attempt 2: The buffer conditions for myrosinase activity were optimised using 
different buffers in CFE preparation. CFEs were prepared from overnight grown 10 ml cultures 
of Nutrient Broth by sonication as reported before. CFEs of E. coli FI10944 in various buffers 
were prepared including 20 mM Na Citrate Buffer (pH 3.0, 4.0, 5.0 and 6.0), sodium citrate 
phosphate buffer (pH 5.0, 6.0 and 7.0), Tris-HCI buffer (pH 7.0, 8.0 and 9.0), sodium 
phosphate buffer (pH 6.0, 7.0 and 8.0). The protein concentrations of CFEs were determined 
by Bradford Assay and the myrosinase activity was determined by God-Perid assay and 
optimum buffer was determined for myrosinase activity. E. coli FI01944 was grown in 500 ml 
of Nutrient Broth without glucosinolates at 37°C overnight (OD600= 1.9). The overnight grown 
culture was centrifuged at 18000 x g for 20 min at 4°C. The cell pellet was resuspended in 20 
mM Na citrate buffer pH 5.0 (9 ml/ g cell paste) with 1X protease inhibitor cocktail (100X 
concentrate, Melford). CFE was prepared by sonication as described in the first purification 
attempt. The CFE was saturated with (NH4)2SO4 at 80% (w/v) saturation at 4°C then 
centrifuged at 3220 x g for 15 min at 4°C. The supernatant was removed and the paste was 
dissolved in 20 mM Na citrate buffer pH 5.0. This protein extract was dialysed against 20 mM 
Na citrate buffer pH 5.0 overnight at 4°C to remove (NH4)2SO4. The dialysed protein extract 
was run on FPLC to perform GF. GF was performed with a Superdex 75 10/300 GL column (GE 
Healthcare). Sample was run on gel filtration using 20 mM Na-citrate plus 200 mM NaCI 
buffer pH 5.0. The buffer was prepared freshly and filtered through Millipore 0.22 µm GSTF 
membrane filter before use. The sample was run with 0.5 ml/min flowrate and fractions (0.5 
ml) were collected. The protein eluates were monitored at 280 nm. The fractions showing 
myrosinase activity were analysed by LCMS/MS to determine the protein sequences.  
3.3.10 Identification of the Protein Sequences Obtained from FPLC by LCMS/MS  
The fractions showing myrosinase activity obtained from FPLC were run on SDS-PAGE gels 
under denaturing, reducing conditions as described in Chapter 2-section 2.3.3. Gel pieces of 
interest were excised and washed with 1 ml of 200 mM ammonium bicarbonate (ABC) in 50% 
(v/v) acetonitrile to equilibrate the gel to pH 8 and remove the stain for 15 min twice.  This 
solution was removed and the gel was washed with 1ml of acetonitrile (Fisher Scientific). 
After acetonitrile wash, solution was removed and left to air dry to remove any remaining 
  
76 
 
acetonitrile. The samples were incubated with 10 mM dithiothreitol in 50 mM ABC for 30 min 
at 60°C to reduce any cysteine thiol side chains then the solution was removed.  The samples 
were alkylated with 1 ml of 100 mM iodoacetamide in 50 mM ABC in the dark at room 
temperature for 30 min. The gel pieces were then washed with 1 ml of 200 mM ABC in 50% 
(v/v) acetonitrile for 15 min twice followed by leaving them in 1 ml of acetonitrile to 
dehydrate and shrink the gel pieces. The protein sample was digested by adding 100 ng of 
trypsin (modified porcine trypsin; Promega), in 10 μl of 10 mM ABC before incubation at 37°C 
for 3 h. After digestion the samples were acidified with 10 μl of 1% (v/v) formic acid for 10 
min. The digest solution was transferred to a clean tube and the gel pieces were then washed 
with 50% acetonitrile and agitated by tapping the tube and incubated for 10 min. Samples 
were frozen using dry ice and stored until mass spectrometry analysis [236]. Sample 
preparation and LCMS/MS run were performed by Dr. Fran Mulholland (IFR).  
The approach of LCMS/MS method and Mascot database (http://www.matrixscience.com/) is 
to take a sample of the protein of interest and digest it with a proteolytic enzyme, trypsin and 
then analyse the digest mixture by mass spectrometry. An instrument with MS/MS capability 
provides information about the structure by recording the fragment ion spectrum of the 
peptide. The experimental mass values are compared with calculated peptide mass or 
fragment ion mass values. An appropriate scoring algorithm is used to identify the closest 
match or matches. If the protein of interest is present in the sequence database, then the 
database pulls out that precise entry. If the sequence database does not contain the protein, 
then the database finds out those entries which exhibit the closest homology.   
3.4 RESULTS 
3.4.1 Myrosinase Activity of Human Gut Bacteria 
In this chapter we mainly focused on E. casseliflavus CP1, E. coli FI10944 and L. agilis R16 
which were reported to have myrosinase activity previously by Dr. Vijitra Luang-In [137]. In 
addition to these strains, 98 bacterial strains with myrosinase activity were isolated by a 
glucoraphanin enrichment method.  Ten of these isolates were identified at genus level by 
16S rDNA sequencing and 5 isolates (Isolate 23, 32, 35, 50 and 57) were found to belong 
Enterobacteriaceae family. The results are shown in Table 3.5 and RDP database results of 
isolates are given in Appendix 3. Because of time limitation, not all of these strains could be 
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further studied. One of the isolates, isolate 50, was selected for further investigation of its 
glucosinolate degrading ability. Its genome was sequenced, assembled and annotated. The 
results from 16S rDNA and genome sequencing revealed that it was a strain of C. freundii and 
it was designated as C. freundii FC50.  
Isolates Genus 
59, 61, 66, 71 Enterococcus 
33, 36, 48, 49, 58, 60 Escherichia/Shigella 
Table 3.5 Identities of 10 human gut isolates at genus level. The isolates were obtained using 
a glucoraphanin enrichment method. 
When E. casseliflavus CP1, E. coli FI10944 and L. agilis R16 (SEM images are shown in Figure 
3.2) were cultured from previously frozen stocks, they were still able to degrade 
glucosinolates in in vitro conditions. The samples prepared from cultures were analysed on 
HPLC and the glucoraphanin degradation by cells was determined compared to negative 
controls which include only glucoraphanin incubated in appropriate media. According to the 
results, E. casseliflavus CP1, L. agilis R16 and E. coli FI10944 used up 7.3 ± 2.0%, 12.4 ± 0.8% 
and 100% of the glucoraphanin supplied to the media respectively (HPLC chromatograms are 
shown in Figure 3.3).  
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Figure 3.2 SEM images of E. casseliflavus CP1 (up left), E. coli FI10944 (up right) and L. agilis 
R16 (below). Scanning electron microscopy was performed using a Zeiss Supra 55 VP FEG 
SEM (Zeiss, Germany) operated at 3 kV by Rachael Stanley at Institute of Food Research.  
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Figure 3.3 HPLC chromatograms of hydrolysis of glucoraphanin by E. casseliflavus CP1, E. 
coli FI10944 and L. agilis R16. SNG; sinigrin, GRP; glucoraphanin. Sinigrin was used as internal 
standard. Sinigrin retention time (5.3-5.4 min), glucoraphanin retention time (4.5-4.7 min). 
Medium controls consisted of glucoraphanin incubated in appropriate media for each 
bacterium.  
 
The growth of E. coli FI10944 was analysed over time. The results are shown in Figure 3.4. 
This growth pattern shows that sinigrin is being used as carbon source by E. coli FI10944 
(Figure 3.4 a, b, d). General media have lots of different carbon sources but sinigrin or 
glucoraphanin was the sole carbon source in these experiments. This explains the low growth 
rate of E. coli FI10944 in M9 minimal media with sinigrin compared to growth rate previously 
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achieved in general media. These experiments showed that E. coli FI10944 reached the 
highest OD600 in ~4 h (Figure 3.4 a, b). With the same amount of glucose in the media instead 
of glucosinolate, the culture could only reach an OD600 of ~0.55 but addition of more glucose 
at 4th hour achieved a higher growth rate indicating the carbon source is the growth limiting 
factor (Figure 3.4 c). This result led the study to try the addition of more sinigrin after 4th hour 
(Figure 3.4 d). This effect almost doubled the growth and showed the availability of free 
glucosinolate (sinigrin) is the growth limiting factor for E. coli FI10944.  
a 
 
Figure 3.4 Growth curves of E. coli FI10944 in M9 minimal media at different growing 
conditions. a) Growth curve at 37°C for 24 h in M9 minimal media with sinigrin (SNG) or 
glucoraphanin (GRP) as sole carbon source. b) Growth curve at 37°C for 16 h in M9 minimal 
media with sinigrin (SNG) at different concentrations (0-10 mM). c) Growth curve at 37°C for 
16 h in M9 minimal media with 10 mM glucose to test the effect of extra glucose on growth 
rate. d) Growth curve at 37°C for 16 h in M9 minimal media with 10 mM sinigrin (SNG) to test 
the effect of extra sinigrin addition at 4th hour.  
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Figure 3.4-Continued 
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d 
 
Figure 3.4-Continued 
C. freundii FC50 showed the same growth profile with E. coli FI10944, it was able to grow in 
M9 minimal media with sinigrin but not in M9 minimal media with glucoraphanin (Figure 3.5 
a). It reached highest OD600 at ~ 5th hour, this is later than E. coli FI10944. The addition of 
more sinigrin at 4th hour resulted in a higher growth rate (Figure 3.5 b).  
 
 
 
 
 
 
 
 
 
 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0 4 8 12 16 20
O
D
60
0
time (h)
10 mM SNG + 10 mM SNG
10 mM SNG
  
83 
 
a 
 
b 
 
Figure 3.5 Growth curves of C. freundii FC50 in M9 minimal media at different growing 
conditions. a) Growth curve at 37°C for 24 h in M9 minimal media with sinigrin (SNG) or 
glucoraphanin (GRP) as sole carbon source. b) Growth curve at 37°C for 16 h in M9 minimal 
media with 10 mM sinigrin (SNG) to test the effect of extra sinigrin addition at 4th hour.  
 
It is not known why E. coli FI10944 and C. freundii FC50 could not use glucoraphanin in the 
media as carbon source and did not grow (Figure 3.4 a and 3.5 a). This might be something 
about the glucoraphanin stock used in the study or a chemical absent from the M9 minimal 
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medium because E. coli FI10944 was able to use up glucoraphanin in fermentation studies 
before when it was grown in Nutrient Broth. In general, this experiment gave us an overview 
of the effect of sinigrin and glucoraphanin as a sole carbon source on E. coli FI10944 and C. 
freundii FC50 growth.  
When CFEs of C. freundii FC50 were tested for myrosinase activity, the myrosinase activity of 
CFEs obtained from cultures grown in Nutrient Broth and Nutrient Broth with 1 mM sinigrin 
were 0.12 ± 0.1 µg glucose/min/mg enzyme and 0.15 ± 0.1 µg glucose/min/mg enzyme 
respectively. CFE obtained from culture grown in Nutrient Broth with 1 mM sinigrin had a 
significantly higher myrosinase activity compared to CFE obtained from the culture grown in 
Nutrient Broth one (p=0.018, two sample two tailed t-test). The genomic DNA of C. freundii 
FC50 was extracted, its genome was sequenced and assembled as described in Chapter 2. 
However, further characterisation of the glucosinolate metabolism by this strain could not be 
studied. 
During the purification of myrosinase of E. coli FI10944, CFEs and protein extracts were 
prepared to be used in FPLC analysis. God-Perid assay was carried out to determine the 
myrosinase activity of these protein extracts using sinigrin as substrate.  Sinapis alba 
myrosinase (Sigma) was used as a positive control. The results are shown in Table 3.6. The 
negative controls did not show any myrosinase activity. Negative control 1 consisted of 
extracts in buffer without substrate. This was set up to check that myrosinase activity was 
originated from CFE enzyme activity not from any glucose left in the extracts.  The negative 
control 2 consisted of only sinigrin in buffer. This was set up to confirm that degradation was 
originated from an enzymatic activity. The results showed that CFE of E. coli FI10944 had 
myrosinase activity on sinigrin.  
Samples Specific Activity 
(µmol glucose/min/mg enzyme) 
Cell-free extract (CFE) 0.08 ± 0.00 
Precipitated extract 0.08 ± 0.00 
Dialysed protein extract 0.15 ± 0.00 
 S. alba myrosinase 0.44 ± 0.05 
Table 3.6 Specific myrosinase activity of extracts of E. coli FI10944. The myrosinase activity 
was assessed by God-Perid assay and sinigrin was used as substrate in the assay. The results 
are given as means of triplicates + SD.  
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As E. coli FI10944 was able to degrade all of the glucoraphanin supplied to Nutrient Broth 
previously. We wished to examine if the myrosinase activity in CFEs of E. coli FI10944 was 
inducible. HPLC was used to assess glucoraphanin degradation by CFEs. Glucoraphanin-
induced CFEs showed a degradation rate of 1.68 ± 0.89 glucoraphanin/µg protein (12.1 ± 4.7% 
degradation of original glucoraphanin concentration).  Uninduced CFEs were able to degrade 
at a rate of 1.37 ± 0.53 nmol glucoraphanin/µg protein (10.4 ± 5.5% degradation of original 
glucoraphanin concentration). There was no significant difference for glucoraphanin 
degradation rate of induced or uninduced CFEs of E. coli FI10944 (p=0.641, two sample two 
tailed t-test). However, it should be noted that samples had high SD values.  
L. agilis R16 was examined to see if pre-culturing in MRS media with glucoraphanin, sinigrin, 
glucose or without glucose would change its myrosinase activity. The glucoraphanin and 
sinigrin degradation of samples were compared to negative controls which consisted of only 
glucoraphanin in MRS media and degradation rates were calculated. The glucosinolate 
contamination from pre-cultures were also taken into account in calculations. Results were 
summarised in Table 3.7. Pre-culturing in different conditions did not produce a remarkable 
difference in sinigrin or glucoraphanin degradation of L. agilis R16. It degraded 97-99% of the 
sinigrin in the MRS media and 9-14% of the glucoraphanin after 24 h incubation. Degradation 
rate of glucoraphanin was low as observed previously. It concluded that L. agilis R16 was not 
able to degrade glucoraphanin at as a high rate as sinigrin even if a pre-culturing in presence 
of glucosinolates was performed.  
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Pre-culturing Conditions 
 
Glucoraphanin 
Degradation (%) 
Sinigrin 
Degradation (%) 
Grown with 1 mM sinigrin 9.1±6.6 97.4±2.6 
Grown with 1 mM glucoraphanin 14.5±2.9 99.3±1.2 
Grown with no glucose 13.0±2.2 99.2±1.2 
Grown with 1 mM glucose  12.6 ±2.8 97.2±2.5 
Table 3.7 Glucoraphanin and sinigrin degradation rates of L. agilis R16 pre-cultured at 
different conditions. L. agilis R16 was pre-cultured in MRS with 1 mM sinigrin, glucoraphanin, 
glucose or without glucose. The results are given as means of triplicates + SD.  
3.4.2 Cloning and Expression of β-glucosidases 
3.4.2.1 Selection of β-glucosidases to Clone and Express 
The search of myrosinase-like genes in human gut bacteria was based on the aphid 
myrosinase sequence (Glycosyl Hydrolase Family 1 - GH1) but after identification of a 
bacterial myrosinase from soil belong to GH3, this sequence was also included in the gene 
search. In the E. casseliflavus CP1 genome, 40 β-glucosidases were found from different 
Glycosyl Hydrolase (GH) families. These β-glucosidases were aligned with aphid myrosinases 
(from Brevicoryne brassicae and Acyrthosiphon pisum) and searched for any significant 
similarity and the presence of conserved amino acid residues that have a key role in 
myrosinase activity.  
The 3 best candidate genes were selected, they are β-glucosidases (EC 3.2.1.21): named as 
ecg1, having 30% identity with aphid myrosinase (from Brevicoryne brassicae); ecg43 having 
31% sequence identity with aphid myrosinase (from Brevicoryne brassicae); ecg44 having 33% 
identity with aphid myrosinase (from Brevicoryne brassicae). The multiple sequence 
alignment of 3 β-glucosidases with aphid myrosinase from Brevicoryne brassicae and 
Acyrthosiphon pisum is shown below (Figure 3.7). The alignment was performed using Clustal 
Omega [237].  
The proton donor and nucleophile are the key elements of myrosinase activity. In B. brassicae 
myrosinase, Glu 167 and Glu 374 were reported to be these elements respectively (Figure 
3.6) [133]. The 3 β-glucosidases possess these amino acid residues as can be seen on the 
alignment (highlighted). His 39 was reported as Zinc+2 binding, dimer forming amino acid 
residue but not conserved in the 3 bacterial β-glucosidases. Tyr 309, Trp 416, Trp 424 and Phe 
432 in aphid myrosinase were reported to form a hydrophobic pocket and enable the 
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recognition of the glucose ring. Tyr 309, and Trp 416 were conserved in 3 β-glucosidases. Trp 
424 was conserved in ecg43 and ecg44 but not in ecg1. Phe 432 residue was not conserved in 
any of the β-glucosidases but there was another hydrophobic amino acid Tyr in this position. 
Trp 123 in aphid myrosinase was reported to be involved in recognition of sulphur by van der 
Waals contact with sulphur of the thioglucosidic bond and this residue was only conserved in 
ecg44 but ecg1 and ecg43 have a Phe instead. 
 
 
Figure 3.6 The structure of the aphid myrosinase. The β-strands are shown in dark blue, α-
helices in light blue and loops in green. The two catalytic glutamic acid residues are shown as 
in red indicating the position of active sites. The image was obtained from Huseybe et al., 
2005 [134].  
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                                                                                                                                               H-39                             
                      *        20         *        40         *       
Brevicoryn : ~~~~~~~~~~~MDYKFPKDFMFGTSTASYQIEGGWNEDGKGENIWDRLVH :  39 
Acyrthosip : MTVQPDKHLKCKYKQFPEKFMLGTASSAYQIEGAWNNDGKTESIWDRVAH :  50 
ecg43      : ~~~~~~~~~~~MDYQFPAGFWWGSAASGPQTEGVFEGDGKGASIWDYWYQ :  39 
ecg1       : ~~~~~~~~~~~MKQTFPTDFLWGASISAHQTEGAYQTDGKGLSVQDTRP- :  38 
ecg44      : ~~~~~~~MDHKQLKEFPNDFLWGSASAAYQVEGAWQEDGKGASVWDDFVR :  43 
                                                                                                                                           
                     60         *        80         *       100       
Brevicoryn : TSPEVIKDGTNGDIACDSYHKYKEDVAIIKDLNLKFYRFSISWARIAPSG :  89 
Acyrthosip : TKQELFADDLDGDIACNSYYKVDEDVKLLKELKVQSYRFSLSWPRILPRG : 100 
ecg43      : QEPEKFFNKVGPEKTSQVYTRYQEDIQLMKETGHTTFRTSIQWSRLFPQG :  89 
ecg1       : ---RDNHEIADFTVAVDHYHQYKEDIALLAEMGIKIFRFSIAWSRIFPEG :  85 
ecg44      : I-PGKTFKATNGDVAVDHYHRFKEDVALMKEQGLKTYRFSIAWTRIFPEG :  92 
                                                                      
                                              W-123                        
                      *       120         *       140         *       
Brevicoryn : VMNSLEPKGIAYYNNLINELIKNDIIPLVTMYHWDLPQYLQD-LGGWVNP : 138 
Acyrthosip : EDSYINPAGVQYYNRLIDKLIENNITPIVTIYHWDLPQCIQD-LGGWCNK : 149 
ecg43      : KG-EVNQKAVDFYNAYIDELIANGIEPFMNLYHFDMPMALQE-KGGWLNR : 137 
ecg1       : RG-TVNQKGLDHYSDVIDELLKHGIQPFVTLNHFDLPQALED-EGGWTKR : 133 
ecg44      : RG-EVNQAGLDFYLALIDELIKAGIEPMVTLYHWDLPRALQEEYGGWESR : 141 
 
                                                                      
                                         E-167                            
                    160         *       180         *       200       
Brevicoryn : IMSDYFKEYARVLFTYFGDRVKWWITFNEPIAVCKGYSIKAYAPNLNLKT : 188 
Acyrthosip : QIIEFFTLYVRVVFRTFGDRVKYWITINEPYLVSESYGNEAGAPALNKSG : 199 
ecg43      : ETVDAYVAFAQTCFTLFGDRVKKWFTHNEPIVPVEGGYLYQFHYPNEINM : 187 
ecg1       : STVEAFAAYAKTLFTAYGDRVTHWLTINEPNIMLLVDQKILGKKIPLSE- : 182 
ecg44      : KIIEDFTNYAAVLFEAFRGKVHYWVSLNEQNIFTSLGYLLAAHPPGVTDP : 191 
                                                                      
                                                                      
                      *       220         *       240         *       
Brevicoryn : TGHYLAGHTQLIAHGKAYRLYEEMFKPTQNGKISISISGVFFMPKNAESD : 238 
Acyrthosip : YGDYLAIHHTILAHATAYHIYNREFRPLQNGQIGISLNMEWYYPKNVSSL : 249 
ecg43      : KHAVQVGFHETLASAKAIKVYHEMN---LDGEIGIILNLTPSYPRDENDP : 234 
ecg1       : --KYQQFHHLMIAEKYAFEACHEIV---PNGKIGPVPNISLVYAAT-SRP : 226 
ecg44      : KRMYEVNHIANLANASVINKFHEMK---IPGKIGPSFAYSPNYPIN-SDP : 237 
                                                                      
                                                                      
                    260         *       280         *       300       
Brevicoryn : DDIETAERANQFERGWFGHPVYKGDYPPIMKKWVDQKSKEEGLPWSKLPK : 288 
Acyrthosip : EDHYAAHRARMWQFGVFAHPLFFGDYPEDVKQGVMETNQFCGISLKRLHD : 299 
ecg43      : EDVKAAQIADAFFNRSFLDPAVKGTFPEELVTIVKELDM--------VPA : 276 
ecg1       : EDNQAALYFNSVRNWAYLDFACFGRYNTVFQDYLNQNGL--------TID : 268 
ecg44      : KNILAAENAEDLMAHYWLDVYLWGEYPIAAMNYLKEQGI--------APT : 279 
                                                                     
 
Figure 3.7 Alignments of putative β-glucosidases; ecg1, ecg43, ecg44 with aphid (B. 
brassicae) myrosinase and pea aphid (A. pisum) myrosinase. Brevicoryn; B. brassicae 
myrosinase, Acyrthosip; A. pisum myrosinase. The acid/base residue Glu 167 (E) and 
nucleophile of B. brassicae myrosinase are highlighted in yellow. Tyr 309 (Y), Trp 416 (W), Trp 
424 (W) and Phe 432 (F) of B. brassicae myrosinase were highlighted in pink. His 39 (H) and 
Trp 123 (W) of B. brassicae myrosinase are highlighted in blue and green, respectively. 
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                                  Y-309                                    
                      *       320         *       340         *     
 
Brevicoryn : FTK-DEIKLLKGTADFYALNHYSSRLVTFG-SDPNP------------NF : 324 
Acyrthosip : FSE-NEKYLIKGTLDFLGINHYFSVHATKLQSTQHQ------------SL : 336 
ecg43      : MEADDLQTIRENTIDLLGINYYQPRRIMKKES------------PIDEAK : 314 
ecg1       : FGPEDEALMKRALPDFVAMNFYTTVTVEQPT----EAGDMKNGISDQQSE : 314 
ecg44      : IEPGDMDLLRSAKPDFLGINYYQTATNAYNPLDGVGAGKMNTTGKKGSSE : 329 
                                                                      
                                                                      
                    360         *       380         *       400       
Brevicoryn : NP-DASYVTSVDEAWLKPN-ETPYIIPVPEGLRKLLIWLKNEYGNPQLLI : 372 
Acyrthosip : KTRDSNFELSLIE-EIPYS-NPTWIKETPKGMRNLLCWIRDTYGNPKIII : 384 
ecg43      : SPMPDDYFDNYDMPNKKMNPYRGW-EIYEKGIYDILTNTRENYGNIKCYI : 363 
ecg1       : DIMERGFYKGFTNTFLKKN-AFNW-TIDPLGLKTTLQTLYDRY-HLPIII : 361 
ecg44      : ETGTPGMFKKAENPFVERT-NWDW-EIDPQGLRIALRRITSRY-RVPVII : 376 
                                                                      
 
              E-374                                                              
                      *       420         *       440         *       
Brevicoryn : TENGYGDDGQLDDFE---------KISYLKNYLNATLQAMYEDKCNVIGY : 413 
Acyrthosip : TENGVSDKGQNEDED--ALI----KRRYHYGYLSAVLNAIYEDGCNVIGY : 428 
ecg43      : SENGMGVEGEERFVNADGVIEDDYRIEFVSDHLKYVHQAI-QEGTNCVGY : 412 
ecg1       : TENGLGA---EDHLEADGTVHDPYRIDYLSQHISQCLAAI-NAGVDLIGY : 407 
ecg44      : TENGLGE---YDKLTDNHQIHDQYRIDYLAGHVHAIKEAI-SDGAEVLGY : 422 
 
                                                                  
               W-416   W-424   F-432                                         
                    460         *       480         *       500       
Brevicoryn : TVWSLLDNFEWFYGYSIHFGLVKIDFNDPQ---RTRTKRESYTYFKNVVS : 460 
Acyrthosip : EVWSFLDSLEWFFGYREKFGMYRVDFNDQN---RSRYPKKSLQFFKQLFQ : 475 
ecg43      : HMWTCMDNWSWTNAYKNRYGFISVDLANDA----KRTVKKSGRWFKEVSD : 458 
ecg1       : SPWSAIDLISVHEGIRKRYGFIYVDRNDAQEKEQKRVRKDSFYWYQKLIE : 457 
ecg44      : CTWSFTDLLSWLNGYQKRYGFVYVDQDETQEGSLARYKKDSFYWYQELIK : 472 
                                                                      
                                        
                              520       
Brevicoryn : TGKP~~~~~~~~~~~~~~~~ : 464 
Acyrthosip : TRTLPDVLNDLYCENNCDRG : 495 
ecg43      : NNGF~~~~~~~~~~~~~~~~ : 462 
ecg1       : VGAIPSLEE~~~~~~~~~~~ : 466 
ecg44      : TNGQEC~~~~~~~~~~~~~~ : 478 
 
 
Figure 3.7-Continued                                           
 
The ecg44 was selected for further experiments as it has most of the conserved amino acid 
residues and showed the highest sequence identity (33%) with aphid myrosinase (B. 
brassicae).  
During the study, the first bacterial myrosinase sequence was identified and it is a periplasmic 
β-glucosidase from GH3, not from GH1 like aphid and plant myrosinases [118]. Based on this 
sequence, the genomes were reinterrogated and new candidate genes were selected for 
cloning and expression. Especially, the importance of a conserved amino acid sequence, SDW, 
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was reported in enzyme activity of C. WYE1 myrosinase [118]. Whilst the candidate genes 
were being selected, this sequence was taken into account as well. One candidate gene with 
the SDW sequence (ecg4) and one without it (ecg39) from E. casseliflavus CP1 were selected. 
In addition, one periplasmic glucosidase from E. coli FI10944 was selected (ecolg3). The 
alignment of selected genes with C. WYE1 myrosinase is shown in Figure 3.8 and SDW 
sequence has been highlighted. The selected genes and their sequence identity with C. WYE1 
myrosinase is shown in Table 3.8.  
Bacterium Gene Enzyme 
Family 
Sequence  
Identity (%) 
E. casseliflavus CP1 ecg44 GH1 *33 
E. casseliflavus CP1 ecg4 GH3  29 
E. casseliflavus CP1 ecg39 GH3  24 
E. coli FI10944 ecolg3 GH3  24 
Table 3.8 The genes cloned and expressed in this part of the study. Sequence identity 
indicates the sequence identity with C. WYE1 myrosinase, except *, * indicates the sequence 
identity with aphid (B. brassicaea) myrosinase. As ecg44 is from GH1 family 
(http://www.cazy.org/)[233], it was compared to aphid myrosinase.  
 
                  *        20         *        40         *       
CMYR   : MLTAFKMNTVSLAVLVCLPLSVSASIQSAQQPELGYDTVPLLHLSGLSFK :  50 
ECG39  : ~~~~~~~~~~~~~~~~~MKIDVN--------------------------- :   6 
ECG4   : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
ECOLG3 : ~~~~~~~~~~~MKWLCSVGIAVSLAL----QPALAD-------------- :  21 
                                                                  
                                                                  
                 60         *        80         *       100       
CMYR   : DLNRDGKLNPYEDWRLSPQTRAADLVKRMSVAEKAGVMMHGTAPAEG--- :  97 
ECG39  : -MRKN---------RLQYTEAAEKILKQMTLKEKVHLMSGNMVLAD---- :  42 
ECG4   : ~~~~~~~~~~~~~~~~METVKLKELIDQMTVAEKVGQLVQLTPDFFAQGG :  34 
ECOLG3 : DLFGNHPL-----TPEARDAFVTELLKKMTVDEKIGQLRLISVGPDNPKE :  66 
                                                                  
                                                                  
                  *       120         *       140         *       
CMYR   : --------------STFGNGSVYDSEATRKMVVDAHVNSLITRLNGEEPA : 133 
ECG39  : -VRR-----DMA------NGQHYNE------------------------- :  55 
ECG4   : EITGPMQQWQMSEDQLFTIGSVLGTHTAE--------------------- :  63 
ECOLG3 : AIR------EMI--KDGQVGAIFNTVTRQ--------------------- :  87 
                                                                  
 
Figure 3.8 Alignment of the putative β-glucosidases with C. WYE1 myrosinase. The SDW 
motif is highlighted in red. CMYR; C. WYE1 myrosinase.  
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                160         *       180         *       200       
CMYR   : RLAEQNNMIQKTAETTRLGIPVTISTDPRNSYQALVGISNPAGKFTQWPE : 183 
ECG39  : -------FPYEAGGNERLNVPSMKFVD------GPRGAVTGRDKTTCFPV :  92 
ECG4   : ---QVYAIQTSYLEKSRLKIPLVFMAD------VI------HGYETIFPI :  98 
ECOLG3 : ---DIRAMQDQVMELSRLKIPLFFAYD------VL------HGQRTVFPI : 122 
                                                                  
                        
                                            
                  *       220         *       240         *       
CMYR   : AIGLGAAGSEALAQEYADHVRREYRAVGITEALSPQADITTEPRWARISG : 233 
ECG39  : SMARGASFDTELEKQIGIAIAKEIKDSGGNFFGGVCINLPYNPGWGRSQE : 142 
ECG4   : PLALASSFDAQLVEEVAKASAKEAAEAGVHVTFSPMADHVKDARWGRVLE : 148 
ECOLG3 : SLGLASSFNLDAVKTVGRVSAYEAADDGLNMTWAPMVDVSRDPRWGRASE : 172 
                                                                  
                                                                  
                260         *       280         *       300       
CMYR   : TFGEDPELAKKLVRGYITGMQKGG-QGLNPQSVAAVVKHWVGYGAAEDGW : 282 
ECG39  : VYGEDSFLLGAMGSALSEGVQSE--------SVVACVKHYAF-NSMENAR : 183 
ECG4   : SNGEDPTLSSVLTAAYVRGYQGTASLAENKQRIAACVKHFIGYGAAEGGR : 198 
ECOLG3 : GFGEDTYLTSTMGKTMVEAMQGKSP--ADRYSVMTSVKHFAAYGAVEGGK : 220 
                                                                  
                                                                  
                  *       320         *       340         *       
CMYR   : DGHNAYGKHTVLSNESLQKHIIPFRGAFEANVAAVMPTYSVMKGVTWNGR : 332 
ECG39  : FKVDVH----ASKRTEREIYLSHFKDVIDSGAASVMTSYNKYFGE----- : 224 
ECG4   : DYHTVD----LSDLELYQNYLPAFQAAIEAGAQLVMTSFNTIHGV----- : 239 
ECOLG3 : EYNTVD----MSPQRLFNDYMPPYKAGLDAGSGAVMVALNSLNGT----- : 261 
                                                                  
                                      SDW                            
                360         *       380         *       400       
CMYR   : ETEQVAAGFSHFLLTDLLRKQNNFSGVIISDWLITNDCDDECVNGSAPGK : 382 
ECG39  : -----HTGNSTYLVRDVLKNEWNFDGFVISDFVNGTR------------- : 256 
ECG4   : -----PATANQPLLQEVLRQKLGFDGLIISDWAAVAELMAHRVAADR--- : 281 
ECOLG3 : -----PATSDSWLLKDVLRDQWGFKGITVSDHGAIKELIKHGTAADP--- : 303 
                                                                  
                                                                  
                  *       420         *       440         *       
CMYR   : KPVAGGMPWGVESLSKERRFVKAVNAGIDQFGG--VTDSAVLVTAVEKGL : 430 
ECG39  : -----------------DTVK-AALAGLDIEMHVTNHYGEKLEKAVEDGL : 288 
ECG4   : ----------------KEAAKKAFTAGVEMDMM-SDCYLNALEQIIHAEP : 314 
ECOLG3 : ----------------EDAVRVALKSGINMSMS-DEYYSKYLPGLIKSGK : 336 
                                                                  
                                                                  
                460         *       480         *       500       
CMYR   : ITQARLDASVERILQQKFELGLFEQPYVDAKLAEKI-----VGAPDTKKA : 475 
ECG39  : VPVETIDDAALRIIRT---LLVFEEARKND-----DSKE-TIDYKKHIRL : 329 
ECG4   : EMNEQLNKAVFHVLSLKNKLGLFEDPFRGLVQGNLAPKLAQETRHL---- : 360 
ECOLG3 : VTMEELDDAARHVLNVKYDMGLFNDPYSHLGPKESDPVDTNAESRLHRKE : 386 
                                                                  
                                                                  
                  *       520         *       540         *       
CMYR   : ADDAQFRTLVLLQN-KNILPLKPGT-KVWLYGADKSAAEK---------- : 513 
ECG39  : ALDAAEQSITLIKNENNCLPLNANIKKVAIFGKLATEEN-TGDRGSSRVY : 378 
ECG4   : SREAAKKTTVLLKN-QALLPLQKKQ-KVALIGPKAAS-KDLLGAWSWIGK : 407 
ECOLG3 : AREVARESLVLLKNRLETLPLKKSA-TIAVVGPLADSKRDVMGSWSAAGV : 435 
                                                                  
                                   
Figure 3.8 Continued 
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                560         *       580         *       600       
CMYR   : --------AGL-------EVVSEPEDADVALMRTSAPFE----------- : 537 
ECG39  : PPYVISYLEGLKKYSPH-IQVIYNEGSDIEL------------------- : 408 
ECG4   : PEAAVSLAEGLSQKEIDLTVLSYPDGEM---------------------- : 435 
ECOLG3 : ADQSVTVLTGIKNAVGENGKVLYAKGANVTSDKGIIDFLNQYEEAVKVDP : 485 
                                                                  
                                                                  
                  *       620         *       640         *       
CMYR   : ---------------QPH-----YNYFFGRRHHE---------------- : 551 
ECG39  : ---------AKTIAREADAAIFVVGYNYDDEGEYTGEAENREVPAGAIFD : 449 
ECG4   : -LTSTFIDEACKVAKEAEVVLLALGETSEEAGEA---------------- : 468 
ECOLG3 : RSPQEMIDEAVQTAKQSDVVVAVVGEAQGMAHEA---------------- : 519 
                                                                  
                                                                  
                660         *       680         *       700       
CMYR   : -----GSLEYREDNKDFAVLKRVSKH-TPVIMTMYMERPAVLTNVTDKTS : 595 
ECG39  : AKGGDRKESLELHSEDILLINQVGPENNNSVVALVGGNTIMIEEWKNAVS : 499 
ECG4   : ----ASLTKLSLSRKQEALIEAVSQVNPRIATILFCGRPLVLTAIEPLCQ : 514 
ECOLG3 : ----SSRTDITIPQSQRDLIAALKATGKPLVLVLMNGRPLALVKEDQQAD : 565 
                                                                  
                                                                  
                  *       720         *       740         *       
CMYR   : GFIANFGLS---DEVFFSRLTSDTPYTARLPFALPSSMASVLKQK----- : 637 
ECG39  : AILFTYYSGMEGGTALAKILFGEANPSGKLPFVIPYKEKDLPQID----- : 544 
ECG4   : AIMIAWFPGSEGGNALADLLMGESEPQGRLAMSFPRAEGQLPMTYAQLST : 564 
ECOLG3 : AILETWFAGTEGGNAIADVLFGDYNPSGKLPMSFPRSVGQIPVYYSHLNT : 615 
                                                                  
                                                                  
                760         *       780         *       800       
CMYR   : -----------------SDEPDDLDTPLFQRGFGLTR~~~~~~~~~~~~~ : 657 
ECG39  : ---WNADQITYEYYHGYAKLEKEGKVPSIPFGYGLSYTNFDISNHDFTID : 591 
ECG4   : GRPLTEENSDQKYISRY---MDEKNEPLFSFGSGMGYGRCTITHTQIINP : 611 
ECOLG3 : GRPYNADK-PNKYTSRY---FDEANGALYPFGYGLSYTTFTVSDVKLSAP : 661 
                                                                  
                                                                  
                  *       820         *       840         *       
CMYR   : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
ECG39  : ----KKLLTAKCTVENIGKLPGAEVVQLYVGFSHSQIDRPIKVLRGFKKV : 637 
ECG4   : QEK-DAPFEVSCTLKNEGDIPHTTTLQLYSRDDVTEVARPMRELKQWQKI : 660 
ECOLG3 : TMKRDGKVTASVQVTNTGKREGATVVQMYLQDVTASMSRPVKQLKGFEKI : 711 
                                                                  
                                                                  
                860         *       880         *       900       
CMYR   : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
ECG39  : HLLPGEKKNITIKCPIEKLKWYNPDSEQWELEEIPYEVYLGNSSSPTDLI : 687 
ECG4   : HLAAAEERQHSFYVTPEDFAYVHSDFS-TKSDPGTISLYLGFAAASAKLI : 709 
ECOLG3 : TLKPGETQTVSFPIDIEALKFWNQQMK-YDAEPGKFNVFIGTDSARVKK- : 759 
                                                                  
                      
                      
CMYR   : ~~~~~~ :   - 
ECG39  : KETITV : 693 
ECG4   : GTLTI~ : 714 
ECOLG3 : GEFELL : 765 
 
                 
Figure 3.8 Continued  
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3.4.2.2 Cloning of Putative β-glucosidases of E. casseliflavus CP1 and E. coli 
FI10944 
Four β-glucosidase genes of E. casseliflavus CP1 and E. coli FI10944 were cloned. One of them 
was from GH1 family (ecg44) and the rest were from GH3 family (ecg4, ecg39, ecolg3). 
Genomic DNA (gDNA) of E. casseliflavus CP1 and E. coli FI10944 were used to amplify the 
genes. The gel electrophoresis of gDNA is shown in Figure 3.9. 
 
 
Figure 3.9 Agarose gel electrophoresis of bacterial gDNA. These gDNAs were used as 
template in PCR to amplify the genes. gDNA samples were run on 0.8 % agarose gel. l; 
Hyperladder, 1; gDNA of E. coli FI10944, 2; gDNA of E. casseliflavus CP1.  
 
Specific primers (Table 3.1) were designed to produce PCR products. Some of the products 
gave a few bands on agarose gel then the PCR was repeated with optimized conditions (Table 
3.2) until specific PCR products with expected sizes were obtained. After amplification, the 
inserts were ligated to double digested pET15b (ecg44) or pet28b (ecg4, ecg39, ecolg3) 
expression vectors (the maps of the vectors are given in Appendix 1) then the gene constructs 
were transformed into E. coli DH5α cells. The cells were plated on L agar with ampicillin (100 
µg/ml final concentration) or kanamycin (30 µ/ml final concentration) plates. Several colonies 
were picked and tested by colony PCR to test if they have the plasmid with the correct gene 
inserts (Figure 3.10).  
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For the ecg44 gene construct, none of the screened colonies were found to have the correct 
insert so the ligation PCR was performed to test if the ligation worked. The ligation PCR was 
performed using the same T7P2, T7T primers (Chapter 2) and the same method as colony 
PCR. The PCR gave the expected gene product ~1600 bp so it was confirmed that the ligation 
worked. The transformation of gene constructs into E. coli cells was repeated using E. coli 
Top10 competent cells (Thermo-Fischer Scientific). The colonies were checked by colony PCR 
again and this time one positive transformant with correct insert was found. This positive 
colony was then grown on L agar with ampicillin (100 µg/ml). After extraction of the 
recombinant plasmid, it was sequenced and confirmed to have no mutation in the gene 
insert. The recombinant pET15b-ecg44 plasmid was transformed into E. coli BL21 (DE3) cells 
for protein expression studies. 
The ecg4, ecg39, ecolg3 were amplified by PCR (Figure 3.9).  Then each gene construct was 
ligated into pET28b vector and transformed into E. coli DH5α cells as described before.  
 
Figure 3.10 Agarose gel electrophoresis of PCR products. PCR products were run on 1% 
agarose gel. l; Hyperladder, c; PCR negative control, 1; ecg4 of E. casseliflavus CP1, 2; ecg39 of 
E. casseliflavus CP1, 3; ecolg3 of E. coli FI10944. The products showed the expected sizes; 
ecg4 (2162 bp), ecg39 (2101 bp), ecolg3 (2321 bp).  
 
After transformation, several colonies were selected randomly and colony PCR was 
performed for each gene construct. The colony PCR results showed that there were gene 
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inserts with correct sizes in the recombinant plasmids (Figure 3.11). A few of the colonies 
with the expected PCR products were selected. They were grown on L agar with kanamycin 
(30 µg/ml) and the recombinant plasmids (pET28b-ecg4, pET28b-ecg39 and pET28b-ecolg3) 
were extracted. Sequencing confirmed that there was no mutation in the gene inserts. The 
recombinant pET28b-ecg4, pET28b-ecg39 and pET28b-ecolg3 plasmids were transformed into 
E. coli BL21 (DE3) cells for protein expression. 
 
Figure 3.11 Agarose gel electrophoresis for colony PCR experiments. l; hyperladder, 1-10; 
selected colonies for E. coli DH5α pET28b-ecg4, 10-20; selected colonies for E. coli DH5α 
pET28b-ecg39, 20-30; selected colonies for E. coli DH5α pET28b-ecolg3. The products were 
run on 1% agarose gel. The expected PCR product sizes; 291 bp for pET28b vector with no 
insert, 2397 bp for recombinant pET28b-ecg4 plasmid, 2301 bp for recombinant pET28b-
ecg39 plasmid, 2547 bp for recombinant pET28b-ecolg3 plasmid. 
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3.4.2.3 Protein Expression and Purification of Putative β-glucosidases of  
E. casseliflavus CP1 and E. coli FI10944 
The protein expression of E. coli DH5α expressing pET28b-ecg4 was tested using different 
time intervals (1, 2, 3, 4 h) at 37°C. The 3 h protein expression induction resulted in the 
highest recombinant ecg44 protein expression, giving the recombinant protein size within the 
expected size (~56 kDa) with 6XHis-tag. The induction for 2 h and 4 h seemed to produce 
similar amount of protein when cell-free extracts (CFE) were checked on SDS-PAGE gel. The 
protein gel image is shown in Figure 3.12a.  The CFEs were checked for the presence of 6X-His 
tag by Western blot as described in Chapter 2 (Figure 3.12b).  
 
Figure 3.12 SDS-PAGE and Western blot of the CFEs from E. coli BL21 (DE3) expressing 
pET15b-ecg44. a) Protein gel where CFEs were run on 10% Bis-Tris gel under denaturing, 
reducing conditions in MES buffer. b) Western blot (using anti-His tag antibody) of CFEs which 
was run within the same order of protein gel in a. 10 µg of protein was loaded per lane. M: 
See Blue Protein Marker, U: CFE obtained from uninduced E. coli BL21 (DE3) expressing 
pET15b-ecg44 cells, I1-I4: CFEs obtained from 1-4 h induced E. coli BL21 (DE3) expressing 
pET15b-ecg44 cells, UC: CFE obtained from uninduced E. coli BL21 (DE3) pET15b cells, C1-C4; 
CFE obtained from 1-4 h induced E. coli BL21 (DE3) pET15b cells (empty vector controls).  
The expression of the recombinant ecg44 protein was determined by Western Blot using a 
His-tag antibody (Novagen). Recombinant proteins with expected protein sizes were 
recognised by the His-tag antibody so the purification of ecg44 was performed using Ni-NTA 
column. The E. coli BL21 (DE3) cells expressing ecg44 were induced for 3 h at 37°C, with 
shaking at 250 rpm. The cells were spun down and Ni-NTA purification was performed as 
described in Chapter 2. All fractions (3.25 µl) from the purification steps were run on a 
protein gel (Figure 3.13).  
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Figure 3.13 SDS-PAGE of the Ni-NTA purified ecg44 proteins from E. coli BL21 (DE3) 
expressing pET15b-ecg44. 3.25 µl of fractions were loaded per lane. Proteins were run on 
10% Bis-Tris Gel under denaturing, reducing conditions in MES buffer. L: Lysate, FT: Flow 
through, W: Wash, E: Eluate, M; Protein marker.  
 
The optimum protein expression conditions of E. coli BL21(DE3) expressing pET28b-ecg4 and 
pET28b-ecg39 were found to be 25°C for 4 h. However, 3 h protein expression induction at 
37°C resulted in a better expression of the recombinant proteins for E. coli BL21(DE3) 
expressing pET28b-ecolg3. Using these optimum conditions, protein expression was induced 
and the cells were centrifuged for 15 min at 3220 x g, 4°C. The supernatant was removed and 
the cell paste was frozen at -20°C. The CFEs were prepared by sonication and run on a protein 
gel (denaturing, reducing conditions). The protein gel image is shown below (Figure 3.14). The 
recombinant ecg4 (82.5 kDa), ecg39 (80.7 kDa) and ecolg3 (87.8 kDa) are visible on the gel 
within expected sizes with 6XHis-tags. The CFEs were checked for the presence of 6X-His tag 
by Western blot as described in Chapter 2 (Figure 3.14b). 
 
98 kDa- 
62------ 
49------  
38------    
M       L       FT     W1    W2     E1      E2     E3 
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Figure 3.14 SDS-PAGE and Western Blot of the CFEs from E. coli BL21 (DE3) expressing 
pET28b-ecg4, pET28b-ecg39 and pET28b-ecolg3. a) Protein gel where CFEs were run on 10% 
Bis-Tris gel under denaturing, reducing conditions in MES buffer. b) Western blot (using anti-
His tag antibody) of CFEs which was run within the same order of protein gel in a. 10 µg of 
protein was loaded per lane. M: See Blue Protein Marker, C (+): ecg44, 6XHis-tagged protein, 
C1 and C2: CFEs obtained from E. coli BL21 (DE3) expressing pET15b (empty vector control), 
IS: Insoluble extract, S: Soluble extract, 1: CFE obtained from E. coli BL21 (DE3) expressing  
pET28b-ecg4, 2: CFE obtained from E. coli BL21 (DE3) expressing pET28b-ecg39, 3: CFE 
obtained from E. coli BL21 (DE3) expressing pET28b-ecolg3. 
The ecg4, ecg39 and ecolg3 were purified in the same way as ecg44 by Ni-NTA purification 
(Figure 3.15).  
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a 
 
 
 
 
 
 
 
 
 
 
 
b 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 SDS-PAGE of the Ni-NTA purified ecg4 (a), ecg39 (b) and ecolg3 (c) proteins from 
E. coli BL21 (DE3) expressing pET28b-ecg4, pET28b-ecg39 and pET28b-ecolg3 respectively. 
3.25 µl of fractions were loaded per lane. Proteins were run on 4-12% Bis-Tris Gel under 
denaturing, reducing conditions in MES buffer. L: Lysate, FT: Flow through, W: Wash, E: 
Eluate, M; Protein marker.  
 
   M       L         FT       W1     W2     E1      E2       E3 
98 kDa- 
62------ 
49------  
38------ 
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Figure 3.15-Continued 
After Ni-NTA purification, ecg44 was dialysed against 25 mM Tris-HCI pH 7.4 buffer. The 
dialysed ecg44 was quantified by Bradford assay. Myrosinase assay (God-Perid) was carried 
out using 200 µg of ecg44 (~12 µM) S. alba myrosinase was used to as a positive control. The 
positive control showed a specific enzyme activity of 0.17 µmol/min/mg enzyme for sinigrin. 
However, ecg44 did not show any myrosinase activity against sinigrin or glucoraphanin.  
The effect of ascorbic acid on myrosinase activity of ecg44 was tested using the God-Perid 
assay.  No myrosinase activity was determined when 1 mM ascorbic acid was used. The 
presence of cofactors (MgCI2 or ZnCI2) or different amount of enzyme (10, 50, 200 µg of 
ecg44) did not make any difference and no myrosinase activity was observed. To test if any 
factor from CFE was needed for myrosinase activity of ecg44, CFE of E. coli BL21(DE3) 
expressing ecg44 was added to purified protein. However, this did not make any difference 
on the enzyme activity. The ecg44 is a β-glucosidase so β-glucosidase activity assay was 
performed using 4-nitrophenyl β-D-glucopyranoside as substrate but it did not show β-
glucosidase activity either. 
The Ni-NTA purified ecg4, ecg39 and ecolg3 were dialysed against 20 mM citrate phosphate 
buffer pH 7.0. The myrosinase activity of dialysed and undialysed ecg4, ecg39 and ecolg3 
proteins were tested using the God-Perid assay. The results revealed that these proteins do 
not have any myrosinase activity. To test if myrosinase activity of these recombinant proteins 
   M       L       FT     W1     W2     E1      E2      E3 
98 kDa- 
62------ 
49------  
38------ 
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is in need of any cofactor from CFE, CFE of E. coli FI10944 showing myrosinase activity was 
added to the recombinant proteins. This did not change the result and recombinant proteins 
did not show myrosinase activity. They were also tested for β-glucosidase activity using 4-
nitrophenyl β-D-glucopyranoside as substrate. β-glucosidase activity of ecg4 and ecg39 were 
2.4 ± 0.1 µmol p-nitrophenol/min/mg enzyme and 0.08 ± 0.02 µmol p-nitrophenol/min/mg 
enzyme respectively when in undialysed proteins. β-glucosidase activity levels in ecg4 and 
ecg39 were found to be 1.6 ± 0.2 p-nitrophenol/min/mg enzyme and 0.07 ± 0.01 p-
nitrophenol/min/mg enzyme respectively when dialysed proteins were used. In summary, 
ecg4 and ecg39 proteins were active, they showed β-glucosidase activity. However, they did 
not show myrosinase activity under the conditions tested.  
3.4.3 Purification of the Bacterial Myrosinase of E. coli FI10944  
In the first attempt to purify the putative bacterial myrosinase, overnight grown culture of E. 
coli FI10944 (OD600 = 1.7) was used to prepare protein extract and then fractionated by 
(NH4)2SO4 precipitation. Precipitate was dialysed and then run on IEX chromatography and 
fractions were collected (Method in section 3.3.8). The fractions A8, A9 and A10 showed 
myrosinase activity within the 13 fractions tested (Figure 3.16). The enzyme activities of 
fractions were 0.11 ± 0.00, 0.24 ± 0.01 and 0.01 ± 0.00 µmol glucose/min/mg enzyme 
respectively. The positive control, a commercial plant myrosinase of S. alba, had an enzyme 
activity of 0.17 µmol glucose/min/mg enzyme. The negative control, with only sinigrin in 
buffer, did not show any enzyme activity. Precipitated and dialysed protein extracts and 
fractions showing myrosinase activity (A8, A9 and A10) were run on a protein gel (Figure 
3.17). Bands shown on Figure 3.17 were excised and analysed by LC-MS\MS. As fraction A9 
showed the highest activity, this fraction was further purified using gel filtration to identify 
the protein responsible for myrosinase activity. 
 
 
 
 
 
 
  
 
1
0
2 
 
Figure 3.16 Chromatogram showing IEX fractions from ammonium sulphate precipitated proteins of E. coli FI10944. The protein eluates were 
monitored at 280 nm. Fractions were collected. 
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Figure 3.17 SDS-PAGE showing protein extracts of E. coli FI10944 and fractions from IEX 
chromatography. 10 µg of protein was loaded per lane. CFE; cell-free extract, PP; precipitated 
protein extract, PDP; precipitated, dialysed protein, M; See blue protein marker, A8-F10; 
fractions from IEX chromatography, X; Protein bands for excision. Proteins were run on 10% 
Bis-Tris Gel under denaturing conditions.  
 
Mascot analysis showed that the excised A8 protein band and its equivalent in A9 are 
flagellin, no glucosidase sequence was obtained from this analysis. The fraction A9 was 
further purified by gel filtration using a Superdex 75 (GE Healthcare) column (Method in 
Chapter 2) and 33 fractions were obtained. These fractions were also tested for myrosinase 
activity. The fraction showing the highest myrosinase activity was further analysed by LC-
MS/MS. When Mascot results were interrogated with E. coli FI10944 genome or compared to 
C. WYE1 myrosinase, no glucosidase sequence or conserved domains related to myrosinase 
activity were found. The results revealed that phosphoglycerate kinases and 
glycerophosphoryl diester phosphodiesterases dominated the fraction.  
In the second attempt of purification of bacterial myrosinase by chromatography, the 
conditions for myrosinase activity were optimised with different buffers. The buffers 20 mM 
Na Citrate pH 5.0 or 6.0 were found to be better for protein yield under the conditions tested 
(Figure 3.18). 
--198kDa 
 --62 
 --49 
 --38 
    CFE       PP        PDP      M          A8           A9         A10 
x x 
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Figure 3.18 Protein yields of CFEs of E. coli FI10944 in various buffers.  All of the buffers were 
at a concentration of 20 mM. The protein amount was determined by Bradford Assay in 
triplicates and the results are given as mean of triplicates ± SD.  
 
 20 mM Na Citrate buffer pH 5.0 was concluded to be better for myrosinase activity under the 
conditions tested (Figure 3.19). CFEs in 20 mM Na Citrate buffer pH 5.0 was tested for 
myrosinase activity by God-Perid assay and they showed a myrosinase activity of 0.13 ± 0.00 
µmol glucose/min/mg enzyme. Optimum pH for myrosinase activity was found to be pH 5.0. 
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Figure 3.19 Specific enzyme activity of CFEs of E. coli FI10944 in various buffers. All of the 
buffers were used at a concentration of 20 mM. The myrosinase assay was performed to 
determine activity and the results are given as mean of triplicates ± SD.  
E. coli FI01944 was grown in 500 ml of Nutrient Broth without glucosinolates at 37°C 
overnight, OD600 of overnight grown culture was 1.9. The protein extract was prepared as 
described before and run on FPLC to perform size exclusion chromatography (Method in 
Chapter 2).  Four of the fractions showed myrosinase activity and one of the fractions was run 
on 10% Bis-Tris gel under denaturing, reducing conditions for 10 min then a protein band was 
excised and analysed by LC-MS/MS.  
When this experiment was run previously, it was found that the fraction showing myrosinase 
activity was dominated by phosphoglycerate kinases. This time, enzyme activity optimisation 
was performed in advance to get a better chance to find out the responsible enzyme for 
myrosinase activity in the fraction. The protein sequences detected in the samples were 
analysed by Mascot (Results are given in Appendix 4). The results concluded that the enzymes 
found in the fraction are strongly related with the glycolysis pathway, including 
phosphoglycerate kinases but glucosidases were also found in the fraction. These 
glucosidases were a predicted cytoplasmic α-amylase (~57 kDa) and a periplasmic trehalase 
(~64 kDa). Notably, cytoplasmic α-amylase showed significant matches. No β-glucosidases 
were identified in the fraction. The conditions used in chromatography in two attempts were 
summarized in Table 3.9.  
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 1st attempt 2nd attempt 
Culturing Media NB with 1 mM sinigrin NB 
 
Purification Method IEX Chromatography 
followed by GF 
GF 
Fractions with 
Myrosinase activity 
A8, A9 and A10 from IEX 
A12 and B12 from GF 
B6, B5, B4, B3 
Fractions tested by 
LCMS/MS 
A8 from IEX 
B12 from GF 
B4 
LCMS/MS Results A8; flagellins 
B12;  
phosphoglycerate kinases, 
diester phosphodiesterases, 
phosphopento mutases, 
NAD(P)H dehydrogenases,  
enolases,  
glucose-6-phosphate 
isomerases, etc. 
B4; 
phosphoglycerate kinases, 
transaldolases, 
triosephosphate isomerases, 
glucose-1-phosphatases, 
cytoplasmic α-amylases, 
glucose-6-phosphate 
isomerases, 
superoxide dismutases, 
periplasmic trehalase, etc. 
Table 3.9 The details and results of chromatography methods used in purification of 
bacterial myrosinase. The fractions obtained and LCMS/MS results of the fractions. NB; 
nutrient broth, IEX; ion exchange, GF; gel filtration. LCMS/MS results indicate the Mascot 
results for each fraction. The experimental mass values are compared with calculated peptide 
mass or fragment ion mass values. An appropriate scoring algorithm was used to identify the 
closest match or matches.  
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3.5 DISCUSSION  
In this chapter, human gut bacteria were tested for myrosinase activity then chromatography 
and cloning methods were used to attempt to identify the myrosinases. E. coli FI10944 was 
not screened for its glucoraphanin degrading ability before this study although it was shown 
to degrade sinigrin [137]. It degraded all of the glucoraphanin supplied to the media after 24 
h. In addition, the glucosinolate degrading ability was observed in CFEs of E. coli FI10944. It 
was suggested that the glucosinolate degrading ability of bacteria may be in the 
membrane/debris fraction because no myrosinase activity was seen in CFEs of L. agilis R16 
[56, 210], E. coli VL8 [56] and E. casseliflavus CP1 [56] but it was present with intact cells. 
However, our study showed that cell wall-associated activity is not always the case. CFEs of E. 
coli FI10944 and C. freundii FC50 showed myrosinase activity. This is in accordance with a 
study reporting myrosinase activity in CFEs of Bifidobacterium and Lactobacillus strains [232]. 
When CFEs of E. coli FI10944 were prepared from induced cells (grown in Nutrient Broth) and 
uninduced cells (grown in Nutrient Broth with 1 mM glucoraphanin), no significant difference 
was seen between degradation rates of induced or uninduced CFEs of E. coli FI10944. These 
results suggest that myrosinase activity of E. coli FI10944 may be constitutive. However, there 
was myrosinase activity in CFEs prepared from uninduced E. coli FI10944 cells. This result 
suggests that myrosinase activity is not always associated with the presence of glucosinolates 
as the inducer. A slight induction effect of sinigrin was observed in CFEs of C. freundii FC50 for 
myrosinase activity. When C. freundii was grown in Nutrient Broth with 1 mM sinigrin instead 
of Nutrient Broth, CFE obtained had slightly higher myrosinase activity. This suggests that 
myrosinase activity in CFE of C. freundii FC50 can be further induced.  
E. casseliflavus CP1 used up 7.3% of the glucoraphanin supplied to the media; this was lower 
than the degradation rate (53%) reported previously by Luang-In et al. (2014) [56]. The same 
media, incubation time (24 h) were used under anaerobic conditions. The bacteria were 
isolated and shortly after used in fermentation studies [56] but we tested the activity after a 
certain storage time away from gut environment. This might be the reason for the loss of 
glucoraphanin degrading ability of E. casseliflavus CP1. During the storage, bacteria might 
have lost a large part of its myrosinase activity. The same effect was seen in our research 
group for antimicrobial activity of gut strains. The gut strains possessing bactericidal effects 
lost their activity during storage [238].  
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L. agilis R16 used up 12.3% of the glucoraphanin in the media that is same range to 10.0% 
reported previously [56]. L. agilis R16 kept its glucoraphanin degrading ability at the same 
rate after long storage time. When, L. agilis R16 was pre-cultured in MRS with 1 mM sinigrin, 
glucoraphanin, glucose or without glucose, it still showed a high sinigrin degradation rate 
(~97-99%) and low glucoraphanin degradation rate (~9-14%). Pre-culturing in media with 
glucosinolates did not produce a remarkable difference for glucoraphanin and sinigrin 
degradation compared to pre-culturing in media with or without glucose. Instead of using one 
step pre-culturing, several pre-culturing steps or using M9 minimal media with glucosinolates 
as the sole carbon source could be investigated. In fact, the glucosinolate side chain (the size 
or structure) might be the limiting factor. As glucoraphanin is a methylsulfinylalkyl-
glucosinolate possessing a sulphoxide group with a high polarity, the sulphoxide group in the 
side chain might be the reason for the lower degradation rate. It was reported that L. agilis 
was able to degrade all of the glucoerucin (reduced form of glucoraphanin) but only 10% of 
the glucoiberin which has sulphoxide group in the structure after 24 h when it was cultured in 
MRS anaerobically [56]. As L. agilis R16 could degrade glucoerucin but not glucoraphanin, it 
might lack an efficient reductase activity to reduce sulphoxide group.  
When the growth of E. coli FI10944 and C. freundii FC50 were examined over time in M9 
minimal media with glucoraphanin and sinigrin, it was found that both strains could grow in 
M9 minimal media with sinigrin. However, they did not grow on M9 minimal media with 
glucoraphanin. When E. coli FI10944 was grown in Nutrient Broth it was able to consume 
glucoraphanin. The reason for glucoraphanin not being used as sole carbon source by E. coli 
FI10944 and C. freundii FC50 might be the lack of a chemical absent in the M9 minimal media.  
In general, our results showed that human gut bacteria have a diverse glucosinolate 
metabolism capacity and action mechanism to degrade different glucosinolates. A reduction 
step which is the reduction of sulphoxide group in glucoraphanin structure is likely to be 
involved in the degradation of glucoraphanin by E. coli FI10944. After reduction of 
glucosinolate, myrosinase in the bacteria may act on the reduced glucosinolate. The same 
reduction activity was proposed to be involved in the degradation of glucoiberin and 
glucoraphanin by Escherichia coli VL8 [56], Escherichia coli Nisssle 1917 and Enterobacter 
cloacae ATCC13047 [55]. In addition, a reductase, methionine sulphoxide reductase A, was 
suggested to be responsible for this reduction [55]. These enzymes and reduction mechanism 
are studied in Chapter 4.  
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To identify the myrosinase of E. coli FI10944, buffer conditions for myrosinase activity were 
optimised and optimum pH for myrosinase activity against sinigrin was found to be pH 5.0. 
This is different from the pH optima of C. WYE1 myrosinase (pH 6.0) [118] and Brevicoryne 
brassicae aphid myrosinase (pH 5.5) [132] for sinigrin degradation. Two attempts were 
performed to identify myrosinase of E. coli FI10944 by FPLC. When crude protein extract of E. 
coli FI10944 was prepared and fractionated by chromatography, no β-glucosidases were 
identified in the fractions. In the second attempt, predicted cytoplasmic α-amylase and 
periplasmic trehalase were identified in the purified fraction. Cytoplasmic α-amylase and 
periplasmic trehalase are enzymes to break down α-bonds in polysaccharides. However, 
glucosinolates are β-thioglycosides so it is unlikely that cytoplasmic α-amylase and 
periplasmic trehalase might be involved in glucosinolate metabolism. So far, it was not 
possible to identify the myrosinase by chromatography. Our results suggested that 
myrosinase activity in CFE of E. coli FI10944 is not inducible. While myrosinase activity in CFE 
of C. freundii was slightly induced by sinigrin and CFEs of C. freundii showed myrosinase 
activity. It will be worth trying to grow C. freundii in M9 minimal media with sinigrin as sole 
carbon source then purify by chromatography as performed for C. WYE1 by Albaser et al. 
(2016)[118].  
Heterologous expression approach was also used to identify the bacterial myrosinase of the 
human gut bacteria. It was challenging to select the glucosidases to clone. The bacteria 
studied have many glucosidases and our selection was based on similarity to identified 
myrosinases.  As all identified and characterised myrosinases were from GH1 family so far the 
selection of genes to clone was based on glucosidases from GH1 family in first place. 
However, the identification of first bacterial myrosinase, C. WYE1 myrosinase [118], changed 
the perspective in this study. This myrosinase belongs to GH3 family so made us to look for 
glucosidases from other families such as GH3. Four genes from E. casseliflavus CP1 and E. coli 
FI10944 were successfully cloned and expressed and 2 of the proteins (ecg4 and ecg39) 
expressed were determined to have β-glucosidase activity against p-NPG but they showed no 
myrosinase activity. These proteins might need some cofactors and conditions for myrosinase 
activity that were not investigated in this study. Two other proteins (ecg44 and ecolg3) did 
not show any enzyme activity. This might be because of misfolding of proteins or the proteins 
might need some cofactors. The optimum temperature for protein expression induction in E. 
coli BL21(DE3) cells encoding pET28b-ecolg3 was found to be 37°C. However, lowering 
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induction temperature could be tried to overcome misfolding risk. As ecolg3 from E. coli 
FI10944 is a periplasmic β-glucosidase, it might also need its natural environment for proper 
folding [239]. Moreover, there are many β-glucosidases in E. casseliflavus CP1 (3 out of 40 
putative β-glucosidases were cloned) and E. coli FI10944 (1 out of 5 putative β-glucosidases 
were cloned) which have not been studied. Three 6-phospho-β-glucosidases encoded by the 
genes bgIA and ascB (GH1) and chbF (GH4) in E. coli O157:H7 were examined for their effect 
on myrosinase activity of E. coli O157:H7 by Cordeiro et al. (2015). It was suggested that 6-
phospho-β-glucosidase encoded by the ascB gene is associated with sinigrin degradation in E. 
coli O157:H7 [240]. Despite its low sequence identity with C. WYE1 myrosinase, 6-phospho-β-
glucosidase encoded by ascB gene in E. coli FI10944 could be cloned and expressed.  
The glucosinolate metabolism in the human gut is not just covered by myrosinases. The role 
of methionine sulphoxide reductases will be discussed in the Chapter 4 in detail. In addition, 
sulfatases that are responsible for transforming glucosinolates into desulfo-glucosinolates are 
also important. Sulfatase of E. coli VL8 was cloned and expressed in E. coli by Luang-In et al. 
(2013) and the enzyme was found to be active against glucosinolates [137]. Our study did not 
focus on sulfatases because they were already characterised. A recent study reported that L. 
agilis R16, E. casseliflavus CP1 and E. coli VL8 could degrade desulfo-glucosinolates and gave 
only nitriles not ITCs as products [57]. As two of the recombinant proteins of E. casseliflavus 
CP1 (ecg4, ecg39) were active and showed β-glucosidase activity against p-NPG, these 
proteins might be checked for their activity against desulfo-glucosinolates. The GC-MS 
method was set up for detection of nitriles but this was yet to be checked. If this degradation 
is possible then it will reveal another mechanism for degradation of glucosinolates by gut 
bacteria. This mechanism may include sulfatase activity followed by β-glucosidase activity to 
produce nitriles as products of glucosinolate degradation. Many other possible mechanisms 
including the importance of phosphorylation of 6-OH group of glucosinolates are suggested in 
the literature [137, 138]. As glucosinolates are β-thioglucosides, it was suggested that 
phosphorylation of glucosinolates by β-glucoside kinase before the action of myrosinase 
might be important for recognition of glucosinolate structure [137]. However, this hypothesis 
has not been tested so far.  
In summary, our attempt to purify bacterial myrosinase from human gut by cloning and 
chromatography approaches could not succeed in identification of the myrosinase. However, 
the data accomplished in this study can be inspiring for future studies. Two β-glucosidases of 
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E. casseliflavus CP1 were successfully cloned, expressed and found to have β-glucosidase 
activity. These two β-glucosidases might have activity against desulfo-glucosinolates. E. coli 
FI10944 and C. freundii FC50 were identified with myrosinase activity and their myrosinase 
activity was not cell wall-associated.  
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CHAPTER FOUR 
 
4 BACTERIAL REDUCTASES FROM HUMAN GUT BACTERIA 
INVOLVED IN GLUCOSINOLATE METABOLISM 
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4.1 INTRODUCTION 
Methionine residues in proteins can be oxidised to methionine sulphoxides (MetSO) and this 
process can damage the biological function of the proteins (Figure 4.1). As methionine is very 
susceptible to oxidation by reactive oxygen species and nitrogen species, organisms are 
evolved to deal with this oxidative damage [152]. Oxidation of methionine to MetSO is 
reversible and MetSO can be reduced back to methionine by separate enzyme systems [155].  
 
Figure 4.1 Structures of methionine and its oxidation product methionine sulphoxide 
Adapted from [152]. 
 
Methionine sulphoxide reductases (Msr) are the enzymes that catalyse the reduction of these 
sulphoxides and repair the enzyme function in many organisms [241]. These enzymes were 
also reported to show specificity for a range of S-stereomers of compounds like N-acetyl-
methionine-S-sulphoxide and S-sulindac [242]. Main Msr enzymes include methionine 
sulphoxide  reductase A (MsrA) and methionine sulphoxide reductase B (MsrB), that are 
responsible for reduction of S-epimers and R-epimers of MetSO respectively in free or protein 
bound MetSO. Another class of Msr can only reduce free MetSO not protein bound MetSO, 
and are called as free methionine sulphoxide reductases (fMsr). If they act on R-epimers of 
free MetSO then they are called as fRMsr. These various Msr enzymes can reduce different 
stereoisomers of MetSO.  In addition, they were suggested to be responsible for the 
reduction of methylsulfinylalkyl glucosinolates like glucoraphanin and glucoiberin to 
methylthioalkyl glucosinolates like glucoerucin and glucoiberverin.  
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The reduction of methylsulfinylalkyl glucosinolates (such as glucoraphanin) is important in 
glucosinolate metabolism. This removes sulphoxide group of methylsulfinylalkyl 
glucosinolates and enables the myrosinase to act on the resulting product. A study reported 
the conversion of glucoraphanin to its reduced counterpart (glucoerucin) by human gut 
microbiota in a fermentation batch model using faecal inoculum and this conversion did not 
occur in heat-sterilised samples. Therefore, it was suggested that reductase activity was 
enzymatic [165]. This reductase activity was reported to be inducible in cell-free extracts 
(CFE) of E. coli VL8 by glucoraphanin or gluconasturtiin. It was suggested that the induction 
was triggered by the glucosinolate core rather than methylsulfinyl structure. The reductase 
activity in CFEs E. coli VL8 was found to be Mg+2 and NADPH dependent and oxygen 
independent [56]. In the literature, MsrA was suggested to be responsible for reduction of 
methylsulfinyl glucosinolates by Escherichia coli Nisssle 1917 and Enterobacter cloacae 
ATCC13047. However, the effect MsrA on methylsulfinyl glucosinolates is yet to be identified. 
In addition, the effect of different Msr enzymes on methylsulfinyl glucosinolates needs 
further investigation.  
This chapter focused on identifying the enzymes that are responsible for reduction of 
methylsulfinyl glucosinolates. To achieve this, 8 putative msr genes from L. agilis R16, E. coli 
FC44 and E. coli VL8 were cloned with a 6X His-tag using a pET15b cloning vector and 
expressed in E. coli BL21 (DE3). The cloned genes were then induced with IPTG for protein 
expression and their activity was assessed.   
4.2 HYPOTHESIS  
Methionine sulphoxide reductases are responsible for reduction of methylsulfinyl 
glucosinolates (such as glucoraphanin) to their reduced counterparts (such as glucoerucin). 
The role of these enzymes in the reduction of glucosinolates can be identified using molecular 
biology techniques.  
4.3 METHODS 
4.3.1 Testing Reductase Activity of Human Gut Bacteria 
E. coli VL8 was obtained using a sinigrin enrichment method from Luang-In et al. (2014) [56] 
and E. coli FC44 was isolated using a glucoraphanin enrichment (Chapter 2-section 2.1.3) 
method in this study. E. coli VL8 was tested for its ability to reduce glucoraphanin to 
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glucoerucin. E. coli VL8 was grown in Nutrient Broth with 1 mM glucoraphanin anaerobically 
for 16 h at 37°C. The cultures (n=3) were centrifuged at 16000 x g for 15 min at 4°C. 
Supernatants were removed and filtered through 0.2 µm PVDF HPLC filters (Avonchem). HPLC 
samples were prepared from these supernatants (200 µl used) and analysed as described in 
Chapter 2-section 2.4.1 to determine the reduction of glucoraphanin to glucoerucin.  
CFEs of E. coli VL8 and E. coli FC44 were examined to see if reduction of glucosinolates is 
inducible by glucosinolates. The cells were cultured in 1 ml of Nutrient Broth with 1 mM 
glucoraphanin (for glucoraphanin induced samples) or without (for uninduced samples). 
These cultures were incubated at 37°C anaerobically for 24 h then the cultures were 
centrifuged at 4000 x g for 15 min at 4°C. Supernatants were removed, pellets were washed 
with 0.1 M citrate phosphate buffer pH 7.0 to remove any traces of glucosinolate, 
isothiocyanate or nitrile products. The washed pellets were resuspended in 0.1 M citrate 
phosphate buffer pH 7.0 with 100X protease inhibitor cocktails (Melford). Sonication was 
used to prepare CFEs of E. coli VL8 and E. coli FC44 (Method is in Chapter 2-section 2.3.1). 
These CFEs were used in assays to test reduction of glucoraphanin. The activity was tested 
using similar conditions that were reported previously to be optimum for reductase activity of 
E. coli VL8 [56]. The reaction mixture (1 ml) contained 300 µl of CFE, 0.25 mM glucoraphanin 
in 0.1 M citrate phosphate buffer pH 7.0 (n=3). Glucoraphanin controls which contain only 
0.25 mM glucoraphanin in 0.1 M citrate phosphate buffer pH 7.0 were also included. These 
reactions were anaerobically incubated for 16 h at 37°C. After incubation, samples were 
centrifuged at 16000 x g for 15 min at 4°C. Supernatants were removed and filtered through 
0.2 µm PVDF HPLC filters. Samples were prepared using 200 µl of the supernatants and 
subjected to HPLC as described in Chapter 2-section 2.4.1.  
4.3.2 Identification of Reductase Genes to Clone and Express 
The genomes of L. agilis R16, E. coli FC44 and E. coli VL8 were sequenced, assembled and 
annotated as described in Chapter 2-section 2.2.13. The genomes were interrogated for 
methionine sulphoxide reductase genes. All of the Msr genes in L. agilis R16, E. coli FC44 and 
E. coli VL8 were selected to identify the responsible enzyme group of Msr for glucosinolate 
reduction.  
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4.3.3 Cloning and Expression of Reductases 
The 3 msrA genes of L. agilis R16 were cloned in first place. The primers introducing new 
restriction sites were designed to amplify the candidate genes and are listed in Table 4.1. The 
nucleotide sequences of the cloned genes are shown in the Appendix 2. PCR was performed 
using High Fidelity Phusion Polymerase (Finnnzymes) as described in Chapter 2-section 2.2.1. 
Gel electrophoresis (Method is in Chapter 2-section 2.2.2) was used to analyse the PCR gene 
products (Table 4.2). PCR conditions and expected product sizes are given in Table 4.2.  
Name Primer Sequence (5’-3’) Restriction Site 
MSRA1-LBAG-F ATTCATATGACAGAGACTGCAATATT NdeI 
MSRA1-LBAG-R AATCGGATCCATTTTCAACGCTTAA Bam HI 
MSRA2-LBAG_F ATTCATATGGAAACAGCAATTTTTG NdeI 
MSRA2-LBAG-R CAACTCGAGCTTAGTCCACTTTAGGTG XhoI 
MSRA3-LBAG-F GACCATATGAAAACAAAACCTGAAG NdeI 
MSRA3-LBAG-R AAGTCTCGAGTTGTGACTGAACCGC XhoI 
MSRB-LBAG-F GATACATATGGATAAACAGCAAGG NdeI 
MSRB-LBAG-R ATTCCTCGAGTTTATTAACTCAATTATTTA XhoI 
fRMsr-LBAG-F TTTCATATGGCTACCACGGAA NdeI 
fRMsr-LBAG-R TGTTCTCGAGCTTACCCACTC XhoI 
fRMsr-FC44-F CATCATATGCTTATTTTAATAGGCTG NdeI 
fRMsr-FC44-R TAAGGATCCTATCAGTAAATGCTACGTT Bam HI 
MsrA-VL8-F CGACCATATGAGTTTATTTGATAAAAAG NdeI 
MsrA-VL8-R TTTGGATCCGTAACGCTATGCT Bam HI 
MsrB-VL8-F TGAGCATATGGCTAATAAACCTTC NdeI 
MsrB-VL8-R CATGCTCGAGATAATGTCATCAAGATTC XhoI 
Table 4.1 Primers used in the PCR experiments to amplify the candidate msr genes. The 
restriction sites are underlined. The altered nucleotides to introduce the restriction sites are 
in bold. 
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Name  TA, time, cycles TE, time Product size 
MSRA1-LBAG-F 
MSRA1-LBAG-R 
54°C, 30 s, 5X             
72°C, 15 s 
 
559 bp 
 64°C, 30 s, 20X     
MSRA2-LBAG-F 
MSRA2-LBAG-R 
54°C, 30 s, 5X  
72°C, 15 s 
 
547 bp 
 67°C, 30 s, 20X   
MSRA3-LBAG-F 
MSRA3-LBAG-R 
55°C, 30 s, 5X  
72°C, 30 s 
 
839 bp 
 67°C, 30 s, 20X   
MSRB-LBAG-F 
MSRB-LBAG-R 
49°C, 30 s, 5X  
72°C, 15 s 
 
462 bp 
 64°C, 30 s, 20X   
fRMsr-LBAG-F 
fRMsr-LBAG-R 
52°C, 30 s, 5X  
72°C, 15 s 
 
538 bp 
 67°C, 30 s, 20X   
fRMsr-FC44-F 
fRMsr-FC44-R 
52°C, 30 s, 5X            
72°C, 20 s 
 
595 bp 
 64°C, 30 s, 20X   
MsrA-VL8-F 
MsrA-VL8-R 
58°C, 30 s, 5X  
72°C, 20 s 
 
661 bp 
 66°C, 30 s, 20X   
MsrB-VL8-F 
MsrB-VL8-R 
49°C, 30 s, 5X  
72°C, 20 s 
 
492 bp 
 65°C, 30 s, 20X   
Table 4.2 Conditions used in the PCR experiments to amplify the candidate msr genes. TA; 
annealing temperature, cycles; number of cycles used in annealing step of PCR. TE; extension 
temperature and time used in PCR, Product size; the expected PCR product sizes for msr 
genes. The annealing step was performed using Tm of 100% sequence match part of primers 
first (5X) and then using the Tm of entire primer (20X).  
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Restricted PCR gene products were ligated to double digested pET15b vectors. The 
recombinant plasmids (Table 4.3) were transformed into E. coli Top10 competent cells 
(Thermo-Fischer Scientific) for msrA1, msrA2, msrA3 and into E. coli DH5α chemically 
competent cells (homemade, See Chapter 2-section 2.2.9) for the rest. Then cells were plated 
on L agar with ampicillin plates (100 µg /ml final concentration). Colonies were screened by 
colony PCR using primers T7P2 (5’-TGAGCGGATAACAATTCCC-3’) and T7T (5’-
GCTAGTTATTGCTCAGCGG-3’) as described in Chapter 2-section 2.2.11. The clones that gave 
positive result for PCR were selected for plasmid purification. The recombinant plasmids were 
purified using EZNA Plasmid Mini Kit II (Omega Bio-Tek) and sequenced using T7P2 and T7T 
primers. Depending on the sequencing results, one of the positive transformants without any 
mutation was selected and transformed into E. coli BL21(DE3) for protein expression studies. 
Protein expression in E. coli BL21(DE3) encoding msr genes was induced with IPTG at a final 
concentration of 0.5 mM. For E. coli BL21(DE3) expressing pET15b-LBAG_msrA1, pET15b-
LBAG_msrA2 pET15b-LBAG_msrA3, inductions were carried out for 4 h at 37°C or 24 h at 
25°C, shaking at 250 rpm. For the rest, protein expressions were held at 25°C for 4 h and 37°C 
for 3 h or 4 h to determine optimum conditions. Control cultures with E. coli BL21(DE3) 
pET15b grown in presence of 0.5 mM IPTG (empty vector controls) and control cultures of E. 
coli BL21(DE3) expressing the cloned genes grown without 0.5 mM IPTG (uninduced cultures) 
were also included.  
Plasmid Relevant Characteristics 
pET15b-LBAG_msrA1 msrA1 gene insert from L. agilis R16 ligated to pET15b 
pET15b-LBAG_msrA2 msrA2 gene insert from L. agilis R16 ligated to pET15b 
pET15b-LBAG_msrA3 msrA3 gene insert from L. agilis R16 ligated to pET15b 
pET15b-LBAG_msrB msrB gene insert from L. agilis R16 ligated to pET15b 
pET15b-LBAG_frmsr frmsr gene insert from L. agilis R16 ligated to pET15b 
pET15b-FC44_frmsr frmsr gene insert from E. coli FC44 ligated to pET15b 
pET15b-VL8_msrA msrA gene insert from E. coli VL8  ligated to pET15b 
pET15b-VL8_msrB msrB gene insert from E. coli VL8  ligated to pET15b 
Table 4.3 Plasmids used and generated in this study.  
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4.3.4 Protein Extraction by Bugbuster 
Bugbuster protein extraction reagent (Novagen) was used to extract proteins according to 
supplier’s advice. To extract the soluble fraction, E. coli cells were harvested from culture by 
centrifugation using a preweighed tube at 3220 x g for 15 min at 4°C. The supernatant was 
removed and pellet was allowed to drain, the wet pellet was weighed and frozen at -20°C 
overnight. Next day, the frozen cell pellet was resuspended at room temperature by pipetting 
or gentle vortexing (5 ml of Bugbuster per gram of wet cell paste). The suspension was 
incubated on a shaking platform slowly for 10 min at room temperature. Then the sample 
was centrifuged at 13,000 x g for 20 min at 4°C. The supernatant was transferred to a fresh 
tube as soluble extract. To purify inclusion bodies, the pellet was resuspended in the same 
volume of Bugbuster HT with a final concentration of 200 µg/ml lysozyme. The suspension 
was vortexed and incubated at room temperature for 5 min then 6 volumes of 1/10 diluted 
Bugbuster HT in deionized water was added to the suspension and vortexed for 1 min. The 
suspension was centrifuged at 13000 x g for 15 min at 4°C and the supernatant was removed. 
The inclusion bodies were suspended in ½ of the original culture volume of 1/10 diluted 
Bugbuster HT, mixed by vortexing  and centrifuged at 3220 x g for 5 min at 4°C. This step was 
repeated for 2 more times. The final pellet was dissolved in 20 mM Tris-HCI 50 mM NaCI 
buffer pH 7.5.  
4.3.5 Purification of Recombinant Proteins  
After protein expression induction, the cells were centrifuged at 3220 x g for 15 min at 4°C. 
The cell paste was used to prepare CFE. The CFEs were prepared by sonication as described in 
Chapter 2-section 2.3.1 and run on a SDS-PAGE gel (denaturing, reducing conditions) 
including negative controls too. The CFEs were checked for the presence of 6XHis-tag by 
Western Blot (Chapter 2-section 2.3.4) and partially purified by Ni-NTA column as described in 
Chapter 2-section 2.3.5.  
After Ni-NTA purification, proteins were dialysed overnight to remove excessive amount of 
imidazole. The proteins were dialysed in Spectra/Por porous membrane tubing with 500-1000 
Da cut off (Spectrum Labs). The membrane tubing was soaked in MQ water for 30 min in 
advance and rinsed with MQ water before use. The dialysis was performed in an appropriate 
amount of buffer (at least 100X bigger in volume of protein volume) for 18 h at 4°C. The 
buffer used in dialysis was 25 mM Tris-HCI buffer pH 7.5 for LBAG_MsrA1, LBAG_MsrA2 and 
LBAG_MsrA3. The dialysis of LBAG-MsrB and VL8_MsrB was carried out using 0.1 M citrate 
  
120 
 
phosphate buffer pH 7.0. The proteins were removed from the tubing and transferred into 
new clean tubes. Quantification of protein amounts was performed by Bradford assay as 
described in Chapter 2-section 2.3.2.  
4.3.6 Testing Reductase Activity of Proteins 
To test glucoraphanin reduction by CFEs or Ni-NTA column purified proteins, reactions were 
set up under different conditions. The optimum conditions reported for reductase activity of 
E. coli VL8 [56] and the studies about Msr [150, 243] were taken into account and the 
methods were adapted from these studies.  
Ni-NTA purified and dialysed (in 25 mM Tris-HCI buffer pH 7.5) eluates of LBAG_MsrA1 and 
LBAG_MsrA2 were used to determine reductase activity in the presence of NADPH or 
dithiothreitol (DTT). For DTT, the reactions contained 25 mM Tris-HCI pH 7.5, 20 mM DTT, 1 
mM glucoraphanin and 10 µg of eluates with or without 10 mM MgCI2 and incubated for 30 
min at 37°C. In addition, the effect of increasing the protein amount to 50 µg and incubation 
time to 1, 2 and 3 h were also tested using Ni-NTA purified MsrA1. For NADPH, the reactions 
were set up in 200 µl consisting 1 mM MgCI2, 1 mM NADPH, 0.25 mM glucoraphanin in 0.1 M 
citrate phosphate buffer pH 7.0 and 10 µg of protein was used in the assays. A glucoraphanin 
control was set up as samples excluding protein. The reactions were incubated for 16 h at 
37°C aerobically.  
CFEs of E. coli BL21 (DE3) expressing pET15b vector (empty vector control), pET15b-
LBAG_msrB, pET15b-LBAG_frmsr, pET15b-FC44_frmsr, pET15b-VL8_msrA and pET15b-
VL8_msrB were prepared using 50 mM Na phosphate buffer pH 7.5 by sonication (Chapter 2-
section 2.3.1), quantified by Bradford assay (Chapter 2-section 2.3.2) and tested for 
glucoraphanin reducing ability. Briefly, a 200 µl reaction mixture contained a buffer of 50 mM 
Na phosphate buffer pH 7.5, 50 mM NaCI, 20 mM DTT, 0.5 mM glucoraphanin and 100 µg of 
protein. Two controls, control 1 excluding protein and control 2 excluding protein and DTT, 
were set up as samples. Samples and controls were incubated for 16 h at 37°C aerobically.  
To test the reductase activity of purified, dialysed (in 0.1 M citrate phosphate buffer pH 7.0) 
eluates of LBAG_MsrB and VL8_MsrB, the reactions were set up under two different 
conditions. First, the reactions were set up in 0.1 M citrate phosphate buffer pH 7.0 with 10 
mM MgCI2, 1 mM NADPH and 0.5 mM glucoraphanin. Second, the activity was tested in 50 
mM Na phosphate buffer pH 7.5 with 50 mM NaCI, 20 mM DTT, 0.5 mM glucoraphanin. The 
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reactions were both set up in a total volume of 200 µl and 10 µg of protein eluates were used. 
Glucoraphanin controls were set up as samples excluding proteins. The samples and controls 
were incubated at 37°C for 16 h aerobically.  
After each incubation period, 400 µl of acetonitrile was added to stop the reaction. Samples 
and controls were filtered through 0.2 µm PVDF HPLC filters. Finally, all these reactions were 
used in sample preparation for HPLC and samples were run on HPLC as described in Chapter 
2-section 2.4.1 to determine reduction of glucoraphanin to glucoerucin.  
4.4 RESULTS 
4.4.1 Reductase Activity of Human Gut Bacteria 
Previously, E. coli VL8 was found to reduce glucoraphanin to glucoerucin by Luang-In et al. 
(2013) [56]. In this study, we examined the reductase activity of E. coli VL8 and E. coli FC44  to 
transform glucoraphanin to its reduced counterpart glucoerucin. E. coli VL8 was able to 
reduce glucoraphanin in Nutrient media after 16 h incubation and it consumed 40.9 ± 1.5% of 
the glucoraphanin. However, the glucoerucin formation did not match to the glucoraphanin 
consumption by cells. The glucoerucin amount was only 1.1 ± 0.2% of the original 
glucoraphanin amount added to the media. As reduction would produce one glucoerucin 
molecule for one glucoraphanin molecule, the depletion of glucoerucin might be explained by 
further metabolism of glucoerucin by myrosinase of E. coli VL8 during 16 h incubation period. 
Identification of these degradation products was not performed in this study.  
E. coli FC44 is a gut bacterium isolated during this study using a glucoraphanin enrichment 
method as described in Chapter 2-section 2.1.3. During this screening, E. coli FC44 was found 
to produce glucoerucin so it was also included in reductase activity assays (Figure 4.2).  
CFEs of E. coli VL8 and E. coli FC44 were prepared by sonication. Cultures with glucoraphanin 
(induced) and without glucoraphanin (uninduced) were used for CFE preparation to test if 
there is an inducible reductase activity in these strains. The reduction rates were based on 
glucoerucin formation and the results are given in Table 4.4. Induced and uninduced CFEs of 
E. coli VL8 showed glucoraphanin reduction at a rate of 1.15 ± 0.20 nmol glucoerucin/µg 
protein and 0.89 ± 0.05 nmol glucoerucin/µg protein respectively. There was no significant 
difference for reduction rate of induced or uninduced CFEs of E. coli VL8 (p=0.10, two sample 
two tailed t-test). Glucoraphanin reduction rates were 1.75 ± 0.32 nmol glucoerucin/µg 
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protein for induced and 2.01 ± 0.09 nmol glucoerucin/µg protein for uninduced CFEs of E. coli 
FC44 respectively. CFEs of E. coli FC44 were found to be more efficient in reducing 
glucoraphanin to glucoerucin. No significant difference was found between induced or 
uninduced CFEs of E. coli FC44 (p=0.26, two sample two tailed t-test), suggesting that 
reductase activity is constitutive.  
 
Figure 4.2 HPLC chromatogram showing reduction of glucoraphanin to glucoerucin by E. coli 
FC44. 1; glucoraphanin, 2; sinigrin (internal standard), 3; glucoerucin. 
 
CFEs  Reduction rate 
 (nmol glucoerucin formed/µg protein) 
Induced CFE of E. coli VL8 1.15 ±  0.20 
Uninduced CFE of E. coli VL8 0.89 ± 0.05 
Induced CFE of E. coli FC44 1.75 ± 0.32 
Uninduced CFE of E. coli FC44 2.01 ± 0.09 
Table 4.4 The reduction of glucoraphanin to glucoerucin by glucoraphanin-induced and 
uninduced CFEs of E. coli VL8 and E. coli FC44. The results are given as mean of triplicates ± 
SD.  
4.4.2 Identification of Putative Sulphoxide Reductases  
The study started with cloning and expression of putative msrA genes of L. agilis R16. Three 
putative methionine sulphoxide reductase A (msrA), one methionine sulphoxide reductase B 
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(msrB) and one free methionine-R-sulphoxide reductase (frmsr) were identified in the 
genome of L. agilis R16. However, E. coli FC44 and E. coli VL8 only have single copies of each 
msr genes. E. coli FC44 and E. coli VL8 share the same msrA nucleotide sequence. There are a 
few nucleotide differences between msrB nucleotide sequences of E. coli FC44 and E. coli VL8 
but they share the same amino acid sequence for MsrB. E. coli FC44 and E. coli VL8 fRMsr also 
share same amino acid sequence except two amino acid residues, so only fRMsr in E. coli 
FC44 was selected for cloning. Amino acid sequences of MsrA, MsrB and fRMsr  from the 
Uniprot database were aligned with MsrA (Figure 4.3), MsrB (Figure 4.4) and fRMsr (Figure 
4.5) of L. agilis R16, E. coli FC44 and E. coli VL8 using Clustal Omega [237].  
Moskovitz et. al. (2000) reported the presence of a shared amino acid sequence among 
MsrAs (GCFWG). Site-directed substitution of each amino acid residue in this conserved 
sequence was found to destroy enzyme activity. However, mutation of Gly residues was 
reported to result in a partial enzyme activity loss [243]. E. coli VL8 and E. coli FC44 have this 
conserved sequence (GCFWG) in their MsrA but L. agilis R16 only shares the ‘GCFW’ part 
(Shown in Figure 4.3).   
Hydrogen bond interactions between Glu 94, Tyr 82 and Tyr 134  in MsrA of E. coli to stabilise 
the oxygen of the sulphoxide was reported by Antonie et al. (2006) [149] and Glu 94 was 
proposed to be an acid/base catalyst [244]. These residues were conserved in MsrA of E. coli 
VL8 and E. coli FC44 at positions 95, 83 and 135 respectively (Figure 4.3). In addition the role 
of Cys 51 as the nucleophile was reported [244] and this residue is conserved at position 52 
(GCFWG sequence) in E. coli FC44 and E. coli VL8 (Figure 4.3). Some bacteria, like Neisseria 
gonorrhoeae, have a fused form of MsrA with MsrB, named as MsrAB [151]. MsrAB was not 
found in the bacteria we studied but MsrAB of Neisseria gonorrhoeae was also included in the 
multiple alignments to see the difference among different types of MsrA. In summary, MsrA 
of E. coli VL8 and 3 MsrAs of L. agilis R16 were selected for cloning. 
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                      *        20         *        40         *       
MSRA_MYCTU : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA3_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA1_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA2_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRAB_NEIG : MKHRTFFSLCAKFGCLLALGACSPKIVDAGTATVPHTLSTLKTADNRPAS :  50 
MSRA2_ARAT : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_ECO12 : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_FC44  : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_VL8   : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_MOUSE : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_HUMAN : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_BOVIN : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
                                                                                                                                          
                     60         *        80         *       100       
MSRA_MYCTU : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA3_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA1_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA2_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRAB_NEIG : VYLKKDKPTLIKFWASWCPLCLSELGQAEKWAQDAKFSSANLITVASPGF : 100 
MSRA2_ARAT : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_ECO12 : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_FC44  : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_VL8   : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_MOUSE : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_HUMAN : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_BOVIN : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   -    
 
                                                                                                                                    
                      *       120         *       140         *       
MSRA_MYCTU : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA3_LBAG : MKTKPEALMRDLYNLIINP------A-TRDWERHLLVQAKNNRQQLSPTG :  43 
MSRA1_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA2_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRAB_NEIG : LHEKKDGEFQKWYAGLNYPKLPVVTDNGGTIAQNLNISVYPSWALIGKDG : 150 
MSRA2_ARAT : ~~~~~~~~~~~~~~~~~~~~~~MDS------------SL----------- :   5 
MSRA_ECO12 : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~MS-----------L :   3 
MSRA_FC44  : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~MS-----------L :   3 
MSRA_VL8   : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~MS-----------L :   3 
MSRA_MOUSE : ~~~~~~~~~~~~~~~~~~~~~~MLSASRRAL--QLLSSANPVR----RMG :  22 
MSRA_HUMAN : ~~~~~~~~~~~~~~~~~~~~~~MLSATRRACQLLLLHSLFPVP----RMG :  24 
MSRA_BOVIN : ~~~~~~~~~~~~~~~~~~~~~~MLSATRRAL--QLFHSLFPIP----RMG :  22                                                                     
                                                                    
 
Figure 4.3 Multiple alignments of Recombinant MsrA proteins with other MsrAs from 
different organisms. The abbreviations used for MsrA from: MYCTU (P9WJM5); 
Mycobacterium tuberculosis, LBAG; L. agilis R16, NEIG (P14930); Neisseria gonorrhoeae, ARAT 
(Q9LY15); Arabidopsis thaliana, ECO12 (P0A744); E. coli strain K12, FC44; E. coli FC44, VL8; E. 
coli VL8, MOUSE (Q9D6Y7); Mus musculus, HUMAN (Q9UJ68); Homo sapiens, BOVIN 
(P54149); Bos taurus. The default settings were used for Clustal Omega. Amino acid 
sequences were obtained from Uniprot database and the entry numbers of sequences are 
given in brackets. The ‘GCFWG’ sequence is shown and highlighted in red. Glu 95 (E) and Cys 
52 (C) residues in E. coli VL8 and E. coli FC44 are highlighted in yellow. Tyr 83 (Y) and Tyr 135 
(Y) residues in E. coli VL8 and E. coli FC44 are highlighted in pink.  
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                    160         *       180         *       200       
MSRA_MYCTU : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA3_LBAG : QL----KQIEADLRPLAMRNNLTPDVM----DFYLAITGNAPMPTKNNVS :  85 
MSRA1_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA2_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRAB_NEIG : DVQRIVKGSINEAQALALIRNPNADLGSLKHSFYKPDTQK---------- : 190 
MSRA2_ARAT : KTQE---PQVVETSPSPVAQEP-PQVADKPAIVPSPIAQEP--------- :  42 
MSRA_ECO12 : FDKK---HLVSPADALPGRNTP-MPVATLHA-----VNGHS--------- :  35 
MSRA_FC44  : FDKK---HLVSPADALPGRNTP-MPVATLHA-----VNGHS--------- :  35 
MSRA_VL8   : FDKK---HLVSPADALPGRNTP-MPVATLHA-----VNGHS--------- :  35 
MSRA_MOUSE : DSAS---KVISAEEALPGRTEP-IPVTAKHH-----VSGNR--------- :  54 
MSRA_HUMAN : NSAS---NIVSPQEALPGRKEQ-TPVAAKHH-----VNGNR--------- :  56 
MSRA_BOVIN : DSAA---KIVSPQEALPGRKEP-LVVAAKHH-----VNGNR--------- :  54 
                                                                                                
                              GCFWG                           Y-83 
                      *       220         *       240         *       
MSRA_MYCTU : ~~~~~~MTSNQKAILAGGCFWGLQDLIRNQPGVVSTRVGYSGGNIPNATY :  44 
MSRA3_LBAG : AYPTLSSPYEERAVFAGGCFWCMVEPFDQRPGINNVISGYTGGSWAQPTY : 135 
MSRA1_LBAG : ~~~~~~~~MTETAIFAGGCFWCMVKPFDQQPGIKSVISGYTGGTVANPTY :  42 
MSRA2_LBAG : ~~~~~~~~~METAIFAGGCFWCMVQPFDSQPGIDSVVSGYTGGHTKNPTY :  41 
MSRAB_NEIG : --KDSAIMNTRTIYLAGGCFWGLEAYFQRIDGVVDAVSGYANGNTENPSY : 238 
MSRA2_ARAT : -DNDVPAPGNEFAEFAAGCFWGVELAFQRIPGVTVTEVGYTHGISHNPSY :  91 
MSRA_ECO12 : --MTNVPDGMEIAIFAMGCFWGVERLFWQLPGVYSTAAGYTGGYTPNPTY :  83 
MSRA_FC44  : --MTNVPDGMEIAIFAMGCFWGVERLFWQLPGVYSTAAGYTGGYTPNPTY :  83 
MSRA_VL8   : --MTNVPDGMEIAIFAMGCFWGVERLFWQLPGVYSTAAGYTGGYTPNPTY :  83 
MSRA_MOUSE : -TVEPFPEGTQMAVFGMGCFWGAERKFWVLKGVYSTQVGFAGGHTRNPTY : 103 
MSRA_HUMAN : -TVEPFPEGTQMAVFGMGCFWGAERKFWVLKGVYSTQVGFAGGYTSNPTY : 105 
MSRA_BOVIN : -TVEPFPEGTQMAVFGMGCFWGAERKFWTLKGVYSTQVGFAGGYTPNPTY : 103 
                                                                      
                        E-95                                              
                    260         *       280         *       300       
MSRA_MYCTU : RNHG----THAEAVEIIFDPTVTDYRTLLEFFFQIHDPTTKDRQGNDRGT :  90 
MSRA3_LBAG : EQVSGQYTGHVEAVEIRYDSRKISYQNLVDIYWQLIDPTDRFGQINDRGS : 185 
MSRA1_LBAG : EQVASHTTGHTEAVKITFDPDVISYADLVEIYWRQTDPTDASGQFQDRGD :  92 
MSRA2_LBAG : EDVKAHTTGHTEAVKITFDPDIISYTELINIYWHQTDPTDAMGQFQDRGD :  91 
MSRAB_NEIG : EDVSYRHTGHAETVKVTYDADKLSLDDILQYYFRVVDPTSLNKQGNDTGT : 288 
MSRA2_ARAT : EDVCTNTTNHAEVVRVQYDPKECTYETLLDLFWSRHNPTTLNRQGELLGA : 141 
MSRA_ECO12 : REVCSGDTGHAEAVRIVYDPSVISYEQLLQVFWENHDPAQGMRQGNDHGT : 133 
MSRA_FC44  : REVCSGDTGHAEAVRIVYDPSVISYEQLLQVFWENHDPAQGMRQGNDHGT : 133 
MSRA_VL8   : REVCSGDTGHAEAVRIVYDPSVISYEQLLQVFWENHDPAQGMRQGNDHGT : 133 
MSRA_MOUSE : KEVCSEKTGHAEVVRVVYRPEHISFEELLKVFWENHDPTQGMRQGNDFGT : 153 
MSRA_HUMAN : KEVCSEKTGHAEVVRVVYQPEHMSFEELLKVFWENHDPTQGMRQGNDHGT : 155 
MSRA_BOVIN : KEVCSGKTGHAEVVRVVFQPEHISFEELLKVFWENHDPTQGMRQGNDHGS : 153                                                                      
  
              Y-135                                                        
                      *       320         *       340         *       
MSRA_MYCTU : SYRSAIFYFDEQQKRIALDTIADVE---ASGLWPGKVVTEVSPAGDFWEA : 137 
MSRA3_LBAG : QYRPVIFYANQHQLTIAQASKQALV---DSQRYQKPIVVAIEPLQQFWPA : 232 
MSRA1_LBAG : SYRPVIFVNSEAQRRTATASRDALA---ASGKFAEPIVTTIEDAKPFYPA : 139 
MSRA2_LBAG : NYRPVIFVNGPEQRRIAEASKRALQ---VSERFSKPIVTAIEDAKPFYPA : 138 
MSRAB_NEIG : QYRSGVYYTDPAEKAVIAAALKREQQKY-----QLPLVVENEPLKNFYDA : 333 
MSRA2_ARAT : QYRSGIYFYTPEQEKLARESLEKEQKKL-----EDKIVTEILPAKKFYKA : 186 
MSRA_ECO12 : QYRSAIYPLTPEQDAAARASLERFQAAMLAADDDRHITTEIANATPFYYA : 183 
MSRA_FC44  : QYRSAIYPLTPEQDAAARASLERFQAAMLAADDDRHITTEIANATPFYYA : 183 
MSRA_VL8   : QYRSAIYPLTPEQDAAARASLERFQAAMLAADDDRHITTEIANATPFYYA : 183 
MSRA_MOUSE : QYRSAVYPTSAVQMEAALRSKEEYQKV-LSKHNFGPITTDIREGQVFYYA : 202 
MSRA_HUMAN : QYRSAIYPTSAKQMEAALSSKENYQKV-LSEHGFGPITTDIREGQTFYYA : 204 
MSRA_BOVIN : QYRSAIYPTSAEHVGAALKSKEDYQKV-LSEHGFGLITTDIREGQTFYYA : 202 
 
Figure 4.3-Continued 
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                    360         *       380         *       400       
MSRA_MYCTU : EPEHQDYLQRYPNGYTC-------HFVRP-GWRL----------PRRTAE : 169 
MSRA3_LBAG : ENYHQDFYRKQPRRYRQLKKAHDHYL----NWLK----------FKNKF~ : 267 
MSRA1_LBAG : EAEHQDFYRRNPFRYQIEEMGGREAFIKQ-HWQ~~~~~~~~~~~~~~~~~ : 171 
MSRA2_LBAG : EARHQRFYKNNPVVFAEQEAGGRADFIAE-QWAD----------APKVD~ : 176 
MSRAB_NEIG : EEYHQDYLIKNPNGYCHIDIRKADEPLPGKTKAAPQGKGFDAATYKKPSD : 383 
MSRA2_ARAT : EEYHQQYLVKGGMHGNAQ-SPAKSCKDPIRCYG~~~~~~~~~~~~~~~~~ : 218 
MSRA_ECO12 : EDDHQQYLHKNPYGYCGIGGIGVCLPPEA~~~~~~~~~~~~~~~~~~~~~ : 212 
MSRA_FC44  : EDDHQQYLHKNPYGYCGIGGIGVCLPPEA~~~~~~~~~~~~~~~~~~~~~ : 212 
MSRA_VL8   : EDDHQQYLHKNPYGYCGIGGIGVCLPPEA~~~~~~~~~~~~~~~~~~~~~ : 212 
MSRA_MOUSE : EDYHQQYLSKNPDGYCGLGGTGVSCPMAIKK~~~~~~~~~~~~~~~~~~~ : 233 
MSRA_HUMAN : EDYHQQYLSKNPNGYCGLGGTGVSCPVGIKK~~~~~~~~~~~~~~~~~~~ : 235 
MSRA_BOVIN : EDYHQQYLSKDPDGYCGLGGTGVSCPLGIKK~~~~~~~~~~~~~~~~~~~ : 233 
                                                                                                                                          
                      *       420         *       440         *       
MSRA_MYCTU : SALRASLSPELGT~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ : 182 
MSRA3_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA1_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA2_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRAB_NEIG : AELKRTLTEEQYQVTQNSATEYAFSHEYDHLFKPGIYVDVVSGEPLFSSA : 433 
MSRA2_ARAT : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_ECO12 : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_FC44  : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_VL8   : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_MOUSE : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_HUMAN : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_BOVIN : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
                                                                                                                                           
                    460         *       480         *       500       
MSRA_MYCTU : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA3_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA1_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA2_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRAB_NEIG : DKYDSGCGWPSFTRPIDAKSVTEHDDFSFNMRRTEVRSRAADSHLGHVFP : 483 
MSRA2_ARAT : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_ECO12 : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_FC44  : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_VL8   : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_MOUSE : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_HUMAN : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_BOVIN : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
                                                                                                                               
                      *       520         *                
MSRA_MYCTU : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA3_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA1_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA2_LBAG : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRAB_NEIG : DGPRDKGGLRYCINGASLKFIPLEQMDAAGYGALKGEVK : 522 
MSRA2_ARAT : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_ECO12 : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_FC44  : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_VL8   : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_MOUSE : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_HUMAN : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRA_BOVIN : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   -                                                           
 
Figure 4.3-Continued 
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Many MsrB from various organisms were aligned with recombinant MsrB proteins (Figure 
4.4). His 103, His 100, Asn 119 and Thr 26 amino acid residues in MsrB of E. coli were 
reported to form hydrogen bonds to stabilise the oxygen of the sulphoxide. These residues 
were conserved in MsrB of E. coli FC44 and E. coli VL8 at positions 104, 101, 120 and 27 
respectively (Figure 4.4). In addition, His 103 amino acid residue was suggested to be the 
acid/base catalyst [244] and conserved at His 104 in MsrB of E. coli VL8 and E. coli FC44. MsrB 
of E. coli VL8 and L. agilis R16 were selected for cloning. 
 
                      *        20         *        40         *       
MSRB1_MOUS : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRB1_BOVI : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRB1_ARAT : MASSTRLTIIQSSFVSARTRLNYVSKTNHSGFACRSLSKPRNLSLSVY-- :  48 
MSRB_LBAG  : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRB3_HUMA : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~MSPRRTLPRPLSLCLSLCLC :  20 
MSRB_ECOLI : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRB_VL8   : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
MSRB_FC44  : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
 
                                                                                                                                        
                     60         *        80         *       100       
MSRB1_MOUS : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~M :   1 
MSRB1_BOVI : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~M :   1 
MSRB1_ARAT : -----SMGSSSSSPKPDNVQEAEKNEFASLSENEWKKRLTPEQYYITRQK :  93 
MSRB_LBAG  : ~~~~~~~~~~~~~~~~~~~~~~~~~~~MDKQQGELRQRLTPEQYAVTQEA :  23 
MSRB3_HUMA : LCLAAALGSAQS-----GSCRDKKNCKVVFSQQELRKRLTPLQYHVTQEK :  65 
MSRB_ECOLI : ~~~~~~~~~~~~~~~~~~~~~~~~~MANKPSAEELKKNLSEMQFYVTQNH :  25 
MSRB_VL8   : ~~~~~~~~~~~~~~~~~~~~~~~~~MANKPSAEELKKNLSEMQFYVTQNH :  25 
MSRB_FC44  : ~~~~~~~~~~~~~~~~~~~~~~~~~MANKPSAEELKKNLSEMQFYVTQNH :  25 
                                                                      
              T-27                                                        
                      *       120         *       140         *       
MSRB1_MOUS : SFCSFFGGEVFQNHFEPGVYVCAKCSYELFSSHSKYAHSSPWPAFTETIH :  51 
MSRB1_BOVI : SFCSFFGGEIFQNHFEPGIYVCAKCGYELFSSRSKYAHSSPWPAFTETIH :  51 
MSRB1_ARAT : GTERAFTGE-YWNSKTPGVYNCVCCDTPLFDSSTKFDSGTGWPSYYQPIG : 142 
MSRB_LBAG  : ATERPFSGE-YDNFYQEGIYVDVVSGQALFSSRDKYDAGCGWPSFTKPID :  72 
MSRB3_HUMA : GTESAFEGE-YTHHKDPGIYKCVVCGTPLFKSETKFDSGSGWPSFHDVIN : 114 
MSRB_ECOLI : GTEPPFTGR-LLHNKRDGVYHCLICDAPLFHSQTKYDSGCGWPSFYEPVS :  74 
MSRB_VL8   : GTEPPFTGR-LLHNKRDGVYHCLICDAPLFHSQTKYDSGCGWPSFYEPVS :  74 
MSRB_FC44  : GTEPPFTGR-LLHNKRDGVYHCLICDAPLFHSQTKYDSGCGWPSFYEPVS :  74 
                                                                    
 
Figure 4.4 Multiple alignments of MsrB proteins from different organisms. The 
abbreviations used for MsrB from: MOUS (Q9JLC3); Mus musculus, BOVI (Q3MHL9); Bos 
taurus, ARAT (Q9C8M2); Arabidopsis thaliana, LBAG; L. agilis R16, HUMAN (Q81XL7); Homo 
sapiens, ECOLI (P0A746); E. coli strain K12, VL8; E. coli VL8, FC44; E. coli FC44. The default 
settings were used for Clustal Omega. Amino acid sequences were obtained from Uniprot 
database and the entry numbers of sequences are given in brackets. His 104 (H) residue in E. 
coli VL8 and E. coli FC44 is highlighted in yellow. Thr 27 (T), His 101 (H) and Asn 120 (N) 
residues in E. coli VL8 and E. coli FC44 are highlighted in pink. 
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                                       H  H-104            N-120                                                          
                    160         *       180         *       200       
MSRB1_MOUS : PDSVTKCPEK-NRPEALKVSCGKCGNGLGHEFLNDGPKRGQSRFUIFSSS : 100 
MSRB1_BOVI : ADSVAKRPEH-NRPGAIKVSCGRCGNGLGHEFLNDGPKRGQSRFUIFSSS : 100 
MSRB1_ARAT : NNVKTKLDLSIIFMPRQEVVCAVCNAHLGHVFDDGPRPT-GKRYCLNSAA : 191 
MSRB_LBAG  : QTNLNEHRDESFGMHRTEVTSTQANSHLGHVFPDGPRDCGGLRYCINSAA : 122 
MSRB3_HUMA : SEAITFTDDFSYGMHRVETSCSQCGAHLGHIFDDGPRPT-GKRYCINSAA : 163 
MSRB_ECOLI : EESIRYIKDLSHGMQRIEIRCGNCDAHLGHVFPDGPQPT-GERYCVNSAS : 123 
MSRB_VL8   : EESIRYIKDLSHGMQRIEIRCGNCDAHLGHVFPDGPQPT-GERYCVNSAS : 123 
MSRB_FC44  : EESIRYIKDLSHGMQRIEIRCGNCDAHLGHVFPDGPQPT-GERYCVNSAS : 123 
                                                                      
                                                 
                      *       220                
MSRB1_MOUS : LKFVPKGKEAAASQGH~~~~~~~~~~~~~ : 116 
MSRB1_BOVI : LKFIPKAEETSASQGQ~~~~~~~~~~~~~ : 116 
MSRB1_ARAT : LKLNALEKTRD~~~~~~~~~~~~~~~~~~ : 202 
MSRB_LBAG  : LKFIPVADLEKAGYGQYQSLFK~~~~~~~ : 144 
MSRB3_HUMA : LSFTPADSSGTAEGGSGVASPAQADKAEL : 192 
MSRB_ECOLI : LRFTDGENGEEING~~~~~~~~~~~~~~~ : 137 
MSRB_VL8   : LRFTDGENGEEING~~~~~~~~~~~~~~~ : 137 
MSRB_FC44  : LRFTDGENGEEING~~~~~~~~~~~~~~~ : 137 
                                                 
 
Figure 4.4-Continued 
  
Many fRMsr from various organisms were aligned with fRMsr proteins in L. agilis R16, E. coli 
FC44 and E. coli VL8 (Figure 4.5). Cys 94 residue was proposed to be a nucleophile in fRMsr of 
E. coli [245] which was conserved as Cys 76 in E. coli FC44 and E. coli VL8. This residue was not 
conserved in fRMsr of L. agilis R16. In addition, the acid/base catalyst in fRMsr of E. coli was 
proposed to be Asp 143 by Boschi-Muller et al. (2014) and was conserved at Asp 124 in L. 
agilis R16 and at Asp 125 in E. coli FC44 and E. coli VL8. fRMsr of E. coli FC44 and L. agilis R16 
were selected for cloning. The initiation of the protein synthesis of fRMsr in E. coli strain in 
the studies [244, 245] starts with a different Met residue and this results in an 18 amino acid 
shift.  
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                      *        20         *        40         *       
fRMsr_YEAS : MGSSTGFHHADHVNYSSNLNKEEILEQLLLSYEGLSDGQVNWVCNLSNAS :  50 
fRMsr_LBAG : ~~~~~~~~~~~~~~~~~~~MATTETSLMNQQLDALLFQETNLVANLANAS :  31 
fRMsr_STAA : ~~~~~~~~~~~~~~~~MTTINPTNYTLLKKQAASLIEDEHHMIAILSNMS :  34 
fRMsr_BACI : ~~~~~MF-H---VEK-QSGDKEKDYQLLLKQLEAMTEDETDQIANYANAS :  40 
fRMsr_ECOL : ~~~~~~~~~~~~~~~~~~MNKTEFYADLNRDFNALMAGETSFLATLANTS :  32 
fRMsr_FC44 : ~~~~~~~~~~~~~~~~~~MNKTEFYADLNRDFNALMAGETSFLATLANTS :  32 
fRMsr_VL8  : ~~~~~~~~~~~~~~~~~~MNKAEFYADLNRDFNALMAGETSFLATLANTS :  32 
                                                                                                                                                                                              
               60         *        80         *       100       
fRMsr_YEAS : SLIWHAYKSLAVDINWAGFYVTQASEENTLILGPFQGKVACQMIQFGKGV : 100 
fRMsr_LBAG : ALLNSTYD----NLNWAGFYLFNE-QTGELDLGPFQGKVACMHIKVGAGV :  76 
fRMsr_STAA : ALLNDNLD----QINWVGFYLLE---QNELILGPFQGHPACVHIPIGKGV :  77 
fRMsr_BACI : ALLYHSLP----EVNWAGFYFAKE-EDGQLVLGPFQGLPACVRIPFGRGV :  85 
fRMsr_ECOL : ALLYERLT----DINWAGFYLLE---DDTLVLGPFQGKIACVRIPVGRGV :  75 
fRMsr_FC44 : ALLYERLT----DINWAGFYLLE---DDTLVLGPFQGKIACVRIPVGRGV :  75 
fRMsr_VL8  : ALLYERLT----DVNWAGFYLLE---DDTLVLGPFQGKIACVRIPVGRGV :  75 
                                                                     
             C-76                     
                      *       120         *       140         *       
fRMsr_YEAS : CGTAASTKETQIVPDVNKYPGHIACDGETKSEIVVPIISNDGKTLGVIDI : 150 
fRMsr_LBAG : VGTAFETQTNQRVADVHQFPGHIACDSASNSEIVVPIT-KDGHQIGVLDV : 125 
fRMsr_STAA : CGTAVSERRTQIVADVHQFEGHIACDANSKSEIVVPIF-KDDKIIGVLDI : 126 
fRMsr_BACI : CGTAYANGKVERVEDVNAFPGHIACDAASQSEIVLPIH-VGGKVVGVLDI : 134 
fRMsr_ECOL : CGTAVARNQVQRIEDVHVFDGHIACDAASNSEIVLPLV-VKNQIIGVLDI : 124 
fRMsr_FC44 : CGTAVARNQVQRIEDVHVFDGHIACDAASNSEIVLPLV-VKNQIIGVLDI : 124 
fRMsr_VL8  : CGTAVARNQVQRIEDVHAFDGHIACDAASNSEIVLPLV-VKNQIIGVLDI : 124 
                                                                                                                                 
             D-125 
                    160         *       180         *        
fRMsr_YEAS : DCLDYEGFDHVDKEFLEKLAKLINKSCVFK~~~~~~~~~~~ : 180 
fRMsr_LBAG : DSPSLDRFNADNEAELTEFVAILTSHID~~~~~~~~~~~~~ : 153 
fRMsr_STAA : DAPITDRFDDNDKEHLEAIVKIIEKQLA~~~~~~~~~~~~~ : 154 
fRMsr_BACI : DSPVKNRFDEIDEKYLSQFAETLEKALAQ~~~~~~~~~~~~ : 163 
fRMsr_ECOL : DSTVFGRFTDEDEQGLRQLVAQLEKVLATTDYKKFFASVAG : 165 
fRMsr_FC44 : DSTVFGRFTDEDEQGLRQLVAQLEKVLATTDYKKFFASVAG : 165 
fRMsr_VL8  : DSTVFGRFTDEDEQGLRQLVAQLEKVLATTDYKKFFASVAG : 165 
                                                             
 
Figure 4.5 Multiple alignments of recombinant fRMsr proteins with fRMsrs from different 
organisms. The abbreviations used for fRMsr from: YEAST (P36088); Saccharomyces 
cerevisiae, LBAG; L. agilis R16, STAA (A0A0D6HHM2); Staphylococcus aureus, BACI 
(A0A0K6L851); Bacillus subtilis, ECOL (P76270); E. coli strain K12, FC44; E. coli FC44, VL8; E. 
coli VL8. The default settings were used for Clustal Omega. Amino acid sequences were 
obtained from Uniprot database and the entry numbers of sequences are given in brackets. 
Cys 76 (C) and Asp 125 (D) amino acid residues in E. coli VL8 and E. coli FC44 are highlighted in 
yellow. 
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4.4.3 Cloning of Methionine Sulphoxide Reductases from L. agilis R16, E. coli VL8 
and E. coli FC44 
The cloned msr genes can be listed as: 3 msrA, 1 msrB and 1 frmsr of L. agilis R16; 1 msrA and 
1 msrB of E. coli VL8; 1 frmsr of E. coli FC44 (Table 4.5). 
Bacteria  Cloned msr genes Abbreviation 
L. agilis R16 3 msrA 
1 msrB 
1 frmsr 
LBAG_ msrA 
LBAG_ msrB 
LBAG_ frmsr 
E. coli VL8 1 msrA 
1 msrB 
VL8_ msrA 
VL8_ msrB 
E. coli FC44 1 frmsr FC44_frmsr 
Table 4.5 Cloned msr genes of L. agilis R16, E. coli V8 and E. coli FC44.  
After transformation of recombinant vectors into E. coli DH5α cells, many transformants were 
checked by colony PCR to test if they have correct gene inserts. The expected sizes of PCR 
products with correct gene inserts from all transformants were observed (Figure 4.6). One of 
the positive transformants was used for recombinant plasmid preparation and sequenced. 
Positive recombinant plasmids were transformed into E. coli BL21(DE3) for protein expression 
and the protein expression induction was performed.  
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Figure 4.6 Agarose gel electrophoresis from colony PCR experiments. a) 1-8; selected 
colonies for E. coli DH5α pET15b-LBAG_msrA1, 8-16; selected colonies for E. coli DH5α 
pET15b-LBAG_msrA2, 17-24; selected colonies for E. coli DH5α pET15b-LBAG_msrA3. b)1-5; 
selected colonies for E. coli DH5α pET15b-LBAG_msrB, 6-10; selected colonies for E. coli DH5α 
pET15b-LBAG_frmsr, 11-15; selected colonies for E. coli DH5α pET15b-FC44_frmsr, 16-20; 
selected colonies for E. coli DH5α pET15b-VL8_msrA, 21-24; selected colonies for E. coli DH5α 
pET15b-VL8_msrB. c)1-7; selected colonies for E. coli DH5α pET15b-LBAG_frmsr, 8-14; 
selected colonies for E. coli DH5α pET15b-FC44_frmsr, 15-24; selected colonies for E. coli 
DH5α pET15b-VL8_msrB. l; hyperladder, c1; negative control for PCR (PCR was set up without 
any genomic DNA), c2; positive control for PCR (PCR was set up with pET15b vector). The 
expected PCR product sizes; 198 bp for pET15b vector with no insert, 709 bp for pET15b-
LBAG_msrA1 plasmid, 727 bp for pET15b-LBAG_msrA2 plasmid, 1018 bp for pET15b-
LBAG_msrA3 plasmid, 643 bp for pET15b-LBAG_msrB, 717 bp for pET15b-LBAG_frmsr 
plasmid, 770 bp for pET15b-FC44_frmsr plasmid, 835 bp for recombinant pET15b-VL8_msrA 
plasmid, 670 bp for pET15b-VL8_msrB plasmid.  
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Figure 4.6-Continued 
 
 
 
 
  
133 
 
4.4.4 Protein Expression and Purification of Methione Sulphoxide Reductases 
from L. agilis R16, E. coli VL8 and E. coli FC44 
The protein expression inductions in E. coli BL21(DE3) expressing pET15b-LBAG_msrA1, 
pET15b-LBAG_msrA2 and pET15b-LBAG_msrA3 were carried out for 4 h at 37°C or 24 h at 
25°C, shaking at 250 rpm. Protein expression induction of MsrA proteins of L. agilis R16 at 
37°C did not produce sufficient recombinant proteins in the soluble fraction. Recombinant 
proteins were seen in insoluble fractions (Lane 11, 13, 14, Figure 4.7) so different induction 
and extraction conditions were tested (Figure 4.8) for MsrA1 protein expression. 
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Figure 4.7 SDS-PAGE and Western Blot of the CFEs obtained from E. coli BL21 (DE3) cells 
expressing pET15b-LBAG_msrA1, pET15b-LBAG_msrA2 and pET15b-LBAG_msrA3. a) Protein 
gel where CFEs were run on 12% Bis-Tris gel under denaturing, reducing conditions in MES 
buffer. b) Western blot (using anti-His tag antibody) within the same order of protein gel in a. 
10 µg of protein was loaded per lane. M; See Blue protein marker. Soluble CFEs of uninduced 
and 4 h induced E. coli BL21 (DE3) cells expressing: 1-2; pET15b (empty vector control), 3-4; 
pET15b-ecg44 (positive control for western-6XHis-tagged protein), 5-6; pET15b-LBAG_msrA1, 
7-8 pET15b-LBAG_msrA2, 9-10; pET15b-LBAG_msrA3, Insoluble CFEs of 4 h induced E. coli 
BL21 (DE3) cells expressing: 11; pET15b-LBAG_msrA3, 12; pET15b-ecg44, 13; pET15b-
LBAG_msrA1, 14; pET15b-LBAG_msrA2. Protein expressions were induced at 37°C with 0.5 
mM IPTG.   
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Protein expression induction at 25°C for 24 h resulted in higher level of expression of MsrA1 
(Lane 5, 6 Figure 4.8). The same profile was seen for MsrA2. After optimisation of induction 
conditions, MsrA1 and MsrA2 proteins were successfully extracted and confirmed to have 
predicted sizes (Table 4.6). These proteins were checked by Western blot for presence of 
6XHis-tag (Figure 4.7) and purified by Ni-NTA column. The purification of MsrA3 was more 
challenging, the targeted protein was not expressed well by the E. coli cells and the Ni-NTA 
purification of MsrA3 failed (Figure 4.9). Many different protein expression conditions were 
tested to optimise the conditions. MsrA3 is mostly found in the insoluble fraction. Reducing 
the IPTG concentration to 0.1 mM and extraction by Bugbuster protein extraction reagent 
(Novagen) improved the extraction of MsrA3 in the soluble fraction (Figure 4.9 BB Lanes, 
circled) but MsrA3 was not used in further enzyme assays.  
 
   Bacterium Protein Predicted Size with  
6XHis-tag (kDa) 
 
pI 
L. agilis R16  MsrA1 
 
21.4 6.2 
L. agilis R16  MsrA2 22 6.2 
L. agilis R16  MsrA3 33.4 10 
L. agilis R16  MsrB 18 6.3 
L. agilis R16 fRMsr 18.3 5.0 
E. coli FC44 fRMsr 22 5.8 
E. coli VL8 MsrA 25.1 6.0 
E. coli VL8 MsrB 17.2 6.5 
Table 4.6 Properties of putative methionine sulphoxide reductases. pI; isolelectric point. 
Predicted sizes and pI of proteins were obtained using the amino acid sequences of the 
proteins by Editseq-sequence editing software (DNAstar).  
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Figure 4.8 SDS-PAGE of CFEs of E. coli BL21 (DE3) expressing pET15b-LBAG_msrA1. 10 µg of 
protein was loaded per lane. M: See Blue Protein Marker. Soluble CFEs obtained from 
induced cells for:  1-2; 3 h at 37°C, 3-4; 4 h at 37°C extracted by Bugbuster, 5-6: 24 h at 25°C. 
Insoluble CFEs obtained from induced cells for: 7-8; 3 h at 37°C, 9-10: 4 h at 37°C extracted by 
Bugbuster, 11-12: 24 h at 25°C. Proteins were run on 12% Bis-Tris Gel under denaturing, 
reducing conditions in MES buffer.  
 
 
Figure 4.9 SDS-PAGE of the Ni-NTA purified MsrA proteins from E. coli BL21 (DE3) 
expressing pET15b-LBAG_msrA1, pET15b-LBAG_msrA2 and pET15b-LBAG_msrA3.  3.25 µl of 
fractions were loaded per lane. FT: Flow through, W: Wash, E: Eluate, M; Protein marker, S: 
Soluble, IS: Insoluble. BB: MsrA3 purified by Bugbuster (Novagen). Proteins were run on 10% 
Bis-Tris Gels under denaturing, reducing conditions in MES buffer.  
  
137 
 
     
To optimise the protein expression for the rest of the Msr proteins, various conditions were 
examined. The protein expressions were carried out at 25°C for 4 h and 37°C for 3 h or 4 h. 
The proteins were induced and CFEs were loaded on a SDS-PAGE gel and checked for their 
expected sizes (See Table 4.6). The optimum protein expression conditions for all of the 
proteins are shown in Table 4.7. Induction at 37°C for 4 h was found to be optimum under the 
conditions tested for LBAG_MsrB and VL8_MsrB. For VL8_MsrA expression, 3 h induction at 
37°C was found to provide higher levels of protein. These proteins showed a different 
expression profile compared to MrsA1 and MsrA2 proteins of L. agilis R16. Protein expression 
induction at 25°C resulted in better expression of MrsA1 and MsrA2 proteins of L. agilis R16. 
The protein expression of LBAG_fRMsr and FC44_fRMsr under conditions tested did not 
produce sufficient proteins in the soluble fraction and proteins were mostly seen in the 
insoluble fraction.   
 
   Bacterium Protein Abbreviation Optimum Protein Expression 
Condition 
L. agilis R16  MsrA1 LBAG_MsrA1 25°C for 24 h 
L. agilis R16  MsrA2 LBAG_MsrA2 25°C for 24 h 
L. agilis R16  MsrA3 LBAG_MsrA3 37°C for 3 h* 
L. agilis R16  MsrB LBAG_MsrB 37°C for 4 h 
L. agilis R16 fRMsr LBAG_fRMsr ND 
E. coli FC44 fRMsr FC44_fRMsr ND 
E. coli VL8 MsrA VL8_MsrA 37°C for 3 h 
E. coli VL8 MsrB VL8_MsrB 37°C for 4 h 
Table 4.7 Optimum conditions of E. coli BL21 (DE3) expressing msr genes. The abbreviations 
of the proteins are shown and these will be used subsequently for naming the proteins. * 
Protein extraction was performed by Bugbuster Reagent (Novagen). ND; Not determined, 
expression of LBAG_fRMsr and FC44_fRMsr under conditions tested resulted in expression of 
the proteins mostly in insoluble fractions.  
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CFEs were prepared using optimum protein expression conditions and tested for the 
presence of 6XHis-tag by Western Blot (See Figure 4.10). Protein expression induction was 
performed at 37°C for 4 h for LBAG_fRMsr and FC44_fRMsr.  
 
Figure 4.10 SDS-PAGE and Western Blot of the soluble CFEs from E. coli BL21 (DE3) 
expressing recombinant pET15b plasmids expressing msr genes. a) Protein gel where CFEs 
were run on 12% Bis-Tris gel under denaturing, reducing conditions in MES buffer. b) Western 
blot (using anti-His tag antibody) within the same order of protein gel in a. 10 µg of protein 
was loaded per lane. M: See Blue Protein Marker. CFEs of E. coli BL21 (DE3) cells expressing: 
1; pET15b (empty vector control) induced at 37°C for 4 h, 2; pET15b-LBAG_msrB induced at 
37°C for 4 h, 3; pET15b-LBAG_frmsr induced at 37°C for 4 h, 4; pET15b-FC44_frmsr induced at 
37°C for 4 h, 5; pET15b-VL8_msrA induced at 37°C for 3 h, 6; pET15b-VL8_msrB induced at 
37°C for 4 h.  
 
Proteins were seen to be bound to the anti-His tag except the FC44_fRMsr (Lane 4, Figure 
4.10) with the expected sizes (Table 4.6). No binding to the anti-His tag was observed for 
FC44_fRMsr. LBAG_MsrB and VL8_MsrB were purified by Ni-NTA columns. Ni-NTA 
purification was performed successfully; eluates were obtained with expected protein sizes 
(Figure 4.11).   
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Figure 4.11 SDS-PAGE of Ni-NTA purified MsrB proteins from E. coli BL21 (DE3) expressing  
pET15b-LBAG_msrB and pET15b-VL8_msrB. 3.25 µl of fractions were loaded per lane. M: See 
Blue Protein Marker, FT: Flow through, W: Wash, E: Eluate, M; Protein marker, Proteins were 
run on 10% Bis-Tris Gels under denaturing, reducing conditions in MES buffer. The predicted 
sizes of LBAG_MsrB and VL8_MsrB are 18 kDa and 17.2 kDa, respectively.  
4.4.5 Reductase Activity of Recombinant Methionine Sulphoxide Reductases  
Ni-NTA purified, dialysed eluates of MsrA1 and MsrA2 were used to determine glucoraphanin 
reduction in the presence of dithiothreitol (DTT). Samples were analysed by HPLC to check 
glucoraphanin degradation and formation of glucoerucin after 30 min incubation. MsrA1 was 
more effective for glucoerucin formation than MsrA2 (Figure 4.12). MsrA1 and MsrA2 showed 
glucoerucin formation at a rate of 0.57 ± 0.04 nmol glucoerucin/µg protein and 0.13 ± 0.00 
nmol glucoerucin/µg protein respectively. MsrA1 was also tested for reductase activity with 
longer incubation times (1, 2 and 3 h) and higher protein amount (50 µg). None of these 
changes in the enzyme assays increased the rate of glucoerucin formation for MsrA1 (data 
not shown). This reduction did not occur in the control samples without eluates. This suggests 
that the reduction is an enzymatic reaction. When 1 mM of NADPH was used as reducing 
agent instead of 20 mM DTT with 1 mM MgCI2 in the assays, no glucoerucin formation was 
obtained. This study was continued to focus on other bacteria such as E. coli VL8 and E. coli 
FC44. In addition, the role of other types of Msr enzymes was investigated.  
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Figure 4.12 Reduction of glucoraphanin to glucoerucin by MsrA1 and MsrA2.  Glucoraphanin 
amount left and glucoerucin amount formed after 30 min incubation are shown. Samples and 
controls contained 1 mM glucoraphanin originally. Control indicates the glucoraphanin 
control without any protein that was incubated for 30 min. Assays were set up using same 
amount of protein (10 µg). Error bars = standard deviation (n=3).  
 
 
CFEs were tested for reductase activity against 0.5 mM glucoraphanin to examine if they can 
reduce glucoraphanin to glucoerucin. CFEs of E. coli BL21 (DE3) expressing pET15b-
LBAG_msrB, pET15b-LBAG_frmsr, pET15b-FC44_frmsr, pET15b-VL8_msrA and pET15b-
VL8_msrB were tested for reductase activity using 20 mM DTT as reducing agent. The results 
are shown in Figure 4.13. In the presence of DTT without CFE (control 1), glucoraphanin was 
converted to glucoerucin with a rate of 0.08 ± 0.03 nmol glucoerucin/µg protein. In absence 
of DTT and any CFE (control 2), there was no glucoerucin formation but glucoraphanin 
degradation occurred. In addition, control including CFE of E. coli BL21(DE3) pET15b (empty 
vector control) showed glucoraphanin degradation but there was no glucoerucin formation in 
these controls. LBAG_fRMsr, IS44_ fRMsr and VL8_MsrA samples showed glucoerucin 
formation at a similar rate (~0.06 ± 0.01 nmol glucoerucin/µg protein) which was also similar 
to control 1. LBAG_MsrB and VL8_MsrB reduced glucoraphanin at a rate of 0.31 ± 0.02 nmol 
glucoerucin/µg protein and 0.68 ± 0.02 nmol glucoerucin/µg protein, respectively.  
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Figure 4.13 Reduction of glucoraphanin to glucoerucin by CFEs of E. coli BL21(DE3) 
expressing msr genes. Control 1 indicates the glucoraphanin control without any CFE, Control 
2 indicates the control without CFE and DTT addition. Vector Control is the sample that 
includes CFE of E. coli BL21(DE3) with empty pET15b vector. Samples and controls contained 
0.5 mM glucoraphanin originally. Assays were set up using same amount of protein (100 µg). 
Error bars = standard deviation (n=3). 
 
MsrB proteins are likely to be responsible for the reductase activity of E. coli VL8 and L. agilis 
R16. LBAG_MsrB and VL8_MsrB showed higher reduction rates compared to control 1 (See 
chromatograms, Figure 4.14). Notably, the reductase activity of VL8_MsrB was remarkable 
because it was able to reduce almost all of the glucoraphanin to glucoerucin. 
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b 
 
Figure 4.14 HPLC chromatograms showing reduction of glucoraphanin to glucoerucin by 
CFEs of E. coli BL21(DE3) cells expressing pET15b-LBAG_msrB (a) and pET15b-VL8_msrB (b). 
1; glucoraphanin, 2; sinigrin (internal standard), 3; glucoerucin.  
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Ni-NTA purified, dialysed eluates of LBAG_MsrB and VL8_MsrB were used to determine 
enzyme activity in the presence of DTT or NADPH as reducing agent. These reactions were 
used in the sample preparation for HPLC and analysed on HPLC to check the formation of 
glucoerucin. The reduction rates were based on glucoerucin formation and are given in Table 
4.8. In addition, the concentrations of glucoraphanin left and glucoerucin formed is shown in 
Figure 4.15. Controls including NADPH or DTT showed a reduction rate of 0.13 ± 0.01 nmol 
glucoerucin/µg protein and 0.51 nmol ± 0.02 nmol/glucoerucin/µg protein respectively. 
Reduction rate of LBAG_MsrB was 0.14 ± 0.01 nmol glucoerucin/µg protein and 1.03 ± 0.11 
nmol glucoerucin/µg protein using NADPH and DTT as reducing agent respectively. VL8_MsrB 
showed a reduction rate of 0.15 ± 0.01 nmol glucoerucin/µg protein when NADPH was used 
as reducing agent. However, it reduced glucoraphanin to glucoerucin with a rate of 5.42 ± 
0.18 nmol glucoerucin/µg protein when DTT was used instead of NADPH.  
 
Samples 
Reduction rate (nmol glucoerucin/µg protein) 
NADPH DTT 
Control 0.13 ± 0.01 0.51 ± 0.01 
LBAG_MsrB 0.14 ± 0.01 1.03 ± 0.11 
VL8_MsrB 0.15 ± 0.01 5.42 ± 0.18 
Table 4.8 The reduction rate of glucoraphanin to glucoerucin by Ni-NTA purified LBAG_MsrB 
and VL8_MsrB using NADPH or DTT as reducing agent. The reactions were set up with 1 mM 
NADPH or 20 mM DTT as reducing agent. Assays were set up using same amount of protein 
(10 µg). Results were given as mean of triplicates ± standard deviation. 
 
 
VL8_MsrB could reduce glucoraphanin to glucoerucin with a high rate in presence of DTT as 
reducing agent. The reduction by VL8_MsrB was very low when NADPH used as a reducing 
agent (Figure 4.15).  
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Figure 4.15 Reduction of glucoraphanin by Ni-NTA purified LBAG_MsrB and VL8_MsrB.   
Control indicates the glucoraphanin control without any eluate. The reactions were set up 
with 1 mM NADPH or 20 mM DTT as reducing agent. Samples and controls contained 0.5 mM 
glucoraphanin originally. Assays were set up using same amount of protein (10 µg). Error bars 
= standard deviation (n=3). 
4.5 DISCUSSION 
Significant inter-individual variations have been observed in the degradation of glucosinolates 
to ITCs by human gut bacteria [246]. The myrosinase activity of gut bacteria against different 
glucosinolates may vary and gut bacteria may use alternative pathways to degrade 
glucosinolates. For instance, some gut isolates were able to degrade methylsulfinylalkyl 
glucosinolates (such as glucoraphanin) directly to its corresponding isothiocyanate 
(sulforaphane for glucoraphanin) while others require a reduction step that converts 
methylsulfinylalkyl glucosinolates into methylthioalkyl glucosinolates followed by hydrolysis 
to isothiocyanates [55, 56]. Therefore this reduction step is essential in understanding the 
diverse routes of glucosinolate metabolism to maximize the health promoting effects of ITCs.  
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E. coli VL8 and E. coli FC44 converted the glucoraphanin in the media to its reduced 
counterpart, glucoerucin so these strains were further studied for their reductase activity. 
CFEs of E. coli VL8 and E. coli FC44 prepared from cells grown overnight with or without 
glucosinolate supplementation were able to reduce glucoraphanin to glucoerucin. Luang-In et 
al. (2014) reported that reductase activity in CFE of E. coli VL8 was inducible by glucoraphanin 
and CFE of E. coli VL8 was unable to reduce glucoraphanin without a glucosinolate 
supplementation to the media used in CFE preparation [56]. However, no induction effect 
was found for reductase activity in CFEs of E. coli VL8 and E. coli FC44. The same culture 
(nutrient broth) to grow cells and same buffer (0.1 M citrate phosphate buffer pH 7.0) to 
prepare CFE were used in our study. The differences were the method to prepare CFEs and 
the source of the substrate (glucoraphanin).  Instead of using a cell-disrupter, sonication was 
used in our study. Glucoraphanin used in our study was either supplied to us from a human 
intervention study in IFR (purchased from Intertek) or purchased from a company (Cambridge 
Biosciences). However, Luang-In et al. (2014) have prepared their own glucoraphanin by 
oxidation of glucoerucin with hydrogen peroxide [56]. There was no comment about ITC or 
other degradation products in their study. If glucoraphanin was reduced to glucoerucin in 
uninduced CFEs, glucoerucin might have been degraded by myrosinase activity rapidly and 
not detected in their samples. Another possibility is that the glucoraphanin used in our study 
might be more amenable to reductase activity. Our results suggested that reductase activity 
in CFEs of E. coli VL8 and E. coli FC44 may be constitutive.  
Methionine sulphoxide reductase A (MsrA) was suggested to be responsible for reducing 
methylsulfinylalkyl glucosinolates (such as glucoraphanin) into methylthioalkyl glucosinolates 
(such as glucoerucin) [55]. To test this hypothesis, partially purified MsrAs were tested for 
reductase activity against glucoraphanin (Intertek) in the presence of different reducing 
agents but the degradation rate of glucoraphanin to glucoerucin was low. Increasing 
incubation time and protein amount was also tested but these effects did not improve the 
reductase activity of MsrAs. This low glucoraphanin reduction rate was in accordance with 
the low glucoraphanin degradation rate by L. agilis R16 reported previously because L. agilis 
R16 degraded only 10 ± 2% of the glucoraphanin in the media after 24 h [56].  
It was also thought that different types of Msr enzymes can have a role in reduction of 
glucosinolates because they can reduce different epimers of methionine sulphoxide. For 
instance, MsrAs can only reduce free and protein-based S-epimers of methionine sulphoxide. 
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In the literature, glucoraphanin extracted from B. oleracea var italica (broccoli) and A. 
thaliana was reported to be a pure epimer of R configuration at the sulphoxide group [247]. 
No information was provided to us by suppliers about configuration of the methyl sulphoxide 
of glucoraphanin, they might be a pure epimer (R or S) or a mix of these two epimers. 
Therefore, different Msr enzymes were investigated in our study including MsrA, MsrB and 
fRMsr of L. agilis R16, E. coli VL8 and E. coli FC44.   
FC44_fRMsr failed to bind the anti-His tag during Western Blot. This might be a problem 
about protein production or may suggest that there had been protein degradation. Lin et al. 
(2007) studied the fRMsr of E. coli sharing the same amino acid with fRMsr of E. coli FC44. 
They reported the initiation of the protein synthesis 18 amino acids upstream from the first 
methionine and presence of larger version of fRMsr. Moreover, it was reported that the 
purified protein was a mix of both versions of the fRMsr showing the same Msr activity [245]. 
There was no indication of signal peptide. Maybe, the full length of protein has better 
stability or solubility so it was needed to clone the larger version of the protein for a 
successful  protein expression with 6XHis-Tag.  
When CFEs of E. coli BL21(DE3) expressing msr genes were tested for reductase activity, it 
was found that the sum of the glucoraphanin amount left and glucoerucin amount formed did 
not match with the original glucoraphanin concentration. This effect was seen in controls 
without any reducing agent and protein. The reason might be the purity of glucoraphanin 
stock used in the study. It should be noted that glucoraphanin stock (from Cambridge 
Biosciences) used in this part of the study was different from the one used for testing 
reductase activity of LBAG_MsrA1 and LBAG_MsrA2 (from Intertek). Notably, vector control 
which included CFE of E. coli BL21(DE3) cells expressing empty pET15b vector had a low 
glucoraphanin amount left compared to controls without any glucoerucin formation. It is not 
known if this effect might be caused by the metabolism of glucoraphanin by CFE.  Another 
issue is the formation of glucoerucin in controls including only DTT without any protein 
extract. This might suggest a non enzymatic reduction and the longer incubation time might 
be the reason for this effect. When purified LBAG_MsrA1 and LBAG_MsrA2 were tested for 
reductase activity, samples and controls were incubated for 30 min and there was no 
glucoerucin formation in controls. To overcome this, the effect of shorter incubation times 
could be tested.  
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As expression of FC44_ fRMsr with 6XHis-tag failed, it is not possible to comment on its role in 
reductase activity of E. coli FC44. However, it is unlikely that LBAG_fRMsr and VL8_MsrA are 
responsible for reduction of glucoerucin because CFEs consisting these proteins showed 
similar reduction rates compared to control. However, shortening the incubation time might 
eliminate the reduction of glucoraphanin by control and give a better idea about the roles of 
these proteins in reductase activity.  
Our results indicate that MsrB may be responsible for reduction glucoraphanin to glucoerucin 
because CFEs consisting LBAG_MsrB and VL8_MsrB showed remarkable reduction of 
glucoraphanin to glucoerucin compared to control. Luang-In et al. (2014) reported that 
reductase activity in CFEs of E. coli VL8 was oxygen-independent, NADPH and Mg+2 dependent 
[56]. When Ni-NTA purified LBAG_MsrB and VL8_MsrB were tested for reductase activity in 
presence of 1 mM NADPH with 1 mM MgCI2, reduction rates were low and similar to control. 
Using 20 mM DTT as a reducing agent resulted in higher reduction rates and showed that DTT 
can be used as a reducing agent to test reductase activity in vitro. The reduced thioredoxin 
was reported to be the reducing agent in vivo in reduction of methionine sulphoxides and DTT 
was shown to substitute it in vitro [141, 163]. It also suggested that MsrB may be the 
responsible enzyme for reduction of glucoraphanin to glucoerucin in L. agilis R16 and E. coli 
VL8. The role of MsrB in reductase activity suggested that the glucoraphanin stock used was 
mainly included R-epimer of sulphoxide group as has been suggested to occur in plants [247]. 
It should be taken into account that MsrA has specificity for the S-epimer, MsrB and fRMsr 
have specificities for R-epimer of methionine sulphoxide and it is important to use a substrate 
that mimics the substrate found in the plant to determine which enzyme is responsible for 
activity. When reductase activity of purified MsrA1 and MsrA2 of L. agilis R16 was tested, a 
different glucoraphanin stock was used. If this previous glucoraphanin stock contained small 
amount of S-epimer of sulphoxide group, this might be the reason for the low levels of MsrA 
activity.  It is not known why LBAG_fRMsr could not reduce glucoraphanin as fRMsr has 
specificity for free form of R epimer of methyl sulphoxide but this could be related to low 
levels of protein production in the soluble CFE.  
When reductase activity of LBAG_MsrB and VL8_MsrB were compared to each other, it 
explained the difference in glucoraphanin degradation rates of L. agilis R16 and E. coli VL8. As 
reported previously, L. agilis R16 was degraded 10 ± 2% of glucoraphanin in the media but E. 
coli VL8 was able to degrade 91 ± 7% of the glucoraphanin in the media after 24 h incubation 
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[56]. This showed that E. coli VL8 has more efficient reductase activity compared to L. agilis 
R16,  resulting in higher glucoraphanin degradation rates.  
Unfortunately, we could not determine the optimum conditions for reductase activity of 
LBAG_MsrB and VL8_MsrB. The effect of temperature, buffer, pH, other reducing agents, etc. 
should be investigated. As reductase activity in CFEs of E. coli VL8 was reported to be oxygen-
independent, all assays were performed under aerobic conditions. However, the effect of 
oxygen can be still tested for confirmation. Sulforaphane was a substrate for reductase 
activity of E. coli VL8 CFE [137], it was expected that MsrB can also reduce sulforaphane and 
further examination of the substrate range will be interesting.  
In summary, it was found that MsrB is likely to be the responsible enzyme in reduction of 
glucoraphanin possessing R-epimer of sulphoxide in its structure. This study was the first to 
confirm the role of Msr enzymes in reduction of glucosinolates with a sulphoxide group in 
their side chain. This finding provides us a better understanding about the diverse routes of 
glucosinolate metabolism by gut bacteria.  
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CHAPTER FIVE 
 
5 CHARACTERISATION OF A BACTERIAL MYROSINASE OF 
SOIL ORIGIN 
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5.1 INTRODUCTION 
The first bacterial myrosinase was purified in 1974 from Enterobacter cloacae but it was not 
extended to  further  identification of the gene or amino acid sequence [231]. Since then a 
limited number of studies have investigated the metabolism of glucosinolates by different 
bacteria. These studies attempted to identify and characterise the enzyme but with limited 
success [137, 232] Some studies reported the glucosinolate metabolism by human gut 
bacteria in vitro [56], in rat models [112, 213] or using in vitro fermentation models [165, 
212]. These studies contributed to our understanding of the glucosinolate metabolism by 
human gut bacteria. However, identification of the responsible enzyme or enzyme groups and 
their characterisation could not be achieved. To maximize the health promoting effects of 
glucosinolate degradation products, isothiocyanates, we need a better understanding of 
bacterial myrosinases. In this context, identification and characterisation of bacterial 
myrosinases is crucial.  
Recently, a C. WYE1 strain was isolated from soil and this strain was reported to have 
glucosinolate degrading ability. An enrichment method using the sinigrin as sole carbon 
source was used to isolate this bacterium. The enzyme responsible for myrosinase activity 
was purified by a chromatography approach that combined ion exchange chromatography 
and gel filtration. Later, N-terminal and internal amino acid sequence of the myrosinase was 
determined and enzyme activity partially characterised using cell-free extracts. It was found 
to be a periplasmic β-glucosidase from GH3 family with a signal peptide [118]. So far, 
identified myrosinases in plants [119], aphids [132] or beetles [248] were reported to belong 
to the GH1 family so this myrosinase was the first of its own kind. It was found be activated 
by ascorbate like plant myrosinases [118]. The identification of this myrosinase changed our 
perspective in this study and we then focused on β-glucosidases from GH3 too to identify a 
bacterial myrosinase from the human gut. Rossiter Group at Imperial College  attempted to 
clone and express this myrosinase gene in E. coli (unpublished data). Unfortunately, their 
attempt to clone the myrosinase gene was not successful and  they did not pursue this 
further. This chapter focuses on cloning and expression of C. WYE1 myrosinase (cmyr) and 
characterisation of this enzyme. 
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5.2  HYPOTHESIS 
C. WYE1 showed myrosinase activity. The reported myrosinase activity of C. WYE1 is the 
product of the expression of a periplasmic β-glucosidase from GH3 family.  
5.3 MATERIALS AND METHODS 
5.3.1 Strain Identification and Preparation of Phylogenetic Tree 
The strain C. WYE1 was kindly provided to by John Rossiter from Imperial College London. The 
genome of C. WYE1 was sequenced, assembled and annotated as described in Chapter 2-
section 2.2.13. 16S rDNA sequencing was performed to assign the strain to a specific species, 
method was performed as described in Chapter 2- section 2.2.12. To determine the 
phylogeny of C. WYE1, a phylogenetic tree was constructed as described in Chapter 2-section 
2.2.14.  
5.3.2 Comparison of C. WYE1 Myrosinase with Other Myrosinases 
Amino acid sequences of different myrosinases from different origins were selected using the 
Uniprot database. These myrosinases were aligned with cmyr using Clustal Omega [237].  
5.3.3 Cloning and Expression of Myrosinase Gene 
As cmyr was reported to have a signal peptide, a cloning vector which has 6XHis-tag site in 
both N-terminal and C-terminal site (pET28b) was used. Primers were designed to introduce 
new restriction sites by changing nucleotides and to enable in-frame translation of C-terminal 
6XHis-tag by insertion of a new nucleotide to the reverse primer. This allowed  the expression 
of the protein with two 6XHis-tags at N-terminal and C-terminal sites. Then it was possible to 
purify protein by Ni-NTA column even if the N-terminal tag is being cleaved off. The primers 
were designed to amplify the cmyr are given in Table 5.1, the restriction sites are underlined. 
The nucleotide sequence of the cloned gene is shown in the Appendix 2. PCR insert was 
amplified (PCR conditions are given in Table 5.2) and double restricted by NdeI/XhoI and 
ligated to NdeI/XhoI double restricted pET28b vector (Novagen) then this gene construct was 
transformed into E. coli DH5α cells as described in Chapter 2-section 2.2.10 and the cells were 
plated on L agar with kanamycin (30 µg/ml, final concentration).   
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Name Primer Sequence (5``-3`) Restriction Site 
CMYR-F GGAACATATGCTCACTGCTTTTAAGA NdeI 
CMYR-R CAGACTCGAGACGTGTCAGTCCGAAT XhoI 
Table 5.1 Primers used in the PCR experiments to amplify the cmyr. The restriction sites are 
underlined. The altered nucleotides to introduce the restriction sites are in bold.  The inserted 
nucleotide is highlighted. 
 
Name TA, time, cycles TE, time Product size 
CMYR-F 
CMYR-R 
54°C, 30 s, 5X           
72°C, 1 min 
 
 1998 bp 
 68°C, 30 s, 20X     
Table 5.2 Conditions used in the PCR experiments to amplify the cmyr gene. TA; annealing 
temperature, cycles; cycles used in annealing step of PCR, TE; extension temperature and time 
used in PCR, Product size; the expected PCR product sizes for β-glucosidase genes. The 
annealing step was performed using Tm of 100% sequence match part of primers first (5X) and 
then using the Tm of entire primer (20X).  
 
Colonies were screened by colony PCR using primers T7P2 (5’-TGAGCGGATAACAATTCCC) and 
T7T (5’-GCTAGTTATTGCTCAGCGG) to select the positive transformants. The clones that gave 
positive result for PCR were selected and inoculated in L Broth with kanamycin (30 µg/ml final 
concentration) to grow overnight at 37°C, with shaking at 250 rpm. The recombinant plasmids 
were extracted using EZNA Plasmid Mini Kit II (Omega Bio-Tek) and sequenced using T7P2 (5’-
3’: TGAGCGGATAACAATTCCC), T7T (5’-3’: GCTAGTTATTGCTCAGCGC) and an internal primer 
(5’-3’: GACCCTGAGCTGGCTAAA).  After confirmation that there were no mutations on cloned 
insert, the recombinant plasmid was transformed into E. coli BL21 (DE3) for protein 
expression (Method is in Chapter 2-section 2.2.10).  
E. coli BL21 (DE3) expressing pET28b-cmyr was induced with 0.5 mM IPTG. Protein expression 
induction was carried out in two ways either at 25°C for 24 h or at 37°C for 3 h.  After protein 
induction, CFEs were prepared by sonication as described in Chapter 2-section 2.3.1. Soluble 
and insoluble fractions were run on SDS-PAGE gel as described in Chapter 2-section 2.3.3.  
5.3.4 Purification of Myrosinase and Measurement of Enzyme Activity 
The CFEs were checked for the presence of the expressed protein by Western blot using 
antibodies raised against 6X-His tag (Chapter 2-section 2.3.4) and then cmyr was purified by 
affinity purification using Ni-NTA column (Chapter 2-section 2.3.5). Partially purified cmyr was 
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dialysed to remove excessive amount of imidazole from Ni-NTA column purification. 
Spectra/Por porous membrane tubing with 500-1000Da cut off (Spectrum Labs) was used for 
dialysis. The protein was dialysed against 20 mM citrate phosphate buffer pH 6.0 for 18 h at 
4°C. The protein concentration of the dialysed fractions was quantified by Bradford assay and 
God-Perid assay was used to determine the enzyme activity of protein. These methods were 
explained in detail in Chapter 2 sections 2.3.2 and 2.3.6 respectively.   
5.3.5 Dialysis and Filtration of Purified Protein for Crystallography  
Ni-NTA purified cmyr was dialysed against 50 mM Tris-HCI 20 mM NaCI pH 7.0 buffer for 18 h 
at 4°C. Later, cmyr was filtered and concentrated for crystallography studies. Amicon Ultra 4-
50k filters (Millipore) were used according to supplier’s advice. The sample was loaded on to 
the filter unit and spun down at 4000 x g for 20 min at 4°C then concentrated samples were 
removed from filter device. The concentration of cmyr was adjusted to 10 mg/ml and sent to 
Imperial College London for crystallography studies.  
5.3.6 Intact Mass Analysis 
Dialysed protein sample was concentrated to 50 µM, this protein sample was analysed by 
LCMS to determine the intact mass of the protein. Protein intact mass was analysed on a 
Synapt G2-Si mass spectrometer coupled to an Acquity UPLC system (Waters, UK). An aliquot 
of ~300 pmoles of protein was injected onto an Aeris Widepore 3.6u C4 Column 50 x 2.1 mm 
(Phenomenex). Elution was performed by a gradient of 5-90% acetonitrile in 5 min with a flow 
rate of 0.4 ml/min. Masslynx 4.1 software (Waters) was used to control the spectrometer and 
it was operated in positive MS-TOF and resolution mode with a capillary voltage of 2.5 kV and 
a cone voltage of 40 V. Leu-enkephalin peptide (1 ng/ml, Waters) was infused at 3 µl/min as a 
lock mass and measured every 20 s. The spectra were produced by combining a number of 
scans, and deconvoluted using the MaxEnt1 tool in Masslynx. LCMS run was performed by Dr. 
Gerhard Saalbach (JIC, Norwich).  
5.3.7 Characterisation of Myrosinase  
The myrosinase activity of C. WYE1 was assayed using cell-free extracts previously by Albaser 
et al. (2016)[118]. In this study, the protein with 6XHis-tag was partially purified and further 
characterisation was performed. The optimum pH, temperature and buffer for myrosinase 
activity were studied and enzyme kinetics experiments were performed to determine Km  and 
Vmax for sinigrin.  
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The optimum pH was tested in 20 mM citrate phosphate buffer (pH range of 3.6-7.6). 
Dialysed cmyr was added to the 300 µl mixture of sinigrin (2 mM, final), protein (24 ng) in 20 
mM citrate phosphate buffer at a pH range of 3.0 - 7.6. The assay mixture was incubated at 
37°C for 1 h and reaction was stopped by boiling the tubes for 5 min to inactivate the 
myrosinase. God-Perid assay was used to determine the glucose released. The optimum 
temperature was tested over a range of temperatures (5-70°C). The reaction mixtures were 
set up in 300 µl of volume consisting sinigrin (2 mM), protein (25 ng) in citrate phosphate 
buffer pH 6.0, incubated for 30 min and glucose release was measured by God-Perid assay.  
To assess the the Michaelis-Menten constant (Km) and maximum velocity (Vmax) for sinigrin, 
0.1-5 mM range of sinigrin was incubated with cmyr (24 ng) in 300 µl of citrate phosphate 
buffer pH 6.0 at 25°C for 10 min then activity was determined by God-Perid assay. The 
Lineweaver-Burk plot method was used to determine Km and Vmax. The myrosinase activity of 
cmyr was tested using 2 mM of different glucosinolates (sinigrin, glucoiberin, progoitrin, 
glucoerucin, gluroraphanin, glucotrapaeolin, gluconasturtiin and glucobrassicin) by God-Perid 
assay (Chapter 2-section 2.3.6). The assay was undertaken at optimum temperature and 
buffer conditions for myrosinase activity. In addition, the stability of myrosinase activity of 
cmyr was tested in 20 mM citrate phosphate buffer pH 6.0 over 5 weeks at 4°C.  
5.4 RESULTS 
5.4.1 Strain Identification and Preparation of Phylogenetic Tree 
Rossiter Group at Imperial College isolated a strain with myrosinase activity from soil. We 
found that this soil isolate belongs to the family Enterobacteriaceae and the genus 
Citrobacter. 16s rDNA sequencing results matched with 20 known Citrobacter species. It was 
isolated from soil nearby Wye (Kent, UK) so named as C. WYE1 to show the origin of the 
isolate by Dr. John Rossiter before. 16s rDNA could not assign the strain to a specific species 
so a phylogenetic tree was constructed (Figure 5.1). The results suggested that C. WYE1 is 
likely to be a new species.  
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Figure 5.1 Phylogenetic tree of C. WYE1 compared with other Citrobacter species. Draft 
genomes of different Citrobacter species were obtained from Genbank whole genome 
shotgun projects. Core genome SNPs in draft genomes and C. WYE1 were used to prepare the 
phylogenetic tree using the parSNP program Version 1.2 by Dr. Arnoud Van Vliet (IFR). 
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5.4.2 The Relevance of C. WYE1 Myrosinase to Other Myrosinases 
The protein sequence of cmyr was aligned with other myrosinases identified so far (Figure 
5.2). There is a high homology among plant myrosinases from A. thaliana, Eutrema 
japonicum, S. alba, B. napus and B. oleracea var. alboglabra. The proton donor and 
nucleophile were reported to be Gln 207 and Glu 426 residues respectively in S. alba 
myrosinase obtained from Uniprot database and conserved among plant myrosinases aligned 
below (Figure 5.2). In B. brassicae myrosinase (aphid myrosinase), Glu 374 was reported to be 
the nucleophile and Glu 167 was reported as the proton donor [133]. These two key amino 
acid residues were not conserved in cmyr and it was found to be quite distinct from aphid and 
plant myrosinases. The importance of the conserved motif ’SDW’ in cmyr possessing aspartic 
acid (D) as the nucleophile was suggested by Albaser et al. (2016) [118].  
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                      *        20         *        40         *       
CMYR       : MLTAFKMNTVSLAVLVCLPLSVSASIQSAQQPELGYDTVPLLHLSGLSFK :  50 
BREBR_Myro : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ :   - 
ARATH_Myro : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~MKLLMLAFV :   9 
EUTJA_Myro : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~MKLHGLALV :   9 
SINAL_Myro : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~MKLLHGLALV :  10 
BRANA_Myro : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~MKLLHGLALV :  10 
BRAOA_Myro : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~MKLLHGLALV :  10 
                                                                                                                                           
                     60         *        80         *       100       
CMYR       : DLNRDGKLNPYEDWRLSPQTRAADLVKRMSVAEKAGVMMHGTAPAEGSTF : 100 
BREBR_Myro : ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~MDYKF :   5 
ARATH_Myro : FLLALATCKGD-E---------------FVCEENEPFTCNQTKLFNSGNF :  43 
EUTJA_Myro : FLLAVATCKAVED---------------ITCQEKEPFTCSNTDSLNSKSF :  44 
SINAL_Myro : FLLAAASCKADEE---------------ITCEENEPFTCSNTDILSSKNF :  45 
BRANA_Myro : FLLAAASCKADEE---------------ITCEENNPFTCSNTDILSSKNF :  45 
BRAOA_Myro : FLLAAASCKADEE---------------ITCEENNPFTCSNTDILSSKNF :  45 
                                                                                                                                           
                     *       120         *       140         *       
CMYR       : GNGSVYDSEATRKMVVDAHVNSLITRLNGEEPARLAEQNNMIQKTAETTR : 150 
BREBR_Myro : PKDFMFG------------------------------------------- :  12 
ARATH_Myro : EKGFIFG------------------------------------------- :  50 
EUTJA_Myro : GKDFIFG------------------------------------------- :  51 
SINAL_Myro : GKDFIFG------------------------------------------- :  52 
BRANA_Myro : GKDFIFG------------------------------------------- :  52 
BRAOA_Myro : GKDFIFG------------------------------------------- :  52 
                                                                                                                                           
                    160         *       180         *       200       
CMYR       : LGIPVTISTDPRNSYQALVGISNPAG-------KFTQWPEAIGLGAAGSE : 193 
BREBR_Myro : ---------TSTASYQIEGGWNEDGKGENIWDRLVHTSPEVI-KDGTNGD :  52 
ARATH_Myro : ---------VASSAYQVEGG---RGRGLNVWDSFTHRFPEKGGADLGNGD :  88 
EUTJA_Myro : ---------VASSAYQIEGG---RGRGPNTWDAFTHRYPEKGGPDLANGD :  89 
SINAL_Myro : ---------VASSAYQIEGG---RGRGVNVWDGFSHRYPEKSGSDLKNGD :  90 
BRANA_Myro : ---------VASSAYQIEGG---RGRGVNVWDGFSHRYPEKAGSDLKNGD :  90 
BRAOA_Myro : ---------VASSAYQIEGG---RGRGVNVWDGFSHRYPEKSGSDLKNGD :  90 
 
                                                                      
                      *       220         *       240         *       
CMYR       : ALAQEYADHVRREYRAVGITEALSPQADITTEPRWARISGTFGEDPELAK : 243 
BREBR_Myro : IACDSYHKYK----EDVAIIKDLNL-KFYRFSISWARIAPSG-------- :  89 
ARATH_Myro : TTCDSYTLWQ----KDIDVMDELNS-TGYRFSIAWSRLLPKG-------- : 125 
EUTJA_Myro : TTCESYTNWQ----KDIDIMDELNA-TGYRFSFAWSRIIPKG-------- : 126 
SINAL_Myro : TSCESYTRWK----KDVEIMGELNA-TGYRFSFAWSRIVPKG-------- : 127 
BRANA_Myro : TTCESYTRWQ----KDVDVMGELNA-TGYRFSFAWSRIIPKG-------- : 127 
BRAOA_Myro : TTCESYTRWQ----KDVDVMGELNA-TGYRFSFAWSRIIPKG-------- : 127 
                                                                      
                                         
Figure 5.2 The multiple alignment of cmyr with some of the identified myrosinases. The 
abbreviations were used for myrosinase from: CMYR; C. WYE1, BREBR (Q95X01); B. brassicae 
(aphid), ARAT (P37702); A. thaliana, EUTJA (Q4AE75); E. japonicum, SINAL (P29092); S. alba, 
BRANA (Q00326); B. napus, BRAO (A6XG32); B. oleracea var. alboglabra. The default settings 
were used for Clustal Omega. The entry numbers of sequences at Uniprot database are given 
in brackets. SDW motif was highlighted in red. The proton donor and nucleophile in S. alba 
myrosinase are in Gln 207 (Q) and Glu 426 (E) positions, respectively and they are highlighted 
in yellow.  
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                    260         *       280         *       300      
CMYR       : KLVRGYITGMQKGGQGLNPQSVAAVVKHWVGYGAAEDGWDGHNAYGKHTV : 293 
BREBR_Myro : -----------VM-NSLEPKGIA-----------------------YYNN : 104 
ARATH_Myro : -----------KRSRGVNPGAIK-----------------------YYNG : 141 
EUTJA_Myro : -----------KVSRGVNQGGLD-----------------------YYHQ : 142 
SINAL_Myro : -----------KVSRGVDQAGLD-----------------------YYHN : 143 
BRANA_Myro : -----------KVSRGVNQGGLD-----------------------YYHK : 143 
BRAOA_Myro : -----------KVSRGVNQGGLD-----------------------YYHK : 143 
                                                                      
                                                                      
                      *       320         *       340         *       
CMYR       : LSNESLQKHIIPFRGAFEANVAAVMPTYSVMKGVTWNGRE---------- : 333 
BREBR_Myro : LINELIKNDIIPLVTMYHWDLPQYLQD-----LGGWVNPIMSDYFKEYAR : 149 
ARATH_Myro : LIDGLVAKNMTPFVTLFHWDLPQTLQD----EYNGFLNKTIVDDFKDYAD : 187 
EUTJA_Myro : LIDGLIAKKITPFVTLYHWDLPQTLQD----EYEGFLNRTIIDDFRDYAD : 188 
SINAL_Myro : LIDALLEKNITPFVTLFHWDLPQTLQD----EYEGFLDRQIIQDFKDYAD : 189 
BRANA_Myro : LIDALLEKNITPFVTLFHWDLPQTLQD----EYEGFLDRQIIQDFKDYAD : 189 
BRAOA_Myro : LIDALLEKNITPFVTLFHWDLPQTLQD----EYEGFLDRQIIQDFKDYAD : 189 
                                                                      
                              Q          
                    360         *       380         *       400       
CMYR       : -------------------------------------------------- :  - 
BREBR_Myro : VLFTYFGDRVKWWITFNEPIAV-CKGYSIKAYAPNLN------------- : 185 
ARATH_Myro : LCFELFGDRVKNWITINQLYTVPTRGYALGTDAPGRCSPKID--VRCPGG : 235 
EUTJA_Myro : LCFKEFGGKVKHWITINQLYTVPTRGYGIATDAPGRCSPAID--KRCYGG : 236 
SINAL_Myro : LCFKEFGGKVKNWITINQLYTVPTRGYALGTDAPGRCSPKVDTKQRCYGG : 239 
BRANA_Myro : LCFKEFGGKVKHWITINQLYTVPTRGYAIGTDAPGRCSPMVDTKHRCYGG : 239 
BRAOA_Myro : LCFKEFGGKVKHWITINQLYTVPTRGYAIGTDAPGRCSPMVDTKHRCYGG : 239 
                                                                      
                                                      SDW                
                      *       420         *       440         *       
CMYR       : ---TEQVAAG----FSHFLLTDLLR------KQNNFSGVIISDWLITNDC : 370 
BREBR_Myro : LKTTGHYLAGHTQLIAHGKAYRLYEEMFKPTQNGKISISISGVFFMPKNA : 235 
ARATH_Myro : NSSTEPYIVAHNQLLAHAAAVDVYRTKYKDDQKGMIGPVMITRWFLPFDH : 285 
EUTJA_Myro : NSSTEPYIVAHNQLLAHAAVVNLYRTKYKF-QGGKIGTVMITRWFLPFDE : 285 
SINAL_Myro : NSSTEPYIVAHNQLLAHAAIVDLYRTNYAF-QNGKIGPVMITRWFLPYDE : 288 
BRANA_Myro : NSSTEPYIVAHNQLLAHATVVDLYRTKYKF-QKGKIGPVMITRWFLPFDE : 288 
BRAOA_Myro : NSSTEPYIVAHNQLLAHATVVDLYRTKYKF-QKGKIGPVMITRWFLPFDE : 288 
                                                                      
                                                                      
                    460         *       480         *       500       
CMYR       : DD-ECVNGSAPGKKPVAGGMPWGVESLSKERRFVKAVNAGIDQFGGVTDS : 419 
BREBR_Myro : ESDDDIETAERA-------------------------------------- : 247 
ARATH_Myro : SQ-ESKDATERA-------------------------------------- : 296 
EUTJA_Myro : NDKDCIDATERM-------------------------------------- : 297 
SINAL_Myro : SDPACIEAAERM-------------------------------------- : 300 
BRANA_Myro : SDPASIEAAERM-------------------------------------- : 300 
BRAOA_Myro : SDPASIEAAERM-------------------------------------- : 300 
                                                                      
                                                                      
                      *       520         *       540         *       
CMYR       : AVLVTAVEKGLITQARLDASVERILQQKFELGLFEQPYVDAKLAE---KI : 466 
BREBR_Myro : --------------------------NQFERGWFGHPVYKGDYPPIMKKW : 271 
ARATH_Myro : --------------------------KIFFHGWFMGPLTEGKYPDIMREY : 320 
EUTJA_Myro : --------------------------KEFFFGWFMEPLTKGRYPDIMRKI : 321 
SINAL_Myro : --------------------------NQFFHGWYMEPLTKGRYPDIMRQI : 324 
BRANA_Myro : --------------------------NQFFHGWYMEPLTKGRYPDIMRQI : 324 
BRAOA_Myro : --------------------------NQFFHGWYMEPLTKGRYPDIMRQI : 324 
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Figure 5.2-Continued                                         
                                                                      
                    560         *       580         *       600       
CMYR       : VGAPDTKK-----------------AADDAQFRTLV------LLQNKNIL : 493 
BREBR_Myro : VDQKSKEEGLPWSKLPKFTKDEIKLLKGTADFYALNHYSSRLVTFGSDPN : 321 
ARATH_Myro : VG----------DRLPEFSETEAALVKGSYDFLGLNYYVTQYAQNNQTIV : 360 
EUTJA_Myro : VG----------SKLPNFTEAEARQVAGSYDFLGLNYYVTQYAQPTKTIV : 361 
SINAL_Myro : VG----------SRLPNFTEAEAELVAGSYDFLGLNYYVTQYAKPKPNPY : 364 
BRANA_Myro : VG----------SRLPNFTEEEAELVAGSYDFLGLNYYVTQYAQPKPNPY : 364 
BRAOA_Myro : VG----------SRLPNFTEEEAELVAGSYDFLGLNYYVTQYAQPKPNPY : 364 
                                                                                                                                           
                      *       620         *       640         *       
CMYR       : PLKPGTKVWLYGADKSA----AEKAGLEV------------VSEPEDADV : 527 
BREBR_Myro : PNFNPDASYVTSVDEAW---------------LKPNETPYIIPVPEGLRK : 356 
ARATH_Myro : PSDVHTALMDSRTTLTSKNATGHAPGPPF------NAAS--YYYPKGIYY : 402 
EUTJA_Myro : PPENHTAMMDANVTLTYVNSRGELIGPLFAKDDDPKKNS--YYYPKGIYF : 409 
SINAL_Myro : PSETHTALMDAGVDLTFNNSRGEYPGPVFAED----ANS--YYYPKGIYY : 408 
BRANA_Myro : PSETHTAMMDAGVKLTYDNSRGEFLGPLFVEDK-VNGNS--YYYPKGIYY : 411 
BRAOA_Myro : PSETHTAMMDAGVKLTYDNSRGEFLGPLFVEDK-VNGNS--YYYPKGIYY : 411 
                                                                      
                              E         
                    660         *       680         *       700       
CMYR       : ALMRTSAPFEQPHYNYFFGRRHHEGSLEYREDNKDFAVLKRVSKHTPVIM : 577 
BREBR_Myro : LLIWLKNEYGNPQLLITENGYGDDGQ------LDDFEKISYLKNYLNATL : 400 
ARATH_Myro : VMDYFKTTYGDPLIYVTENGFSTPGDEDFEKATADYKRIDYLCSHLCFLS : 452 
EUTJA_Myro : VMDHFRTRYFNPLIYVTENGISSPGTEPREVAIADSKRIDYLCSHLCFLR : 459 
SINAL_Myro : VMDYFKTKYNNPLIYITENGISTPGSESRCEAIADYKRINYLCSHLCFLR : 458 
BRANA_Myro : VMDYFKTKYGDPLIYVTENGFSTPSSENREQAIADYKRIDYLCSHLCFLR : 461 
BRAOA_Myro : VMDYFKTKYGDPLIYVTENGFSTPSSENREQAIADYKRIDYLCSHLCFLR : 461 
                                                                      
                                                                      
                      *       720         *       740         *       
CMYR       : TMYMERPA--------VLTNVTDKTSGFIANFGLSDEVFFSRLTSDTPYT : 619 
BREBR_Myro : QAMYEDKCNVIGYTVWSLLDNFEWFYGYSIHFGLVKIDFND-PQRTRTKR : 449 
ARATH_Myro : KVIKEKNVNVKGYFAWSLGDNYEFCNGFTVRFGLSYVDFAN-ITGDRDLK : 501 
EUTJA_Myro : KVIKETGVNVKGYFAWSLGDNYEFCKGFTVRFGLSYVNWTD-VT-DRNLK : 507 
SINAL_Myro : KVIREKGVNIRGYFAWALGDNYEFCKGFTVRFGLSYVNWDD-LD-DRNLK : 506 
BRANA_Myro : KVIKEKGVNVRGYFAWALGDNYEFCKGFTVRFGLSYVNWED-LD-DRNLK : 509 
BRAOA_Myro : KVIKEEGVNVRGYFAWALGDNYEFCKGFTVRFGLSYVNWED-LD-DRNLK : 509 
 
                                                                                                                                           
                    760         *       780         *       800       
CMYR       : ------ARL-----------PFALPSSMASVLKQKSDEPDDLDTPLFQRG : 652 
BREBR_Myro : ESYTYFKNVVSTGKP~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ : 464 
ARATH_Myro : ASGKWFQKFINVTDED-STNQDLLRSSVSSKNRDR----KSLADA~~~~~ : 541 
EUTJA_Myro : DSGKWYQRFINVTTNNPPAKQDFLRSSLSFHNKNL-------ADA~~~~~ : 545 
SINAL_Myro : ESGKWYQRFINGTAKN-PVKQDFLRSSLSSQSQKK----R-LAC~~~~~~ : 544 
BRANA_Myro : ESGKWYQRFINGTVKN-AVKQDFLRSSLSSQSQKK----R-FADA~~~~~ : 548 
BRAOA_Myro : ESGKWYQRFINGTVKN-SAKQDFLRSSLSSQSQKK----R-LADA~~~~~ : 548 
                                                                                             
                         
CMYR       : FGLTR : 657 
BREBR_Myro : ~~~~~ :   - 
ARATH_Myro : ~~~~~ :   - 
EUTJA_Myro : ~~~~~ :   - 
SINAL_Myro : ~~~~~ :   - 
BRANA_Myro : ~~~~~ :   - 
BRAOA_Myro : ~~~~~ :   - 
 
Figure 5.2 Continued                         
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5.4.3 Cloning and Expression of Myrosinase Gene 
The gene insert was amplified by PCR. The predicted size of the insert was 1998 bp as shown 
by gel electrophoresis (See Figure 5.3). In addition, double digested pET28b vector was run on 
DNA gel (Figure 5.3). After transformation of recombinant vector into E. coli DH5α cells, 
transformants on plates (10 clonies were picked) were checked by colony PCR, results are 
given in Figure 5.4. 
 
Figure 5.3 Agarose gel electrophoresis of cmyr insert and double digested pET28b vector. 
Samples were run on 1% agarose gel. l; hyperladder, c (-); negative control for PCR (PCR was 
set up without any genomic DNA), ins; cmyr insert, vec; Nde/XhoI digested pET28b.  
The expected size of colony PCR products with correct gene insert was 2190 bp and expected 
sizes of the product bands from all transformants were observed (Figure 5.4). One of the 
positive transformants was used for the recombinant plasmid preparation. This recombinant 
plasmid  was sequenced and confirmed to have no mutation in the gene insert. This 
recombinant plasmid was transformed into E. coli BL21(DE3) and the induction of  protein 
expression  was performed by addition of IPTG.  
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Figure 5.4 Agarose gel electrophoresis for colony PCR experiments. PCR products were run 
on 1% agarose gel. l; hyperladder, c1; negative control for PCR (PCR was set up without any 
genomic DNA), c2; positive control for PCR (PCR was set up with pET28b vector), 1-10; PCR 
products of selected colonies.  
Soluble and insoluble extracts from protein expression were run on SDS-PAGE gel (Figure 5.5). 
Protein expression at 25°C for 24 h resulted in yield of expressed cmyr in the soluble fraction 
(Figure 5.5- the protein band is shown) compared to protein expression at 37°C for 3 h. 
Protein expression at 37°C for 3 h results in cmyr to be in the insoluble fraction (Figure 5.5-
Lane 8).  
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Figure 5.5 SDS-PAGE of the CFEs from E. coli BL21 (DE3) expressing pET28b-cmyr. 10 µg of 
protein was loaded per lane. M: See Blue Protein Marker, 1-2: soluble and insoluble CFEs 
obtained from uninduced E. coli BL21 (DE3) expressing pET28b-cmyr grown at 25°C for 24 h 
respectively, 3-4: soluble and insoluble CFEs obtained from induced (at 25°C for 24 h) E. coli 
BL21 (DE3) expressing pET28b-cmyr respectively, 5-6: soluble and insoluble CFEs obtained 
from uninduced E. coli BL21 (DE3) expressing pET28b-cmyr grown at 37°C for 3 h respectively. 
7-8: soluble and insoluble CFEs obtained from induced (at 37°C for 3 h) E. coli BL21 (DE3) 
expressing pET28b-cmyr respectively. Protein gel was run on 4-12% Bis-Tris gel under 
denaturing, reducing conditions in MES buffer. Insoluble CFEs were difficult to load on gel so 
the protein bands are not as clear as soluble ones.  
 
5.4.4 Western Blotting and Purification of Myrosinase 
The CFEs were prepared and checked for the presence of 6X-His tag by Western blot (Figure 
5.6) using a His-tag antibody (Novagen). When protein expression was performed at 25°C for 
4 h instead of 24 h and it also produced a better yield of cmyr protein. The expected protein 
size of cmyr with N- and C-terminal 6X-His tags was 75 kDa. Recombinant proteins with 
expected protein sizes were found to be recognised by the His-tag antibody so purification of 
cmyr using Ni-NTA column was performed.  
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Figure 5.6 SDS-PAGE of soluble and insoluble extracts from E. coli BL21(DE3) expressing 
pET28b-cmyr. a) Protein gel where CFEs were run on 4-12% Bis-Tris gel under denaturing, 
reducing conditions in MES buffer. b) Western blot (using anti-His tag antibody) within the 
same order of protein gel in a. 10 µg of protein was loaded per lane. 1; E. coli BL21(DE3) 
pET28b soluble CFE, 2; A protein with 6XHis-tag (positive control for Western blotting), 3-4; 
Soluble and insoluble CFEs of uninduced cells grown at 25°C for 4 h , 5-6; Soluble and 
insoluble CFEs of induced (25°C, 4 h) cells, 7-8; Soluble and insoluble CFEs of uninduced cells 
grown at 37°C for 3 h, 9-10; Soluble and insoluble CFEs of induced (37°C, 3 h) cells.  
 
The cmyr was purified by Ni-NTA column (Figure 5.7) and the protein levels were quantified 
by the Bradford assay.  
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Figure 5.7 SDS-PAGE of the Ni-NTA purified Cmyr protein from E. coli BL21 (DE3) expressing 
pET28b-cmyr. 3.25 µl of fractions were loaded per lane. Proteins were run on 4-12% Bis-Tris 
Gel under denaturing, reducing conditions in MES buffer. L: Lysate, FT: Flow through, W: 
Wash, E: Eluate, M; Protein marker. The expected protein size of cmyr with N- and C-terminal 
6X-His tags was 75 kDa.  
The presence of two strong bands in the Western Blot (Figure 5.6 b- Lane 10) was observed. It 
was hypothesized that these bands might present the whole protein and the protein with 
signal peptide cleaved off. This was further investigated by intact mass analysis after 
purification of cmyr. When cmyr has two 6XHis-tags at N and C terminal site, the predicted 
size of the protein is ~75 kDa. However if the signal peptide was cleaved off then the 
predicted size is ~70 kDa. Intact mass analysis showed that cmyr has a measured mass of 
70,332 Da so, it was suggesting that the signal peptide was cleaved off correctly (See Figure 
5.8 for MS chromatogram) as predicted size of recombinant cmyr without signal peptide is 
~70 kDa. Purified, dialysed and filtered cmyr was adjusted to a concentration of 10 mg/ml and 
the sample was sent to Imperial College London for crystallography. This part of the study is 
still ongoing.  
 
M     L     FT   W1  W2   E1   E2    E3 
98 kDa--- 
62---------  
49--------- 
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Figure 5.8 The MS spectrum for cmyr. Appropriate fragments of cmyr were determined in 
positive MS-TOF.  
 
5.4.5 Myrosinase Activity of Recombinant cmyr  
The myrosinase activity of dialysed and undialysed proteins were tested by God-Perid assay. 
The results showed that recombinant cmyr was active against sinigrin. Dialysis had a positive 
effect on myrosinase activity of proteins. When the eluate was used in the assay without 
dialysis, it showed an activity of 25.4 ± 0.74 µmol glucose/min/mg enzyme. Dialysed eluate of 
Cmyr had a specific enzyme activity of 57.2 ± 9.4 µmol glucose/min/mg enzyme. Dialysed 
protein showed more than two fold higher enzyme activity compared to the enzyme activity 
of undialysed protein. S. alba myrosinase (Sigma Aldrich) was used as a positive control and 
gave a positive result for myrosinase activity (0.33 ± 0.05 µmol glucose/min/mg enzyme). 
Negative control (without protein) did not show any myrosinase activity.  
When myrosinase activity of cmyr was tested in 20 mM citrate phosphate buffer within a pH 
range of 3.6-7.6, pH 6.0 was found to be optimum for myrosinase activity (Figure 5.9). The 
myrosinase activity was found to be gradually reduced above pH 6.0.  
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Figure 5.9 pH optimum range of recombinant cmyr myrosinase activity in 20 mM citrate 
phosphate buffer. The myrosinase activity was determined at 37°C for 1 h by God-Perid 
assay. Error bars = standard deviation (n=3).  
 
When myrosinase activity of recombinant cmyr was tested for its stability over a range of 
temperatures (5-70°C), the optimum temperature was found to be 25°C under the conditions 
tested (Figure 5.10). The enzyme activity was reduced significantly over 30°C and further 
diminished over 50°C.  
 
 
 
Figure 5.10 Temperature stability of C. WYE1 myrosinase in 20 mM citrate phosphate buffer 
pH 6.0. The myrosinase activity was determined by God-Perid assay. Error bars = standard 
deviation (n=3). 
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The optimum temperature of cmyr for myrosinase activity was different from plant 
myrosinases [118, 253] which their optimum temperatures are generally higher (around 45-
50°C).  The aphid (B. brassicae) [137] and plant (A. rusticana) myrosinase [118] were reported 
to retain their activity at 4°C for months but it was not reported what percentage of the 
activity remained. When the stability of myrosinase activity over time was analysed, 
myrosinase lost 97% of its original enzyme activity in 5 weeks when kept at 4°C.  This result 
required us to use fresh made Ni-NTA purified proteins for assays each time.   
5.4.6 Enzyme Activity and Kinetics 
The kinetic parameters of the purified cmyr were determined  using sinigrin as substrate. Km 
and Vmax were estimated as 0.2 mM and 0.033 mmol/min/mg for sinigrin at pH 6.0 and 25°C 
(Figure 5.11).  
 
Figure 5.11 Kinetic analysis of cmyr using sinigrin as substrate. Specific activity 
(mmol/min/mg enzyme) of cmyr (24 ng incubated) at different concentrations of sinigrin (0.1-
5 mM) was used to prepare Lineweaver Burk plot.  
5.4.7 Substrate Specificity of Recombinant cmyr 
The enzyme activity of cmyr against different glucosinolates including sinigrin, glucoiberin, 
progoitrin, glucoerucin, gluroraphanin, glucotrapaeolin, gluconasturtiin and glucobrassicin 
were tested by God-Perid assay (Figure 5.12). Cmyr showed activity towards all of the 
glucosinolates except gluconasturtiin and glucobrassicin. The specific activity of cmyr for 
sinigrin was highest, followed by glucoiberin > progoitrin > glucoerucin > glucoraphanin > 
glucotrapaeolin > gluconasturtiin=0. The cmyr had similar specific activity for glucoerucin, 
y = 6.0384x + 30.103
R² = 0.9815
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glucoiberin and progoitrin but the activity of glucoraphanin and glucotrapaeolin was lower 
compared to those. The cmyr was not tested for activity against gluconasturtiin and 
glucobrassicin previously [118] and tested in this study but there was no activity towards 
gluconasturtiin under the conditions tested and glucobrassicin stock used in the assay gave 
false positive result.  
 
Figure 5.12 The myrosinase activity of cmyr towards different glucosinolates. The 
myrosinase activity was determined at 25°C in 20 mM citrate phosphate buffer by God-Perid 
assay. Error bars = standard deviation (n=3).  
5.4.8 Stability of Myrosinase Activity of Recombinant cmyr   
Dialysed and filtered cmyr was tested for the stability of its myrosinase activity in 20 mM 
citrate phosphate buffer pH 6.0 at 4°C.  According to results, cmyr lost half of its original 
myrosinase activity in a week. In 5 weeks, cmyr could only keep 3% of the original activity. 
This data was especially important and used in the planning of the characterisation studies.  
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Figure 5.13 Stability of myrosinase activity of cmyr in 20 mM citrate phosphate buffer pH 
6.0 at 4°C over time. The myrosinase activity was determined at 25°C in 20 mM citrate 
phosphate buffer by God-Perid assay. Error bars = standard deviation (n=3). 
 
5.5 DISCUSSION 
The publication of cmyr activity during the course of this study led to changes in the 
experimental plans for the investigation of bacterial myrosinases from human gut. As 
bacterial myrosinases were suggested to be more closely related to aphid myrosinases than 
plant myrosinases [56], the search for potential myrosinases in the genomes of human gut 
bacteria was initially based on aphid myrosinase amino acid sequences. Aphid myrosinases 
belong to GH1 enzyme family so we were unfortunately excluding the enzymes from GH3 and 
others. As cmyr is a periplasmic β-glucosidase from GH3 family, we also included enzymes 
from GH3 for cloning experiments to identify a β-glucosidase responsible for myrosinase 
activity.  
The myrosinase activity of C. WYE1 was characterised using CFEs and the myrosinase gene 
(cmyr) was identified previously by Albaser et al. [118].  In this study, cmyr gene was cloned 
and expressed in E. coli with both N and C-terminal 6XHis-tags. The protein with 6xHis-tag 
was purified and further characterisation was carried out. Dialysis of Ni-NTA purified protein 
enhanced myrosinase activity of cmyr. The optimum pH, temperature and buffer for 
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myrosinase activity were found to be same with the study of Albaser et al.(2016) [118]. Km 
and Vmax values were reported to be 0.46 mM and 4.91 mmol dm-3 min-1 mg-1 respectively by 
Albaser et al. (2016). Our results are different from their results but this was expected as they 
used CFE in their study. Km value of aphid (Brevicoryne brassicae) myrosinase for sinigrin was 
investigated by two different research groups and it was found to be 0.41 mM (at pH 4.5, 
30°C)[136] and 0.61 mM (at pH 5.5, 30°C)[132]. The Km value of the cmyr (0.2 mM) for sinigrin 
was lower than these values indicating a higher affinity for sinigrin and similar to Km value of 
plant (Lepidium latifolium L.) myrosinase (0.17 mM, at pH 6.0, 37°C) [249].  
The optimum pH of 6 for cmyr myrosinase activity was found to be similar to some plant 
myrosinases such as from Brassica napus [135], Armoracia rusticana [117] and  Lepidium 
latifolum L. [249]. It was lower than fungous myrosinase [250] and higher than aphid 
myrosinase [133]. The myrosinase activity of cmyr was found to be gradually reduced above 
pH 6.0 that was different from plant myrosinases such as Brassica napus [135] and Armoracia 
rusticana [117] myrosinases. Li et al. (2005) reported that optimum pH was 5.7 for 
horseradish (Armoracia rusticana) myrosinase and myrosinase activity was reported to be 
retained 80% of the maximum activity between pH 5.0-8.0 values. However, there was a 
significant decrease in myrosinase activity above optimum pH especially above pH 7.0 for 
cmyr. This might be explained by the origin of the C. WYE1 as an adaptation to soil pH. It was 
isolated from soil from Kent (UK) and UK soil was reported to be acidic in general 
(https://commons.wikimedia.org/wiki/File:World_Soil_pH.svg).  
The cmyr showed a variable specificity to different glucosinolates. The preference of aliphatic 
glucosinolates (glucoiberin, progoitrin, glucoerucin and glucoraphanin) over aromatic 
glucosinolates (glucotropaeolin and gluconasturtiin) might indicate the importance of the side 
chain for myrosinase activity of cmyr.  Selective glucosinolate breakdown profile was seen in 
many myrosinases including aphid (B. brassicae) myrosinase [132, 136], plant myrosinases 
[125, 126, 249].  For instance, aphid (B. brassicae) myrosinase was assessed to have higher 
specificity for sinigrin than glucotropaeolin in two seperate studies [132, 136]. A plant 
(Lepidium latifolum L.) myrosinase showed a better myrosinase activity against sinigrin 
compared to glucoraphanin [249]. Two myrosinase isoenzymes isolated by James and 
Rossiter (1991) showed better specificity for aliphatic glucosinolates rather than indole 
glucosinolates [125], while another study reported the existance of a myrosinase that was 
highly specific for epi-progoitrin [126].  
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Ascorbate is reported to be an activator for plant myrosinases [117, 119, 249]. However, 
aphid myrosinases of B. brassicae and Lipaphis erysini are reported to be unaffected by the 
presence of ascorbate [133]. The effect of ascorbate on cmyr myrosinase activity was not 
determined in this study but it was already reported that the enzyme was activated with 
ascorbate by a factor of 1.67 [118].  
Successful cloning and expression of myrosinase made it possible to produce large amounts 
of protein for further characterisation. The importance of a conserved amino acid sequence, 
SDW, was reported for the enzyme activity of cmyr and aspartic acid (D) was suggested as the 
nucleophile by Albaser et al. (2016) [118]. However, crystallography studies for the enzyme in 
complex with glucosinolates are needed for confirmation of this and identification of the acid 
catalyst, nucleophile and other important amino acid residues for myrosinase activity. The 
crystallisation of this myrosinase is being performed in collaboration with Imperial College 
London. 
In summary, the identification of cmyr is important to have a better understanding of 
glucosinolate metabolism by bacteria as all identified and characterised myrosinases are from 
GH1 family so far. The cmyr was also used as a control positive in the other parts of the study. 
In this chapter, recombinant cmyr was characterised and will be crystallised to determine its 
structure in the future. Crystallography studies about cmyr may give us a clearer idea of the 
nature and activity of this new GH3 class bacterial myrosinases. 
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CHAPTER SIX 
 
6 CONCLUSIONS AND FUTURE WORK 
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6.1 CONCLUSIONS AND FUTURE WORK 
Several studies have investigated the glucosinolate metabolism by human gut bacteria so far 
but the mechanisms are still not well understood [56, 57, 112, 165, 211-213, 216]. Especially, 
very little is known about the enzymes involved in glucosinolate metabolism. This study 
mainly aimed to identify and characterise these enzymes involved in the metabolism of 
glucosinolates including the specific roles of some myrosinases and reductases. To achieve 
this, the candidate genes were cloned and expressed then enzymatic assays were performed 
to assess the activity of these proteins. To identify the first bacterial myrosinase from human 
gut, a cloning approach and a FPLC approach which is a combination of ion exchange 
chromatography and gel filtration was used. The bacterial strains that were examined for 
their myrosinase or reductase activity are given in Table 6.1.  
Bacterial Strain Source of the strain Activity 
L. agilis R16 [56] Human gut (provided to us) Myrosinase, reductase 
E. coli VL8 [56] Human gut (provided to us) Reductase 
E. coli FI10944 Human gut (provided to us) Myrosinase 
E. casseliflavus CP1 [56] Human gut (provided to us) Myrosinase 
E. coli FC44 Human gut (isolated in this study) Reductase 
C. freundii FC50 Human gut (isolated in this study) Myrosinase 
C. WYE1 [118] Soil (provided to us) Myrosinase 
Table 6.1The list of bacterial strains studied in this research.   
Three strains (E. coli FI10944, E. coli VL8, E. casseliflavus CP1) were previously isolated by our 
collaborator, Dr. Vijitra Luang In, using a sinigrin enrichment method. C. WYE1 was isolated 
from soil by Dr. Abdulhadi Albaser using a sinigrin enrichment method. L. agilis R16 was 
included to the study because it was reported to have myrosinase activity previously [210]. E. 
coli VL8, L. agilis R16 and E. casseliflavus CP1 were found to be capable of metabolising 
glucosinolates with different efficiencies [56]. In addition to these previously isolated strains, 
a glucoraphanin enrichment method was performed in our study and isolated 98 more 
human gut bacteria with glucosinolate metabolism. Fifteen of these isolates were determined 
to degrade all of the glucoraphanin supplied in the media and ten of them were identified by 
16S rDNA sequencing at the genus level. These isolates were identified with myrosinase 
activity but not all of them were further studied. Two of the human gut strains, E. coli FC44 
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and C.  freundii FC50, were further studied for their reductase and myrosinase activities 
respectively.  
In Chapter 3, L. agilis R16 and E. casseliflavus CP1 were tested for their glucosinolate 
degrading ability. Interestingly, the glucoraphanin degradation rate by E. casseliflavus CP1 
was lower in this study compared to the degradation rate reported previously by Luang-In et 
al. (2014)[56]. This was possibly an effect of long time storage of the strain away from its 
original environment. L. agilis R16 showed a low glucoraphanin degradation rate which was 
similar to the degradation rate reported previously [56]. It was thought that pre-culturing in 
media with glucosinolates might have an effect of glucoraphanin degradation ability of L. 
agilis R16. However, pre-culturing with glucosinolates did not cause the anticipated increase 
in glucoraphanin or sinigrin degradation rates by this strain under the conditions tested.  
When E. coli FI10944 and C. freundii FC50 were screened for myrosinase activity, myrosinase 
activity was detected in CFEs of both strains. Therefore, it was concluded that the myrosinase 
activity in these strains was not cell-associated. This result was contradictory to the previous 
studies reporting the necessity of intact cells for myrosinase activity from E. coli VL8 [56], L. 
agilis R16 [56, 210], E. casseliflavus CP1 [56] and E. coli O157:H7 [217]. As myrosinase activity 
was reported to be cell-associated and not identified in CFEs of bacteria so far, it was 
proposed that the phoshotransferase system (PTS) is involved in uptake and phosphorylation 
of glucosinolates by β-glucoside kinase and it was suggested that the disruption of cell-
integrity destroyed the action of PTS and myrosinase activity could not be achieved [56]. This 
can be possible for E. casseliflavus CP1 as no myrosinase activity of CFEs or recombinant β-
glucosidases was observed. However, our results showed that myrosinase activity is not 
always cell wall-associated. The myrosinase activity in CFEs of E. coli FI10944 and C. freundii 
FC50 was examined to see if it could be induced by adding glucosinolate to the original 
growth media. It was found that both induced and uninduced CFEs of these two strains had 
myrosinase activity. The results suggested that the myrosinase activity in CFEs of E. coli 
FI10944 and C. freundii FC50 may be constitutively expressed.  
To identify the genes encoding myrosinase activity, putative β-glucosidase genes of E. coli 
FI10944 (ecolg3) and E. casseliflavus CP1 (ecg4, ecg39, ecg44) were cloned and the proteins 
expressed successfully (Chapter 3). However, none of them were identified with myrosinase 
activity. Two of them (ecg4, ecg39) showed β-glucosidase activity against 4-nitrophenyl β-D-
glucopyranoside so it was concluded that these two enzymes were active but did not act on 
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glucosinolates. As we hypothesized that specific β-glucosidases are responsible for 
myrosinase activity, either these enzymes were not the right β-glucosidase for myrosinase 
activity or glucosinolate metabolism by gut bacteria is more complex than we originally 
thought. Desulfo-glucosinolates were reported to be degraded by E. coli VL8, L. agilis R16 and 
E. casseliflavus CP1 to form nitriles as the only final products [57, 137]. Nitrile formation is not 
the main focus in this study but this bioconversion is also important because it suggests the 
presence of an alternative pathway for glucosinolate metabolism by gut bacteria (Figure 6.1). 
This alternative pathway includes sulfatase activity to form desulfo-glucosinolates and then β-
glucosidase activity to produce nitriles. The sulfatases from E. coli VL8 were cloned, expressed 
and characterised by our collaborator previously, where they found that the crude extracts of 
recombinant sulfatase from E. coli VL8 was found to have sulfatase activity [137]. A 
recombinant β-glucosidase from Caldocellum saccharolyticum was able to transform desulfo-
glucosinolates into nitriles [251]. Considering these studies, ecg4 and ecg39 could be checked 
for their activity towards desulfo-glucosinolates. This can shed light on the proposed 
metabolism of desulfo-glucosinolates by gut bacteria such as E. casseliflavus CP1 and confirm 
the existence of an alternative pathway (Figure 6.1). Setting up a GC-MS method for 
identification of nitriles was achieved but ecg4 and ecg39 was not examined for their ability 
to degrade desulfo-glucosinolates.  
 
Figure 6.1 Proposed metabolism of desulfo-glucosinolates by human gut bacteria. R 
indicates the side chain in glucosinolate structure.  
A study showed that the disruption of 3 β-glucosidases (bgIA, ascB, chbF) in E. coli O157:H7 
affected its myrosinase activity [240]. They concluded that bgIA and ascB were involved in 
myrosinase activity. However, disruption of these genes did not completely abolish the 
myrosinase activity [240].  E. casseliflavus CP1 and E. coli FI10944 have 40 and 6 potential 
glucosidases in their genome respectively. In this study, we cloned and expressed the four 
most likely β-glucosidases based on their sequence similarities with identified bacterial and 
aphid myrosinases. This number of β-glucosidases we cloned represents only a small fraction 
of all putative glucosidases. Disruption of these genes and screening the mutants for 
myrosinase activity would take time but it could be tried. The putative glucosidase genes in E. 
casseliflavus CP1 and E. coli FI10944 could be disrupted then myrosinase activity of the 
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mutant E. casseliflavus CP1 and E. coli FI10944 strains could be assessed. If any correlation 
would be found between the disruption of genes and the decrease in the myrosinase activity, 
the genes could be cloned and expressed in E. coli and their myrosinase activity could be 
determined. 
When purification of bacterial myrosinase in E. coli FI10944 by FPLC was attempted, only 
cytoplasmic α-amylase and periplasmic trehalase were identified in fractions showing 
myrosinase activity. These enzymes can act on α-glucosidic bonds. Therefore, it is unlikely 
that these enzymes can play a role in degradation of β-thioglucosides (glucosinolates). The 
FPLC fraction with myrosinase activity was analysed by LCMS/MS and the enzymes found in 
high abundance were phosphoglycerate kinases and triosephosphate isomerases which 
belong to the glycolysis pathway. Their presence is possibly associated with utilisation of 
glucose in glucosinolates, not with glucosinolate degradation by human gut bacteria. In brief, 
identification of bacterial myrosinase from human gut could not have been achieved using 
cloning and chromatography approaches. However, the results from chapter 3 emphasized 
the different capacity and diverse routes of glucosinolate metabolism by human gut bacteria.  
A myrosinase from the bacterial strain of C. WYE1 of soil origin was identified when it was 
grown in M9 minimal media including sinigrin as the sole carbon source [118]. This 
experiment was carried out in our study with E. coli FI10944 in minimal media with 1 mM 
sinigrin but E. coli FI10944 failed to grow in these conditions. Using a different glucosinolate 
as a sole carbon source could support the growth of E. coli FI10944, this culture might be 
used for the purification of the myrosinase of E. coli FI10944. C. freundii FC50 is also a good 
candidate for a further study thanks to its myrosinase activity. Its genome was assembled and 
annotated. A candidate gene (a periplasmic β-glucosidase) has 25% amino acid sequence 
identity with C. WYE1 myrosinase (cmyr). This gene might be a good candidate to clone and 
express. Besides, this strain can be used to purify the myrosinase by chromatographic 
methods as described for C. WYE1 by Albaser et al. (2016) [118].  
In chapter 4, E. coli VL8 and E. coli FC44 were studied for their ability to reduce glucoraphanin 
to glucoerucin. The CFEs of both strains were able to reduce glucoraphanin to glucoerucin so 
CFEs were tested to see whether the reductase activity in CFEs was inducible or not by 
glucoraphanin supplied to the media. It was found that glucoraphanin induced or uninduced 
CFEs of E. coli VL8 and E. coli FC44 had similar reductase activity. This suggested that 
reductase activity in CFEs of E. coli VL8 and E. coli FC44 may be constitutive which contradicts 
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previous work where it was reported that uninduced CFE of E. coli VL8 was unable to reduce 
glucoraphanin [56].  
In addition, the difference in glucoraphanin degradation rates between L. agilis R16 and E. 
coli VL8 was investigated and we aimed to identify the reductase responsible for converting 
methylsulfinylalkyl glucosinolates (such as glucoraphanin) into methylthioalkyl glucosinolates 
(glucoerucin). To identify the reductases involved in glucosinolate metabolism, the study was 
focused on methionine sulphoxide reductases because MsrA was proposed to be responsible 
for reduction of glucosinolates [55]. There was no information about stereoisomerism of 
sulphoxide group in the glucoraphanin used in our study, it might consist of glucoraphanin 
with S or R-epimer of sulphoxide group. However, glucoraphanin extracted from Brassica 
oleracea var italica (broccoli) and Arabidopsis thaliana was found to be a pure epimer of R 
configuration at the sulphoxide group [247]. As MsrA can only act on the S-epimer of methyl 
sulphoxide, MsrB and fRMsr which can act on R-epimers of methyl sulphoxide were also 
investigated for their role in reducing glucoraphanin. MsrB of L. agilis R16 and E. coli VL8 were 
identified with their ability to reduce glucoraphanin to glucoerucin. Especially, MsrB of E. coli 
VL8 showed 5 times higher reduction rate compared to MsrB of L. agilis R16. This difference 
also explained the high glucoraphanin degradation rate by E. coli VL8 compared to L. agilis 
R16. Under the conditions tested, MsrB was likely to be the responsible enzyme for reduction 
of glucoraphanin. However, it was also noted that stereochemistry of sulphoxide group in 
glucoraphanin side chain can alter the role of MsrB in reduction.  
MsrB was the very first reductase identified with glucosinolate reducing ability. Identification 
of this enzyme provided a clearer understanding of the metabolism of methylsulfinylalkyl 
glucosinolates such as glucoraphanin by human gut bacteria (See Figure 6.2). Future work 
should have included a GC-MS method to identify ITCs as degradation products as well. In this 
way, the proposed mechanisms (Figure 6.2) in glucosinolate metabolism could be studied in 
greater detail.   
Many experiments are needed to get a better understanding of the role of MsrB in 
glucosinolate metabolism. First, reductase activity of MsrB on different substrates can be 
tested. The reductase activity of MsrB on other methylsulfinylalkyl glucosinolates such as 
glucoiberin or glucoallysin and ITCs such as sulforaphane, iberin or allysin can be tested. As E. 
coli VL8 was able to reduce sulforaphane to erucin [56], MsrB of E. coli VL8 is expected to 
reduce sulforaphane to erucin as well. It is also likely and should be examined that if MsrB can 
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reduce sulforaphane nitrile to erucin nitrile. These experiments will enlighten the proposed 
glucosinolate metabolism by gut bacteria (Figure 6.2). Stereochemistry of sulphoxide group 
should be taken into account. The role of MsrA on reduction of glucosinolates possessing S-
epimer of sulphoxide can be tested. Secondly, MsrB can be added to media to favor the 
degradation of methylsulfinylalkyl glucosinolates such as glucoraphanin. Strains like L. agilis 
R16 which show low glucoraphanin degradation rates (~12% after 24 h) can be tested for 
myrosinase activity when MsrB is supplemented to the media. If MsrB addition can increase 
the glucoraphanin degradation rate, further animal model studies or human intervention 
studies investigating the effect of MsrB on glucosinolate metabolism can be performed. 
Encapsulation of MsrB or bacteria that constitutively express MrsB might enable the transfer 
of active MsrB to the gut to increase the glucoraphanin transformation by gut bacteria and 
enhance the health benefits of ITCs.  
Thirdly, MsrB can be investigated for oxidation of methylthioalkyl glucosinolates (such as 
glucoerucin) to methylsulfinylalkyl glucosinolates (such as glucoraphanin). In addition to its 
role in reduction of methionine sulphoxide to methionine, MsrA was also found to be a 
methionine oxidase to catalyse the oxidation of methionine to methionine sulfoxide in 
proteins and peptides when reducing agent was absent or inaccessible [252]. This 
phenomenon can be tested for MsrA and MsrB using glucosinolates and ITCs. Interconversion 
between sulforaphane and erucin (reduced form of sulforaphane) (See Figure 6.2) was 
reported in mice [115] and in humans [253]. It was suggested that this interconversion can 
take place post absorption, in tissues [253]. Based on our results, MsrB is likely to be 
responsible for reduction of glucoraphanin and MsrB is also found in mammals including mice 
and humans. If interconversion between sulforaphane and erucin is possible in tissues and 
MsrB can show oxidase activity then MsrB may be the responsible enzyme for this 
interconversion in vivo as well.  
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Figure 6.2 Proposed glucosinolate metabolism pathway of methylsulfinylalkyl 
glucosinolates by human gut bacteria.  
 
In chapter 5, myrosinase of C. WYE1 (cmyr) of soil origin was investigated. The myrosinase 
activity of C. WYE1 was characterised using CFE and the myrosinase gene was identified 
previously by Albaser et al. (2016)[118]. In the current study, this gene was cloned and 
expressed in E. coli with a 6XHis-tag. The protein with the His-tag was purified and further 
characterised. The same optimum pH, temperature and buffer conditions for myrosinase 
activity of cmyr were obtained as in the study of Albaser et al. (2016)[118]. When the Km value 
of the cmyr for sinigrin was compared to other myrosinases, it was found that cmyr has a 
higher affinity for sinigrin compared to aphid myrosinase [132, 136] and a similar affinity 
compared to plant myrosinase [249]. This emphasizes the huge potential of cmyr for 
myrosinase activity. In addition to sinigrin, cmyr showed a variable affinity to different 
glucosinolates such as glucoraphanin and progoitrin. Identification of this bacterial 
myrosinase was an important step for a better understanding of the bacterial myrosinases. 
There are many questions about cmyr that need to be answered. The effect of ascorbate was 
studied by Albaser et al. (2016) using CFE of C. WYE1 and it was found that ascorbate is an 
activator for cmyr [118]. This effect was not tested using purified recombinant cmyr. When 
the effect of many inorganic salts (such as MgCI2 and FeCI2) on myrosinase activity of 
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Enterobacter cloacae was studied, different inorganic salts were reported to have mostly 
diverse inhibition effects on myrosinase activity [231]. For instance, only 32% of the original 
activity was kept when 1 mM FeCI2 was added to the assays [231]. Therefore, the effect of 
different inorganic salts can be tested. As the human gut also harbors simple sugars as carbon 
source for bacteria [254], the effect of different sugars (such as glucose or fructose) on 
myrosinase activity of cmyr should be also investigated.  
Even if cmyr is from C. WYE1 of soil origin, human gut also harbors Citrobacter strains such as 
C. freundii FC50 isolated from human gut in this study. Therefore, structural characterisation 
of cmyr can answer lots of questions about bacterial myrosinases from human gut. Large 
amounts of cmyr were obtained by successful cloning and expression to be used for further 
characterisation. To achieve structural characterisation, the crystallisation of this myrosinase 
is already being performed in collaboration with Imperial College London.  
In conclusion, a better understanding of bacterial myrosinases and reductases involved in 
glucosinolate metabolism is required to maximise the health benefits of ITCs. Such 
understanding can enable the identification of a probiotic strain with myrosinase activity from 
human gut. This would improve the efficiency of consumed glucosinolates for people who are 
unable to utilise glucosinolates and benefit efficiently from them. Our study focused on 
identification and characterisation of myrosinases and reductases and achieved the 
identification of MsrB with glucosinolate reducing ability. In addition, findings about 
myrosinase and reductase activity of studied strains which were contradictory to previous 
studies were obtained and new human gut isolates with high myrosinase activities such as C. 
freundii FC50 was identified.  
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APPENDIX 2 : The Nucleotide Sequences of the Cloned Genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ecg4 
gtggagaccgtaaaactaaaagaactgattgaccaaatgaccgtagctgaaaaagtgggtcagttagtccaactga
cgccagatttttttgcacaaggaggagaaatcacgggtccgatgcagcaatggcaaatgagtgaagaccaattattt
acgattggttctgtgttgggcactcatactgctgaacaagtatatgccatccaaacgtcttatcttgagaaaagtcgttt
aaagattccccttgtttttatggcagatgttatccatgggtatgaaacgattttcccaattccgcttgccttagcctcttc
ctttgatgcgcagttagtggaagaggttgctaaagcttcagcgaaagaagcggcagaagctggtgtccatgtcacgt
tttcaccgatggcggatcatgtcaaagacgcgcgctggggaagggtcttggaaagtaatggggaagatcccacctta
tcttctgtattgacggctgcttatgtacgagggtatcaaggaactgcttcccttgcagaaaataaacagcgaattgccg
cttgtgtcaaacactttatcggctatggcgctgcagaaggtggacgggactaccataccgttgatttgtccgatctgga
gctctatcagaattatttgcccgcgtttcaggctgcgattgaagcaggggcacaattagtaatgacctcctttaatacg
atccacggtgttcctgccaccgcaaatcaacccttattgcaggaagtattacgacaaaagctgggattcgacggcttg
atcatctcagattgggcagcggtagcggaattgatggcgcatcgtgtcgctgctgatcgaaaggaagccgcaaaga
aagcttttactgctggcgtggaaatggatatgatgagcgattgctatctgaatgcattggaacaaatcattcatgcag
aacctgaaatgaacgagcagctaaataaggctgtctttcatgtgttaagcttaaaaaataagttgggtctttttgaag
acccttttagaggattagtgcagggcaacttagcaccaaaattagcgcaggaaacacgccacctttcacgagaagc
agcaaagaaaacaacggttcttctgaaaaaccaagcactgttaccgttgcagaaaaagcaaaaggtcgcgttgatc
ggccccaaagcagcttcgaaggatcttttgggggcttggtcgtggatcggcaaaccggaggctgcggtctccttagcg
gagggtctttctcaaaaagaaattgacttaactgtcttatcgtatcctgatggggaaatgctgacgagtacctttattg
atgaggcgtgtaaagttgctaaagaagctgaggttgttttattggctctgggggaaactagcgaggaagcgggaga
agcggcaagtctgaccaaactttctttatcaagaaagcaagaagcattgattgaagcagtaagtcaggtcaatccta
ggatcgcaacgattcttttctgtggcagaccactggttttgaccgccatcgagcctctttgccaagccatcatgattgcc
tggttccctggatcagaaggaggcaatgcgttggcagatttgttgatgggcgagtctgaaccgcaaggacgtttagct
atgagttttcctcgagcagaaggccaattaccgatgacctatgctcaactctctacagggcgtccactgactgaagag
aatagtgatcaaaaatacatttcgcgttatatggatgaaaaaaatgagccattgttttcttttggctcggggatgggct
atggtcgatgcacgatcacccacacccaaatcattaatcctcaggaaaaggatgcaccatttgaggtcagctgcacg
ttgaaaaatgagggagatataccgcataccacgacactgcaactctatagcagagacgatgttacagaagtagcgc
gaccgatgcgggaattaaaacaatggcaaaaaatccatcttgctgcagccgaagaaaggcagcattcattctatgtt
acaccagaggattttgcttatgttcattccgatttctcgacaaaaagtgatcctggtacgatttctttataccttggcttt
gctgctgcctcagcgaagttgattggtacgctcacgatttaa 
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ecg39 
atgaaaattgatgtgaatatgagaaaaaatcggctccaatatacggaagcagctgagaagattttgaagcaaatgaccc
taaaagaaaaagtgcacttgatgagcggcaatatggttttagcagatgtaagaagggatatggcaaatgggcagcatta
caacgaatttccttatgaggccggtggaaatgaacgattgaatgttccctccatgaaatttgtagacggtcctcgcggtgc
agtaaccggcagagacaaaacaacttgttttccagtttctatggcaaggggcgcttccttcgacactgagttagaaaagc
aaattggaatagcgattgcgaaagaaatcaaagatagtggtgggaatttttttggcggcgtgtgtattaatttaccttata
atcccggttgggggcgcagtcaagaagtctacggagaagattcattccttctcggtgcgatgggatctgccctttcagaag
gtgttcaatctgaaagtgtggttgcttgcgtcaagcattatgcatttaacagtatggaaaatgctcgttttaaagtcgatgtt
catgctagcaaaagaacagaacgagaaatttatttatcgcattttaaagatgttattgattctggtgcagcttcggtaatg
acttcttataataaatattttggcgaacatactggtaatagtacttatttagttcgagatgtactaaaaaatgaatggaattt
cgacggctttgtcattagtgatttcgttaacggaacgagagacactgtaaaagcagcattggcaggattagatattgaaa
tgcatgtaacaaatcattacggagaaaaattagaaaaagctgtcgaagatggattagtacctgtagaaacaattgacga
tgctgcattaagaattattcgtaccctactcgtctttgaagaagctaggaaaaacgatgattccaaagaaaccattgatta
caaaaaacatatacgtctagctttagatgctgcagaacaatcgattactttgataaaaaatgaaaacaactgtcttccttt
aaacgcaaatattaaaaaagttgctatttttggaaaattagcgactgaagaaaatacaggcgatcgtggttctagtcgag
tttatcctccctatgttatcagttatttagaaggattaaaaaaatactctccacacattcaggttatttataacgaaggatca
gatattgaattagcaaaaacgattgccagagaagcggacgcagcgatttttgttgttggatataattatgatgatgaaggt
gaatatactggtgaagcagaaaacagagaggttcctgctggtgcgatttttgacgctaaaggcggtgatcgaaaagaat
cattagaactccattctgaagatattttactaataaaccaagttggcccagaaaacaataattcagttgttgctttagttgg
tggtaacacaattatgattgaagaatggaaaaatgcagtatctgcgattctctttacctactactcaggaatggaaggtgg
cacagcgctggcaaaaatcctctttggagaagccaatccgagtggaaaactcccatttgtaatcccttacaaagagaaa
gatctgccacagattgattggaatgcagatcaaatcacctatgaatattaccatggatatgcgaagttggaaaaggaagg
aaaagtgccttcgattccttttggttatgggctttcttataccaattttgatatttcaaaccatgattttacaatagataaaaa
gcttttgacagcaaaatgtacagttgaaaacatagggaaactacctggagcagaagttgttcaattatatgtaggattta
gtcactcgcaaatcgatcgtcccatcaaagtattacgcgggttcaagaaagtgcatctacttcctggagaaaaaaagaat
attacgattaaatgtcctatcgaaaaattgaaatggtacaatcctgattctgaacaatgggagctagaagaaattccttac
gaagtctatctaggaaacagcagttcaccaacagatttaataaaagaaactataactgtttaa 
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ecg44 
ttggatcataaacaactaaaagaattccccaatgattttttatggggttcagcatcagcagcctatcaagtagaaggcgca
tggcaagaagacggcaaaggcgcttcggtttgggacgattttgtccgcattcccggaaaaacctttaaagcaactaacgg
agatgtcgcggtcgaccattaccaccgcttcaaagaagatgttgccttgatgaaagaacaaggattgaaaacctatcgtt
tttccattgcttggacacggatttttccagaaggacgaggagaagtcaatcaagcagggttagacttttatttagcattgat
cgatgaactgataaaagcagggatcgaaccgatggtgaccttgtaccattgggatctgccacgagctttgcaagaagaa
tacggtggctgggaatctcgcaaaatcattgaagatttcaccaactatgcagctgtattgtttgaagcctttcgcggcaaa
gtccactattgggtcagcttgaatgaacaaaatatctttacttcgttaggctatcttttagctgcccatccaccaggagtga
ccgatcctaaacggatgtatgaagtcaatcatatcgctaacttggcgaatgcttcggtgatcaacaagttccatgagatga
aaatcccagggaaaatcggaccaagtttcgcctactcaccaaactacccaatcaacagcgacccgaaaaatattttggc
agctgaaaacgcggaagacttgatggcgcattattggttagacgtctatctatggggcgaatacccgattgcggcaatga
attacttgaaagagcaagggatcgcaccaacgatcgaaccaggagatatggacttgctgcgttcagcaaaaccagattt
cttagggatcaactattaccaaacagcaacaaatgcctacaatccattagatggtgtcggtgcggggaaaatgaacacc
actgggaaaaaaggcagctccgaagaaaccgggacaccaggaatgttcaaaaaagccgaaaatccatttgtggaacg
gacgaattgggattgggagatcgatcctcaagggctgcggatcgctttacgacgaatcactagccgttatcgggtgcctgt
gatcattacggaaaacggacttggtgaatacgacaaactaaccgacaatcatcaaatccatgaccaataccgcatcgat
tatttagcagggcatgtccatgccatcaaagaagcgatcagcgacggcgcggaagttcttggctattgcacctggtccttc
actgatttgctaagctggttgaacggctaccaaaaacgctatggctttgtctatgtcgaccaagatgaaacgcaagaagg
atctttggcacgctacaagaaagacagcttctactggtaccaagagctgatcaaaaccaacgggcaagagtgctag 
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ecolg3 
atgaaatggctatgttcagtaggaatcgcggtgagtctggccctgcagccagcactggcggatgatttattcggcaacca
tccattaacgcccgaagcgcgggatgcgttcgtcaccgaactgcttaagaaaatgacagttgatgagaaaattggtcag
ctgcgcttaatcagcgtcggcccggataacccgaaagaggcgatccgcgagatgatcaaagacggtcaggttggggcg
attttcaacaccgtaacccgtcaggatatccgcgccatgcaggatcaggtgatggaattaagccgcctgaaaattcctct
tttctttgcttacgacgtgctgcacggtcagcgcacggtgttcccgattagcctcggtctggcctcgtcttttaacctcgatg
cagtgaaaacggtcggacgtgtctctgcttatgaagcggcagatgatggcctgaatatgacctgggcaccgatggtcga
tgtctcgcgcgatccgcgctggggacgtgcttccgaaggttttggcgaagatacgtatctcacctcaacaatgggtaaaa
ccatggtggaagcgatgcagggtaaaagcccggcagatcgctactcggtgatgaccagcgtcaaacactttgccgcata
cggcgcggtagaaggcggtaaagagtacaacaccgtcgatatgagtccgcagcgcctgtttaatgattatatgccgccg
tacaaagcggggctggacgcaggcagcggcgcggtgatggtggcgctgaactcgctgaacggcacgccagccacctcc
gattcctggctgctgaaagatgttctgcgcgaccagtggggctttaaaggcatcaccgtttccgatcacggtgcaatcaa
agagctgattaaacatggcacggcggcagacccggaagatgcggtgcgcgtggcgctgaaatccggaatcaacatga
gtatgagcgacgagtattactcgaagtatctgcctgggttgatcaaatccggcaaagtgacgatggaagagctggacga
tgctgcccgccatgtactgaacgttaaatatgatatgggattgtttaacgacccatacagccatttggggccgaaagagt
ctgacccggtggataccaatgccgaaagccgcctgcaccgtaaagaagcgcgtgaagtggcgcgcgaaagcctggtgt
tgctgaaaaaccgtctcgaaacgttaccgctgaaaaaatcggccaccattgcggtggttgggccactggcggacagtaa
acgtgacgtgatgggcagctggtccgcagccggtgttgccgatcaatccgtgaccgtactgaccgggatcaaaaatgcc
gtcggtgaaaacggtaaagtgctgtatgccaaaggggcgaacgttaccagtgacaaaggcattatcgatttcctgaatc
agtatgaagaagcggtcaaagtcgatccgcgttcgccgcaagagatgattgatgaagcggtgcagacggcgaaacaat
ctgatgtggtggtggctgtagtcggtgaagcacaggggatggcgcacgaagcctccagccggaccgatatcactattcc
gcaaagccaacgtgacttgattgcggcgctgaaagccaccggtaaaccgctggtgctggtgctgatgaacgggcgtccg
ctggcgctggtgaaagaagatcagcaggctgatgcgattctggaaacctggtttgcggggactgaaggcggtaatgca
attgccgatgtattgtttggcgattacaacccgtccggcaagctgccaatgtccttcccgcgttctgtcgggcagatcccg
gtgtactacagccatctgaataccggtcgcccgtataatgccgacaagccgaacaaatacacttcgcgttattttgatga
agctaacggggcgttgtatccgttcggctatgggctgagctacaccactttcaccgtctctgatgtgaaactttctgcgccg
accatgaagcgtgacggcaaagtgactgccagcgtgcaggtgacgaacaccggtaagcgcgagggggccacggtagt
gcagatgtacttgcaggatgtgacggcttccatgagtcgccctgtgaaacagctgaaaggctttgagaaaatcaccctg
aaaccgggcgaaactcagactgtcagcttcccgatcgatattgaggcgctgaagttctggaatcaacagatgaaatatg
acgccgagcctggcaagttcaatgtatttatcggcactgattccgcacgcgttaagaaaggcgagtttgagttgctgtaa 
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LBAG_ msrA1 
atgacagagactgcaatatttgctggtggctgtttctggtgcatggtcaaaccgtttgatcaacagcccgggatcaagtc
agtcatttcaggttacactggtggtaccgtcgctaatccgacgtatgaacaagttgccagccacacgactgggcatactg
aagcggttaaaatcacttttgacccagatgtaatcagttatgctgacttggtcgaaatttactggcgtcagactgatccaa
ccgatgcttctggccaatttcaggaccgtggtgacagttatcgaccggtaatttttgttaatagtgaagctcaacgtcgaa
ctgcaactgcttcaagagatgcacttgcggctagcggtaagtttgctgagccgattgtgacaaccattgaagatgcgaag
ccattttatcccgcagaagccgagcaccaagacttttatcgacgcaatccattccgttatcaaatcgaagaaatgggtgg
tcgtgaggcgtttattaagcaacattggcaataa 
 
LBAG_ msrA2 
atggaaacagcaatttttgcgggtggatgtttttggtgcatggttcagccttttgatagtcaacccggaatcgacagtgttg
tctcgggttatactggtggacacacgaaaaatcccacttacgaagacgtcaaagcgcatacgacgggtcatactgaagc
tgtcaaaattacgtttgatcccgatatcattagttacacggaattaatcaatatttattggcatcaaacggatcctactgat
gcaatggggcaatttcaagatcgtggtgataattatcggccggtcatttttgtgaatggtccggaacaacggcggatcgc
ggaagcgtctaaacgggcattacaggtgagcgaacgatttagtaaaccaattgtaacggcgattgaggatgccaaacc
attttatccagccgaggcacgccaccaacgcttttataaaaataatccagtggtatttgcggaacaagaagcgggtggc
cgcgctgatttcatcgccgagcagtgggccgatgcacctaaagtggactaa 
 
LBAG_ msrA3 
atgaaaacaaaacctgaagccttaatgcgcgacttatacaacttaatcatcaacccagcgacgcgtgactgggaacgcc
atttactagtccaggccaagaataatcggcaacaactatcgccgactgggcaactaaaacagattgaagctgatttgcg
accattagctatgcggaataacttgactccggatgttatggacttttatcttgccatcactggcaacgcacccatgccgac
taaaaacaatgtatcggcttacccaacccttagttcgccttatgaagaacgggcagtctttgctggtgggtgtttttggtgc
atggttgagccctttgatcagcgtcccggtattaataatgtgatttctggctataccggtggttcgtgggcccaaccgacct
atgaacaagttagtggtcaatatacgggacacgttgaagccgtggaaatcagatacgattcccgtaaaatctcgtatca
aaatcttgtcgatatttattggcaactaattgatccgaccgaccgctttggacagatcaatgatcgcggtagccaataccg
gccagtcattttttatgctaatcaacatcaattaaccattgcgcaagcatccaaacaagcgcttgtggactcgcaacgtta
tcaaaaaccaattgtcgtggccattgagcccttacagcaattttggccagcagaaaattatcatcaggatttttaccgcaa
acaaccccggcgctaccgacaactgaaaaaagcccatgatcactatctaaattggttgaaattcaaaaacaaattctag 
 
LBAG_ msrB 
atggataaacagcaaggtgaattacgacagcgtctaacgcctgaacaatacgccgttactcaagaggcagcgaccgaa
cggccatttagcggtgagtatgataacttttaccaggaaggtatttacgttgatgtagttagtggtcaagcactctttagct
cgcgtgacaaatatgatgcgggttgtgggtggccatccttcactaaaccaatcgatcagactaatcttaacgaacaccgt
gacgagtcgtttggcatgcatcgaacagaagtgactagcacacaagcaaactcacatttaggtcacgtctttccagatg
ggccacgagattgcggcgggcttcgttattgtattaattcagcagcactgaagttcattccagttgccgaccttgaaaagg
ctggttatggtcagtatcagagtttatttaaataa 
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LBAG_frmsr 
atggctaccacggaaacatcacttatgaaccaacaactcgacgccctattgtttcaagaaactaacctggtcgcgaactt
agctaatgctagtgccctcctcaacagtacttatgacaaccttaactgggccggcttttacttatttaacgaacaaactgg
cgagctcgacttaggtcccttccaaggcaaagtcgcttgcatgcacatcaaagttggggctggtgtcgtcggaactgcttt
tgaaacgcaaacgaaccaacgggtagccgatgtccatcaattccccggccacatcgcttgtgacagtgccagcaactct
gagatcgtggtcccaatcaccaaggacggccaccaaatcggcgtactcgatgtcgactctccatcattagaccgattcaa
tgctgataacgaagctgaattgactgagtttgtggcgattctaacgtcacacattgactaa 
 
VL8_msrA 
atgagtttatttgataaaaagcatctggtttcccccgccgatgccctgcctggacgtaacaccccgatgcccgtagccacg
ctgcatgcggtcaacggtcactcaatgaccaatgtacctgacggaatggagattgccatttttgcgatgggttgtttctgg
ggtgtggagcgtctgttctggcagttacccggcgtttacagcaccgccgcaggctataccggaggctatacgccaaatcc
gacttatcgggaagtgtgctccggtgatacgggtcatgccgaagcggtacgcattgtttacgatccttccgtcatcagcta
tgagcagttgctacaggtattttgggagaatcacgatcccgcccagggaatgcgtcagggcaatgaccacggcacgca
gtatcgttcagcgatttatccgctgaccccagaacaggatgccgcagctcgcgccagtctggaacgttttcaggcggcga
tgcttgccgccgatgatgatcgtcacatcaccacggaaatcgctaacgccacaccgttttattatgccgaagatgaccac
cagcaatatctgcataaaaacccgtatggttactgtggaattggcggaattggcgtctgtctgccaccggaagcatag 
 
VL8_msrB 
atggctaataaaccttcggcagaagaactgaaaaaaaatttgtccgagatgcagttctacgtgacgcagaatcatggga
cagagccgccatttacgggtcgtttactgcataacaagcgtgacggcgtatatcactgtttgatctgcgatgccccgctgt
ttcattcccaaaccaagtatgattccggctgtggctggcccagtttctacgaaccggtgagtgaagaatccattcgttata
tcaaagacttgtcacatgggatgcagcgcatagaaattcgttgcggtaactgtgatgctcatctggggcatgtcttccccg
acgggccgcagccaacgggtgaacgttattgtgttaactcagcctctttacgctttaccgatggcgaaaacggcgaaga
aatcaacggttga 
 
FC44_frmsr 
atgaacaaaacagaattttacgcggatttaaatcgcgactttaacgcgctgatggcgggagaaaccagttttctggcaa
cgcttgcgaacaccagtgcgttgttatatgagcgtctcactgacataaactgggcaggtttttatttgcttgaggacgata
cactggtactcggaccatttcagggcaaaattgcctgtgtccggatacccgtcgggcgcggcgtgtgcggcactgcggtt
gcccgcaatcaagtgcagcgtatcgaggatgttcatgtgtttgacgggcatattgcctgtgatgcggcgagtaattctga
aattgttctgccgctggtggtgaaaaatcagattattggtgttctcgacatcgatagtaccgtcttcggtcgctttacagac
gaggacgagcaaggcttacgtcagcttgtggcacagcttgaaaaagtgcttgcaacgacggattacaaaaaattctttg
cgagcgtcgcaggataa 
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cmyr 
atgctcactgcttttaagatgaatacggtaagtcttgctgttctggtctgccttccgctgtcggtgtctgccagtattcagag
tgctcagcaacccgagctgggttacgataccgtcccgttacttcatttatcaggcctgtcttttaaagatctgaaccgtgac
ggcaaactgaatccctatgaggactggcgactttcaccgcaaacacgggccgccgatttggttaaacgtatgagcgtcg
ctgaaaaagcaggcgtgatgatgcacggtaccgctcctgccgaaggcagcactttcggcaacggtagcgtctatgacag
cgaggctacccgcaaaatggttgtcgacgcgcatgttaacagtctgatcacccgcctgaacggtgaagaaccggccag
actggctgagcagaacaacatgatacaaaagaccgctgagacaacccggctgggtatccccgtcaccatcagcacgga
tccacgtaactcctatcaggctctggtgggcattagcaaccctgccggaaaattcacgcagtggccggaagctattggcc
tgggtgcggccgggagcgaggcgctggcgcaggaatatgcggatcatgtccggcgcgaataccgggcggtggggatca
ccgaagcactttcaccacaagctgacatcacaacggagcctcgctgggcaaggatcagtggaaccttcggagaagacc
ctgagctggctaaaaagcttgtcagaggatatatcactggcatgcaaaaaggggggcagggccttaatccccagagcg
ttgcggcagtcgtcaaacactgggtcggatatggcgcagcggaagacggctgggatggccataatgcctacggtaagc
ataccgtcctcagtaacgagagcctgcagaaacacattatccctttccgcggcgcctttgaggctaacgtggctgcggtc
atgccgacgtattccgtgatgaaaggcgtaacctggaatggcagggagactgagcaggttgctgctggcttcagtcattt
tctgctgaccgaccttctgagaaagcagaacaacttctccggagtcatcatcagcgactggctcatcactaatgactgtg
atgacgaatgcgttaatggtagtgcgccgggaaaaaaaccggttgccgggggtatgccctggggggttgagtctctttct
aaagagcggagatttgttaaggccgttaacgccggtatcgatcagtttggcggcgtgacggattccgctgtgctggttac
tgccgtagaaaaaggacttatcactcaggcacgtctcgacgcctcggttgaacgtattctgcagcagaaatttgagctgg
gtttattcgaacaaccgtacgtggatgcaaagcttgccgaaaaaattgtcggggctcctgacacgaaaaaagcggcgg
atgacgctcagttccgtacgcttgtattgctacagaataagaacattctgccgctaaaacccggcacaaaagtctggcttt
acggagcggataaaagtgccgccgaaaaagcgggtctggaggtggtttctgagccggaagatgctgatgtcgcgttga
tgcgaaccagtgcccccttcgaacaaccgcattacaactacttttttggtcggcgccatcatgaaggttcccttgaatacc
gggaagacaataaagacttcgcggttctgaagcgggtcagtaaacacacacctgtcatcatgacaatgtacatggagc
gacccgccgtcctgaccaacgtgacggataaaacgagcggttttattgccaactttggactcagtgacgaggttttcttca
gcagactgacgtcagataccccctacacagcgcgccttccattcgcactaccttcctcaatggcgtccgtgcttaaacaa
aaatctgatgagcctgacgatctggacacaccgttattccagcgcggattcggactgacacgctga 
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APPENDIX 3 : RDP Database Results  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
short ID, orientation, similarity score, S_ab score, unique common oligomers and 
sequence full name 
Isolate23  
       domain Bacteria (20)  
          phylum "Proteobacteria" (20)  
             class Gammaproteobacteria (20)  
                order "Enterobacteriales" (20)  
                   family Enterobacteriaceae (20)  
                      genus Escherichia/Shigella (19)  
      S000727873     not_calculated 1.000 1205  Escherichia coli; IF4; AB272358 
      S001602706     not_calculated 1.000 1254  uncultured Escherichia sp.; 50L-A1; 
GQ423062 
      S002043841     not_calculated 1.000 1239  uncultured bacterium; 16slp92-
2h09.w2k; GQ159504 
Isolate32  
       domain Bacteria (20)  
          phylum "Proteobacteria" (20)  
             class Gammaproteobacteria (20)  
                order "Enterobacteriales" (20)  
                   family Enterobacteriaceae (20)  
                      genus Escherichia/Shigella (19)  
S000727873    not_calculated 1.000 1205  Escherichia coli; IF4; AB272358 
S001602706    not_calculated 1.000 1254  uncultured Escherichia sp.; 50L-A1; 
GQ423062               
 S002043841    not_calculated 1.000 1239  uncultured bacterium; 16slp92-2h09.w2k; 
GQ159504 
S002234579    not_calculated 0.999 1228  Escherichia fergusonii; KLU01; HQ214033 
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Isolate33 
       domain Bacteria (20)  
          phylum "Proteobacteria" (20)  
             class Gammaproteobacteria (20)  
                order "Enterobacteriales" (20)  
                   family Enterobacteriaceae (20)  
                      genus Escherichia/Shigella (20)  
S000013935     not_calculated 1.000 1405  Escherichia/Shigella flexneri (T); X96963 
S000021941     not_calculated 1.000 1405  Shigella sonnei; X96964 
S000139289     not_calculated 1.000 1384  Escherichia/Shigella fergusonii (T); ATCC 
35469; AF530475 
S000389727     not_calculated 1.000 1418  Escherichia coli; AF2334513 
 
Isolate35 
      domain Bacteria (20)  
          phylum "Proteobacteria" (20)  
             class Gammaproteobacteria (20)  
                order "Enterobacteriales" (20)  
                   family Enterobacteriaceae (20)  
                      genus Escherichia/Shigella (19)  
  S000727873     not_calculated 1.000 1205  Escherichia coli; IF4; AB272358 
  S001602706     not_calculated 1.000 1254  uncultured Escherichia sp.; 50L-A1; 
GQ423062 
  S002043841     not_calculated 0.999 1239  uncultured bacterium; 16slp92-
2h09.w2k; GQ159504 
  S002234579     not_calculated 0.999 1228  Escherichia fergusonii; KLU01; 
HQ214033 
Isolate 36 
       domain Bacteria (20)  
          phylum "Proteobacteria" (20)  
             class Gammaproteobacteria (20)  
                order "Enterobacteriales" (20)  
                   family Enterobacteriaceae (20)  
                      genus Escherichia/Shigella (20)  
S000013935     not_calculated 1.000 1405  Escherichia/Shigella flexneri (T); X96963 
S000021941     not_calculated 1.000 1405  Shigella sonnei; X96964 
S000139289     not_calculated 1.000 1384  Escherichia/Shigella fergusonii (T); ATCC 
35469; AF530475 
S000250140     not_calculated 1.000 1357  Photorhabdus luminescens; AY444555 
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Isolate 48 
       domain Bacteria (20)  
          phylum "Proteobacteria" (20)  
             class Gammaproteobacteria (20)  
                order "Enterobacteriales" (20)  
                   family Enterobacteriaceae (20)  
                      genus Escherichia/Shigella (20)  
S000013935     not_calculated 1.000 1405  Escherichia/Shigella flexneri (T); X96963 
S000021941     not_calculated 1.000 1405  Shigella sonnei; X96964 
S000139289     not_calculated 1.000 1384  Escherichia/Shigella fergusonii (T); ATCC 
35469; AF530475 
 S000344063     not_calculated 1.000 1376  uncultured bacterium; p-229-o5; 
AF371848 
Isolate 49 
       domain Bacteria (20)  
          phylum "Proteobacteria" (20)  
             class Gammaproteobacteria (20)  
                order "Enterobacteriales" (20)  
                   family Enterobacteriaceae (20)  
                      genus Escherichia/Shigella (20)  
     S000727873     not_calculated 0.994 1205  Escherichia coli; IF4; AB272358 
     S001602706     not_calculated 0.994 1254  uncultured Escherichia sp.; 50L-A1; 
GQ423062 
     S002043841     not_calculated 1.000 1239  uncultured bacterium; 16slp92-
2h09.w2k; GQ159504 
     S002043844     not_calculated 0.995 1314  uncultured bacterium; 16slp92-
2d12.w2k; GQ159507 
 
Isolate50 
       domain Bacteria (20)  
          phylum "Proteobacteria" (20)  
             class Gammaproteobacteria (20)  
                order "Enterobacteriales" (20)  
                   family Enterobacteriaceae (20)  
                      genus Citrobacter (18)  
    S002961729     not_calculated 0.946 1146  Citrobacter freundii; AP9; JN797483 
    S003287113     not_calculated 0.944 1243  Citrobacter freundii; GTC 07890; 
AB741667 
   S003713527     not_calculated 0.936 1211  Citrobacter sp. DL4.2; JQ912532 
   S003715763     not_calculated 0.952 1205  Citrobacter sp. P005; KC252743 
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Isolate 57 
       domain Bacteria (20)  
          phylum "Proteobacteria" (20)  
             class Gammaproteobacteria (20)  
                order "Enterobacteriales" (20)  
                   family Enterobacteriaceae (20)  
                      genus Escherichia/Shigella (19)  
        S000727873     not_calculated 0.994 1205  Escherichia coli; IF4; AB272358 
        S001602706     not_calculated 0.994 1254  uncultured Escherichia sp.; 50L-A1; 
GQ423062 
        S002043841     not_calculated 0.994 1239  uncultured bacterium; 16slp92-
2h09.w2k; GQ159504 
        S002234579     not_calculated 0.991 1228  Escherichia fergusonii; KLU01; 
HQ214033 
 
Isolate58 
       domain Bacteria (20)  
          phylum "Proteobacteria" (20)  
             class Gammaproteobacteria (20)  
                order "Enterobacteriales" (20)  
                   family Enterobacteriaceae (20)  
                      genus Escherichia/Shigella (20)  
         S000727873     not_calculated 1.000 1205  Escherichia coli; IF4; AB272358 
         S001265276     not_calculated 1.000 1284  Shigella sp. 5; FJ594947 
         S001602706     not_calculated 1.000 1254  uncultured Escherichia sp.; 50L-A1; 
GQ423062 
         S002015199     not_calculated 1.000 1283  uncultured bacterium; HERMI16; 
GQ160461 
 
Isolate59 
       domain Bacteria (20)  
          phylum Firmicutes (20)  
             class Bacilli (20)  
                order Lactobacillales (20)  
                   family Enterococcaceae (20)  
                      genus Enterococcus (20)  
  S000012626     not_calculated 1.000 1429  Enterococcus gallinarum (T); AF039900 
  S000387905     not_calculated 1.000 1432  Eubacterium sp. 1275b; AF135452 
  S000615647     not_calculated 1.000 1411  uncultured Enterococcus sp.; F25; 
DQ232852 
  S000709713     not_calculated 1.000 1411  uncultured bacterium; aaa53b05; 
DQ818102 
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Isolate 60 
       domain Bacteria (20)  
          phylum "Proteobacteria" (20)  
             class Gammaproteobacteria (20)  
                order "Enterobacteriales" (20)  
                   family Enterobacteriaceae (20)  
                      genus Escherichia/Shigella (20)  
S003284942     not_calculated 0.995 1292  Escherichia coli; b4; JQ661111 
S003284967     not_calculated 0.995 1295  Escherichia coli; p22; JQ661136 
S003320650     not_calculated 0.995 1297  uncultured bacterium; 
OTU023_Xeno_Clone03; AB694228 
S003320651     not_calculated 0.995 1294  uncultured bacterium; 
OTU023_Xeno_Clone04; AB694229 
Isolate 61 
       domain Bacteria (20)  
          phylum Firmicutes (20)  
             class Bacilli (20)  
                order Lactobacillales (20)  
                   family Enterococcaceae (20)  
                      genus Enterococcus (20)  
    S000012626     not_calculated 0.997 1429  Enterococcus gallinarum (T); AF039900 
    S000387905     not_calculated 0.997 1432  Eubacterium sp. 1275b; AF135452 
    S000390547     not_calculated 0.997 1435  Enterococcus gallinarum; MG25; 
AF277567 
    S000615647     not_calculated 0.997 1411  uncultured Enterococcus sp.; F25; 
DQ232852 
 
Isolate 66 
 
       domain Bacteria (20)  
          phylum Firmicutes (20)  
             class Bacilli (20)  
                order Lactobacillales (20)  
                   family Enterococcaceae (20)  
                      genus Enterococcus (20)  
  S000005780     not_calculated 0.999 1429  Enterococcus casseliflavus (T); AF039903 
  S000650499     not_calculated 0.999 1404  Enterococcus casseliflavus; F00240; 
DQ395282 
  S000950598     not_calculated 0.999 1403  uncultured bacterium; 3; EU124822 
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Isolate 71  
       domain Bacteria (20)  
          phylum Firmicutes (20)  
             class Bacilli (20)  
                order Lactobacillales (20)  
                   family Enterococcaceae (20)  
                      genus Enterococcus (20)  
  S000005780     not_calculated 0.989 1429  Enterococcus casseliflavus (T); AF039903 
  S000650499     not_calculated 0.989 1404  Enterococcus casseliflavus; F00240; 
DQ395282solate71 
  S001187491     not_calculated 0.989 1427  Enterococcus casseliflavus; F32; 
EU151766 
  S001418145     not_calculated 0.989 1397  Enterococcus gallinarum; IMAU10084; 
WZ30-2; FJ915740 
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APPENDIX 4 : Mascot results for FPLC  
The Score stands for an overall protein score. This number reflects the combined scores of all observed mass spectra that can be attached to 
aminoacid sequences within a protein. The mass means the expected mass of the protein given. Number of matches indicates the number of MS/MS 
spectra that were matched to that protein (The significance threshold < 5%). The EmPAI indicates exponentially modified protein abundance index.  
 
Score Mass Number of 
matches 
Number 
of 
significant 
matches 
Number 
of 
sequences 
Number 
of 
significant 
sequences 
emPAI Description 
688 41264 93 45 18 15 4.44 Phosphoglycerate kinase OS=Escherichia coli (strain K12) 
GN=pgk PE=1 SV=2 
430 60483 84 31 23 16 2.04 Periplasmic dipeptide transport protein OS=Escherichia coli 
(strain K12) GN=dppA PE=1 SV=1 
379 35398 49 21 19 11 1.93 Transaldolase OS=Escherichia coli O104:H4 (strain 2009EL-2071) 
GN=tal PE=1 SV=1 
316 35865 62 26 26 16 3.5 Transaldolase A OS=Escherichia coli (strain K12) GN=talA PE=3 
SV=1 
265 38590 38 19 15 10 2.16 Protein tas OS=Escherichia coli (strain K12) GN=tas PE=1 SV=1 
258 60975 57 20 22 13 1.09 Periplasmic oligopeptide-binding protein OS=Escherichia coli 
(strain K12) GN=oppA PE=1 SV=2 
251 48532 39 17 19 10 1.06 sn-glycerol-3-phosphate-binding periplasmic protein UgpB 
OS=Escherichia coli (strain K12) GN=ugpB PE=1 SV=1 
249 27126 51 21 16 11 3.03 Triosephosphate isomerase OS=Escherichia coli (strain K12) 
GN=tpiA PE=1 SV=1 
204 51563 53 20 21 14 1.53 6-phosphogluconate dehydrogenase, decarboxylating 
OS=Escherichia coli (strain K12) GN=gnd PE=1 SV=2 
199 42928 31 14 14 9 1.1 3-oxoacyl-[acyl-carrier-protein] synthase 1 OS=Escherichia coli 
(strain K12) GN=fabB PE=1 SV=1 
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Score Mass Number of 
matches 
Number 
of 
significant 
matches 
Number 
of 
sequences 
Number 
of 
significant 
sequences 
emPAI Description 
178 45996 28 17 12 10 1.14 Glucose-1-phosphatase OS=Escherichia coli (strain K12) GN=agp 
PE=1 SV=1 
164 31639 27 14 13 8 1.46 Uncharacterized oxidoreductase YghA OS=Escherichia coli 
(strain K12) GN=yghA PE=1 SV=1 
150 59863 40 13 21 9 0.71 Phosphoenolpyruvate carboxykinase [ATP] OS=Escherichia coli 
O6:K15:H31 (strain 536 / UPEC) GN=pckA PE=3 SV=1 
139 57003 20 9 6 5 0.4 Cytoplasmic alpha-amylase OS=Escherichia coli (strain K12) 
GN=amyA PE=3 SV=3 
107 23947 19 9 11 5 1.19 Probable phospholipid-binding protein MlaC OS=Escherichia coli 
(strain K12) GN=mlaC PE=1 SV=1 
104 37238 27 11 12 8 1.16 Putative amino-acid ABC transporter-binding protein YhdW 
OS=Escherichia coli O157:H7 GN=yhdW PE=3 SV=1 
104 60900 29 7 13 6 0.37 Protein UshA OS=Escherichia coli (strain K12) GN=ushA PE=1 
SV=2 
53 37292 22 5 9 4 0.53 Outer membrane protein A OS=Escherichia coli (strain K12) 
GN=ompA PE=1 SV=1 
102 61605 37 10 18 6 0.37 Glucose-6-phosphate isomerase OS=Escherichia coli (strain K12) 
GN=pgi PE=1 SV=1 
101 23083 18 7 7 4 0.72 Superoxide dismutase [Mn] OS=Escherichia coli (strain K12) 
GN=sodA PE=1 SV=2 
101 13660 8 3 4 2 0.56 Enamine/imine deaminase OS=Escherichia coli (strain K12) 
GN=ridA PE=1 SV=2 
97 21061 25 8 10 4 1.09 Osmotically-inducible protein Y OS=Escherichia coli (strain K12) 
GN=osmY PE=1 SV=1 
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Score Mass Number of 
matches 
Number 
of 
significant 
matches 
Number 
of 
sequences 
Number 
of 
significant 
sequences 
emPAI Description 
91 53189 17 8 10 4 0.27 Glutamate decarboxylase beta OS=Escherichia coli O6:H1 (strain 
CFT073 / ATCC 700928 / UPEC) GN=gadB PE=3 SV=2 
82 53235 12 8 8 5 0.35 Glutamate decarboxylase alpha OS=Escherichia coli O157:H7 
GN=gadA PE=3 SV=1 
91 57605 26 6 15 5 0.32 Probable D,D-dipeptide-binding periplasmic protein DdpA 
OS=Escherichia coli (strain K12) GN=ddpA PE=2 SV=1 
80 53357 22 7 10 6 0.43 N-succinylglutamate 5-semialdehyde dehydrogenase 
OS=Escherichia coli (strain SE11) GN=astD PE=3 SV=1 
77 43980 19 7 9 6 0.54 Succinylornithine transaminase OS=Escherichia coli (strain ATCC 
8739 / DSM 1576 / Crooks) GN=astC PE=3 SV=1 
75 22441 16 7 6 4 1.01 KHG/KDPG aldolase OS=Escherichia coli (strain K12) GN=eda 
PE=1 SV=1 
73 56462 24 7 11 6 0.4 Glutathione-binding protein GsiB OS=Escherichia coli 
O6:K15:H31 (strain 536 / UPEC) GN=gsiB PE=3 SV=2 
69 98015 25 5 15 5 0.18 Aconitate hydratase 1 OS=Escherichia coli (strain K12) GN=acnA 
PE=1 SV=3 
62 34525 9 4 5 2 0.2 Cysteine synthase A OS=Escherichia coli (strain K12) GN=cysK 
PE=1 SV=2 
61 31300 10 2 5 1 0.11 Molecular chaperone Hsp31 and glyoxalase 3 OS=Escherichia 
coli O1:K1 / APEC GN=hchA PE=3 SV=1 
61 63825 19 7 10 4 0.29 Periplasmic trehalase OS=Escherichia coli (strain ATCC 8739 / 
DSM 1576 / Crooks) GN=treA PE=3 SV=1 
55 21310 14 4 5 1 0.16 Superoxide dismutase [Fe] OS=Escherichia coli (strain K12) 
GN=sodB PE=1 SV=2 
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Score Mass Number of 
matches 
Number 
of 
significant 
matches 
Number 
of 
sequences 
Number 
of 
significant 
sequences 
emPAI Description 
54 8375 9 4 4 3 3.09 Major outer membrane lipoprotein Lpp OS=Escherichia coli 
(strain K12) GN=lpp PE=1 SV=1 
50 26990 5 3 3 2 0.26 7-alpha-hydroxysteroid dehydrogenase OS=Escherichia coli 
(strain K12) GN=hdhA PE=1 SV=1 
 
49 46070 33 5 13 4 0.32 Isocitrate dehydrogenase [NADP] OS=Escherichia coli (strain 
K12) GN=icd PE=1 SV=1 
47 47484 12 3 7 3 0.22 Periplasmic AppA protein OS=Escherichia coli (strain K12) 
GN=appA PE=1 SV=2 
47 40928 20 8 11 5 0.59 Putrescine-binding periplasmic protein OS=Escherichia coli 
(strain K12) GN=potF PE=1 SV=3 
        
45 38395 13 4 7 3 0.28 Aldose 1-epimerase OS=Escherichia coli (strain K12) GN=galM 
PE=1 SV=1 
41 42553 12 3 6 1 0.16 Putative ABC transporter periplasmic-binding protein YdcS 
OS=Escherichia coli (strain K12) GN=ydcS PE=3 SV=1 
40 33096 4 1 2 1 0.1 Glutaminase OS=Escherichia coli O81 (strain ED1a) GN=glsA 
PE=3 SV=1 
40 70902 23 4 14 3 0.2 2',3'-cyclic-nucleotide 2'-phosphodiesterase/3'-nucleotidase 
OS=Escherichia coli (strain K12) GN=cpdB PE=1 SV=2 
39 13785 3 2 2 1 0.25 Protein GlcG OS=Escherichia coli (strain K12) GN=glcG PE=3 
SV=1 
38 36571 9 1 5 1 0.09 6-phosphogluconolactonase OS=Escherichia coli O6:K15:H31 
(strain 536 / UPEC) GN=pgl PE=3 SV=1 
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35 20900 2 1 1 1 0.16 Protein YceI OS=Escherichia coli (strain K12) GN=yceI PE=1 SV=1 
33 49392 10 1 5 1 0.07 N-succinylarginine dihydrolase OS=Escherichia coli (strain SE11) 
GN=astB PE=3 SV=1 
32 14678 5 1 3 1 0.23 Protein YhfA OS=Escherichia coli (strain K12) GN=yhfA PE=1 
SV=1 
28 40874 18 1 8 1 0.08 Glycerophosphoryl diester phosphodiesterase OS=Escherichia 
coli (strain K12) GN=glpQ PE=1 SV=2 
28 33513 8 1 5 1 0.1 Glutamate/aspartate periplasmic-binding protein 
OS=Escherichia coli (strain K12) GN=gltI PE=1 SV=2 
28 9529 2 1 1 1 0.36 DNA-binding protein HU-alpha OS=Escherichia coli (strain ATCC 
9637 / CCM 2024 / DSM 1116 / NCIMB 8666 / NRRL B-766 / W) 
GN=hupA PE=1 SV=1 
27 39223 7 3 4 2 0.18 Leu/Ile/Val-binding protein OS=Escherichia coli (strain K12) 
GN=livJ PE=1 SV=1 
27 43831 11 3 7 3 0.24 Aspartate aminotransferase OS=Escherichia coli (strain K12) 
GN=aspC PE=1 SV=1 
27 13939 2 1 1 1 0.24 Aspartate 1-decarboxylase OS=Escherichia coli (strain K12) 
GN=panD PE=1 SV=1 
23 149076 6 2 2 2 0.04 DNA translocase FtsK OS=Escherichia coli O6:H1 (strain CFT073 / 
ATCC 700928 / UPEC) GN=ftsK PE=3 SV=1 
23 23867 3 1 3 1 0.14 Uncharacterized protein YcgM OS=Escherichia coli (strain K12) 
GN=ycgM PE=1 SV=1 
23 49084 13 4 5 3 0.22 Glutathione reductase OS=Escherichia coli (strain K12) GN=gor 
PE=1 SV=1 
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23 26161 11 1 7 1 0.13 Purine nucleoside phosphorylase DeoD-type OS=Escherichia coli 
(strain K12) GN=deoD PE=1 SV=2 
23 34437 5 1 3 1 0.1 ABC transporter periplasmic-binding protein YtfQ 
OS=Escherichia coli (strain K12) GN=ytfQ PE=1 SV=1 
23 41172 2 1 1 1 0.08 Mannitol-1-phosphate 5-dehydrogenase OS=Escherichia coli 
(strain ATCC 8739 / DSM 1576 / Crooks) GN=mtlD PE=3 SV=1 
23 35681 5 1 3 1 0.09 Glyceraldehyde-3-phosphate dehydrogenase A OS=Escherichia 
coli (strain K12) GN=gapA PE=1 SV=2 
22 69130 2 1 1 1 0.05 Chaperone protein DnaK OS=Escherichia coli (strain K12) 
GN=dnaK PE=1 SV=2 
22 74349 2 1 1 1 0.04 Glycogen debranching enzyme OS=Escherichia coli O6:K15:H31 
(strain 536 / UPEC) GN=glgX PE=3 SV=1 
21 20418 1 1 1 1 0.16 Peptidyl-prolyl cis-trans isomerase A OS=Escherichia coli (strain 
K12) GN=ppiA PE=1 SV=1 
21 4864 2 1 1 1 0.75 Entericidin B OS=Escherichia coli (strain K12) GN=ecnB PE=3 
SV=1 
21 32502 8 1 4 1 0.1 Malate dehydrogenase OS=Escherichia coli O6:K15:H31 (strain 
536 / UPEC) GN=mdh PE=3 SV=1 
20 12799 2 2 1 1 0.27 Protein YchN OS=Escherichia coli (strain K12) GN=ychN PE=1 
SV=1 
20 40614 2 1 1 1 0.08 Macrolide export protein MacA OS=Escherichia coli O157:H7 
GN=macA PE=3 SV=1 
20 102958 3 1 3 1 0.03 Signal transduction histidine-protein kinase BarA OS=Escherichia 
coli (strain K12) GN=barA PE=1 SV=1 
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20 20554 2 1 1 1 0.16 Isochorismatase family protein YecD OS=Escherichia coli (strain 
K12) GN=yecD PE=1 SV=2 
18 33695 6 1 4 1 0.1 Uncharacterized protein YcjY OS=Escherichia coli (strain K12) 
GN=ycjY PE=4 SV=2 
18 23947 2 2 2 2 0.3 Oxygen-insensitive NAD(P)H nitroreductase OS=Escherichia coli 
(strain K12) GN=nfnB PE=1 SV=1 
18 28539 2 1 2 1 0.12 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase 
OS=Escherichia coli O6:K15:H31 (strain 536 / UPEC) GN=gpmA 
PE=3 SV=1 
17 49361 2 1 1 1 0.07 Xanthine permease XanQ OS=Escherichia coli (strain K12) 
GN=xanQ PE=1 SV=2 
17 31535 5 1 3 1 0.11 4-hydroxy-tetrahydrodipicolinate synthase OS=Escherichia coli 
(strain K12) GN=dapA PE=1 SV=1 
17 45410 2 2 1 1 0.07 Putative prophage CPZ-55 integrase OS=Escherichia coli (strain 
K12) GN=intZ PE=3 SV=2 
17 35575 4 1 2 1 0.09 L-arabinose-binding periplasmic protein OS=Escherichia coli 
(strain K12) GN=araF PE=1 SV=2 
16 21219 1 1 1 1 0.16 Thermosensitive gluconokinase OS=Escherichia coli (strain K12) 
GN=idnK PE=3 SV=1 
16 32822 2 1 2 1 0.1 NADPH-dependent 7-cyano-7-deazaguanine reductase 
OS=Escherichia coli O1:K1 / APEC GN=queF PE=3 SV=1 
15 37049 1 1 1 1 0.09 Selenide, water dikinase OS=Escherichia coli O6:K15:H31 (strain 
536 / UPEC) GN=selD PE=3 SV=1 
15 53110 1 1 1 1 0.06 Cytosol non-specific dipeptidase OS=Escherichia coli (strain K12) 
GN=pepD PE=1 SV=3 
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14 46353 3 2 2 1 0.07 High-affinity branched-chain amino acid transport system 
permease protein LivM OS=Escherichia coli (strain K12) GN=livM 
PE=3 SV=2 
14 55242 2 1 1 1 0.06 Probable glutamate/gamma-aminobutyrate antiporter 
OS=Escherichia coli O6:H1 (strain CFT073 / ATCC 700928 / UPEC) 
GN=gadC PE=3 SV=1 
14 25564 2 1 1 1 0.13 Ribonuclease PH OS=Escherichia coli (strain K12 / MC4100 / 
BW2952) GN=rph PE=1 SV=1 
14 36997 1 1 1 1 0.09 Starvation-sensing protein RspB OS=Escherichia coli (strain K12) 
GN=rspB PE=3 SV=1 
14 36570 5 1 1 1 0.09 HTH-type transcriptional regulator GntR OS=Escherichia coli 
(strain K12) GN=gntR PE=1 SV=1 
14 35690 6 1 4 1 0.09 D-galactose-binding periplasmic protein OS=Escherichia coli 
(strain K12) GN=mglB PE=1 SV=1 
14 37621 1 1 1 1 0.09 Regulator of RpoS OS=Escherichia coli (strain K12) GN=rssB PE=1 
SV=1 
13 21141 2 1 1 1 0.16 Murein DD-endopeptidase MepS/Murein LD-carboxypeptidase 
OS=Escherichia coli (strain K12) GN=mepS PE=1 SV=1 
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